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OLFACTORY RECEPTOR ANTAGONISM 
IN THE OR-I7 ALDEHYDE RECEPTOR 
AND THE MAMMALIAN OLFACTORY SYSTEM 
by 
Min Ting Liu 
Advisor: Kevin Ryan 
 The detection of smell is initiated when an odorant binds and activates olfactory receptors 
(ORs) within the nose. Chapter 1 studies the structural requirements for activation of the OR-I7 
aldehyde receptor. Octanal is an agonist of the OR-I7 receptor.1, 2 4-Ethylcyclohexylacetaldehyde 
(1.1), with a cyclohexyl ring that locks the C4-C5 bond of octanal in the gauche conformation, 
was previously found to have higher potency than octanal, suggesting that the OR-I7 receptor 
prefers the gauche conformation of octanal during activation.3 However, 1.1 had only been 
previously tested as a mixture of cis- and trans-isomers, and therefore, it was not possible to 
determine whether the response of 1.1 was stimulated by either or both of the isomers. In order 
to distinguish the response of each isomer, the cis and trans compounds were individually 
synthesized and tested on olfactory sensory neurons (OSNs) that co-express the OR-I7 receptor 
via calcium imaging. Through this study, we gained insight into the preferred conformation of 
the C6-C7 bond of octanal for activation of the OR-I7 receptor.  
Removing the ethyl group of 4-ethylcyclohexylacetaldehyde (1.1) to form 
cyclohexylacetaldehyde (2.2), transforms the molecule from an activator to an inhibitor of OR-
I7.3 Chapter 2 focuses on antagonism of the rodent OR-I7 aldehyde receptor. Besides 2.2, the 
response of octanal can be antagonized by several short aliphatic linear and cyclic aldehydes at 
micromolar concentrations.3 It was proposed that these antagonists compete with octanal for the 
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binding site via their aldehyde moiety, but fail to activate the receptor due to their shorter chain 
lengths. The strength of antagonism for this receptor appeared to correlate with the number of 
aliphatic carbons within 7 Å of the aldehyde when it was modeled in the most extended 
conformation, but the data set was too small to firmly support this. To further test the possibility, 
a structure-activity relationship (SAR) study was carried out in which additional carbons were 
systematically substituted onto the structures of OR-I7 antagonists without exceeding 7 Å. The 
synthesized analogues were tested for their ability to inhibit activation by octanal in OR-I7 
receptors expressed in HEK293 cells using a cyclic AMP detection assay. This work led to more 
precise information on what makes a good OR-I7 antagonist. 
Currently, there is limited data on the determinants of antagonism, but several olfactory 
receptors, such as OR-I7 and mOR-EG, have been reported to be antagonized by odorants which 
are structurally similar to the agonist(s) of the receptor.3, 4 Structural similarities may point to 
similar, orthosteric binding sites within the receptor, as opposed to allosteric binding sites. 
Chapter 3 looks at determinants of antagonism in the mammalian olfactory system as a whole. 
For the OR-I7 receptor, the main difference between the structure of the agonist, octanal, and the 
antagonists is their chain lengths, whereas the agonist of the mOR-EG receptor, eugenol, differs 
from the antagonists by the functional group on the phenyl ring and the position of the double 
bond. For these two receptors, these structural variants may be directing the shift from agonist to 
antagonist. A study was devised to look at the extent of OR antagonism that can be stimulated by 
pairs of structurally similar odorants, differing only in their carbon chain length or their oxygen 
containing functional group. The response of endogenous ORs to these odorants was acquired in 
live olfactory sensory neurons via calcium imaging. The response pattern of over 11,000 cells 
was analyzed. Based on this study, both the chain type and functional group type can be the 
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determinant of OR antagonism, but the carboxyl group inhibited the highest percentage of cells 
out of the three functional groups tested, and cells activated by aldehydes were the most 
susceptible to antagonism. 
In addition to the olfactory studies, which constitute the main part of this thesis, I also did 
some projects involving the study of pre-mRNA and DNA. Chapter 4 describes small molecule 
activators of the pre-mRNA 3’ cleavage reaction. The cleavage and polyadenylation of the 3’ 
end of pre-mRNA is an important process that occurs during the transcription of DNA to RNA. 
It was previously believed that besides a series of cleavage factors, ATP was also required for 
the cleavage step, but in an in vitro study, it was found that even without ATP, creatine 
phosphate was able to initiate cleavage between 10-60 mM concentrations.5 Aside from having a 
structure similar to that of an amino acid, creatine phosphate also contains a phosphate group, so 
it was possible that at high concentration creatine phosphate activated cleavage by inhibiting a 
phosphatase that normally suppresses cleavage,6 but the actual mechanism by which it acts is 
still unclear. Through structure-activity relationship (SAR) studies, we have found a variety of 
new small molecule activators of the in vitro pre-mRNA 3’ cleavage reaction. New activators 
included cp38 (a cyclic peptide PPM1D inhibitor), dipeptide 4.12, abscisic acid, and an arginine 
-naphthylamide analog. The minimal concentration required for in vitro cleavage stimulation 
has been improved from 200 M to the 200 nM-100 M range.  
Chapter 5 describes a preliminary attempt to target the molecular recognition of the DNA 
double helix at a DNA nick, which is a break in one of the two strands of the double helix where 
the phosphate group has been removed. This feature, which occurs thousands of times at any 
given instant in the genome of a mammalian cell due to damage, may provide an opportunity for 
other molecules to bind with the 3’ and 5’ hydroxyl-groups at the DNA nicks. Boronic acids are 
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known to reversibly bind with diols at high affinity to form boronic esters.7 The close proximity 
of the hydroxyl groups at a DNA nick resembles a diol, and could possibly bind with boronic 
acids in a similar, equilibrium-based manner. Boronic acids have been used for the molecular 
recognition of diols and polyols, and could potentially be used in the same way for DNA nicks. 
We tested this possibility on two model studies, one with DNA and one using a surrogate diol, 
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Chapter 1: Preference of the OR-I7 receptor for a particular C6-C7 conformation of 
octanal 
1.1. Introduction: 
1.1.1. Octanal conformation preferred by the OR-I7 receptor 
Olfaction, or the sense of 
smell, is one of the major senses 
used for analyzing the physical 
environment. The detection of 
smell is initiated when odorants 
interact with olfactory receptors 
(a.k.a. odorant receptors) (ORs) expressed in the cell membranes of olfactory sensory neurons 
(OSNs) located within the olfactory epithelium of the nose. ORs belong to the family of G-
protein coupled receptors (GPCRs).1 As depicted on Figure 1.1, when an odorant binds and 
activates an olfactory receptor, a series of intracellular events will occur resulting in the 
sensation of smell.2 The G-protein (Golf) activates adenylyl cyclase to convert ATP to cAMP, 
and the rise in cAMP level leads to the opening of ion channels allowing calcium and sodium 
ions to enter the cell. This change in the cell’s polarity results in an action potential and a signal 
being sent to the main olfactory bulb and then the brain. While ORs make up the largest group of 
GPCRs in the mammalian genome, the OR machinery remains largely unexplored due to the 
difficulty in stabilizing the protein for obtaining a crystal structure.  
Octanal is one of the best natural product agonists of the OR-I7 receptor, a receptor 
specific for aliphatic aldehydes.3, 4 Due to the flexibility of its aliphatic chain, octanal could 
theoretically adopt hundreds of different conformations with similar energies. In an effort to 
 
Figure 1.1: Signal transduction pathway of the olfactory system during 
the activation of the olfactory receptor.  
(OR=Olfactory receptor and AC=Adenylyl cyclase) 
2 
 
learn about the conformation(s) of octanal that activates the OR-I7 receptor, the Ryan lab 
previously compared the response of octanal to that of 4-ethylcyclohexylacetaldehyde (1.1), 
which has a cyclohexyl ring that locks the C4-C5 bond of octanal in the gauche conformation 








































Figure 1.2: The gauche conformation of octanal. Line structures (top) and Newman projections (bottom, front 
carbon: C5, back carbon: C4) of octanal, 1.1, 1.2 and 1.3 in the gauche conformation. The EC50 values were 
obtained from calcium imaging of the rat OR-I7 receptor.5 
 
Compound 1.1 (EC50=1.0 µM) was found to have approximately equal potency compared to 
octanal (EC50=1.8 µM), suggesting that the OR-I7 receptor prefers or at least tolerates the gauche 
conformation of octanal during activation.5 However, 1.1 was tested as a mixture of cis and trans 
isomers (1:2.4), so that it was ambiguous as to whether the response of the receptor was due to 
activation by both or only one of the isomers. Knowing the individual response of the two 
isomers would not only reveal the source of the response coming from the mixture, 1.1, but also 
the preference of the OR-I7 receptor for the conformation of the C6-C7 bond on octanal. 
The cis- (1.2) and trans-isomer (1.3) are conformationally restricted isomers of octanal. 
















conformation, which is present in only ~10 closely related isomers of octanal. The cis- (1.2) and 
trans-isomer (1.3) restrict the conformation of octanal differently by locking the C5-C6 bond at 
two of the possible positions adopted by octanal while in the gauche conformation at C4-C5. A 
greater potency in either one of the isomer would indicate a conformational preference by the 
OR-I7 receptor for the corresponding octanal conformation simulated by the analog. 
1.2. Experimental Design: 
1.2.1. Synthesis of 1.2 and 1.3  
To determine the response of the individual isomers, the cis-isomer (1.2) and the trans-
isomer (1.3) of 1.1 were each synthesized. (The synthetic route to 1.2 and 1.3 was initially 
suggested by Prof. Mark Biscoe, and optimized by my colleague, Yadi Li.) The cis-isomer (1.2) 
was synthesized from 4-ethylcyclohexanone (Scheme 1.1A). 4-Ethylcyclohexanone was 
subjected to a Horner-Wadsworth-Emmons reaction to form the α,β-unsaturated ester, 1.2a. The 
cis-intermediate was achieved through selective reduction of 1.2a with L-selectride6, 7 to obtain 
the cis-ester, 1.2b. The bulkiness of L-selectride directed the reaction on the less hindered side 
resulting in the cis-ester. The ester, 1.2b, was then LAH reduced to the alcohol, 1.2c, which was 
PCC oxidized to the cis-aldehyde, 1.2.  
The trans-isomer, 1.3, was synthesized from the commercially available trans-4-
ethylcyclohexylcarboxylic acid (Scheme 1.1B). Since the starting compound already contains the 
1,4-trans structure, the trans-aldehyde, 1.3, was obtained after homologation of the 
functionalized chain. The carboxylic acid was LAH reduced to the alcohol, 1.3a, which was then 
PCC oxidized to the aldehyde 1.3b. Aldehyde 1.3b was homologated by an extra carbon via a 
Wittig reaction to form the alkene 1.3c. The alkene, 1.3c, was subjected to a hydroboration-
oxidation reaction to form the alcohol, 1.3d, which was then PCC oxidized to form the trans-
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aldehyde, 1.3. (For this study, 1.2 was synthesized from 4-ethylcyclohexanone following the 
procedures of Yadi Li and 1.3 was prepared from 1.3d, which was synthesized from trans-4-





Scheme 1.1: Synthesis of 1.2 and 1.3.  
 
1.2.2. Systems for testing 1.2 and 1.3 
4-Ethylcyclohexylacetaldehyde (1.1) was originally tested by the Firestein lab (Zita 
Peterlin, Columbia University) through calcium imaging of rat olfactory sensory neurons that 
were infected with an adenovirus encoding the rat OR-I7 and green fluorescent protein (GFP) to 
mark which cells were infected and expressing OR-I7,5 but this system was no longer available 
for testing 1.2 and 1.3. The cis- (1.2) and trans-isomer (1.3) were thus tested first by the 
Matsunami lab (Jianghai Ho, Duke University) using a luciferase assay9 on modified HEK293 
cells (called Hana3A cells) transfected with the OR-I7 receptor. The Matsunami lab found that 
the mouse I7 receptor (which differs by 15 amino acid residues compared to the homologous rat 
receptor, but which retains the aliphatic aldehyde pharmacology of the rat receptor10) is more 
highly and more reproducibly expressed in HEK293 cells, and so we switched to the mouse OR-
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I7. The luciferase technique developed in the Matsunami lab was implemented at elevated 
temperature (37°C) during which differential evaporation of odorants may occur (further 
explained in Section 2.2.1). Therefore, the cis- (1.2) and trans-isomer (1.3) of 4-
ethylcyclohexylacetaldehyde (1.1) were re-tested in our lab through calcium imaging on OSNs 
of a transgenic UBI7 mouse11, 12 (provided by Dr. Leonardo Belluscio at NIH). The UBI7 mice 
have a copy of the OR-I7 transgene (two copies in homozygous mice, which we used) “knocked 
in” at the olfactory marker protein (OMP) genomic loci. The OMP, and hence OR-I7, is 
expressed in all OSNs but expression starts when the cell attains maturity, while endogenous 
ORs begin expression earlier in development. The concentration level of OR-I7 expressed in this 
recombinant way is thus lower than the normal OR expression level. 
1.2.3. Limitations of the UBI7 mouse 
In rodents, each mature OSN chooses only one of the ~1100 olfactory receptors for 
expression.13-15 However, for the transgenic UBI7 mouse (i.e. the homozygous mice that we use; 
there are two copies of the transgene in each OSN), mature olfactory sensory neurons very likely 
express an endogenous receptor chosen earlier in development by the cell in addition to the OR-
I7 receptor (Figure 1.3).11, 12 (Here, expression means that the receptor’s messenger RNA, 
mRNA, is made by transcription of the transgene and then translated into protein that is 
transported to the cell membrane of the OSN in the cilia, the tip of the OSN’s dendrite.) At first, 
we expected octanal, an agonist of OR-I7, to activate 100% of the OSNs of the homozygous 
UBI7 mouse, instead of the ~6% OSNs (at 100 µM, Figure 1.4A) that are normally activated by 
octanal in wild-type (WT) mice. However, in UBI7 cells, the OR-I7 receptor is known to be 
expressed at a lower level compared to that of the endogenous receptors (possibly as low as <1% 
of the expression level of endogenous receptors12) due to the nature of the transgenic mouse 
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construction. While every cell should be expressing the OR-I7 receptor to some extent, the 
expression level may not be high enough to be detected by calcium imaging, which is less 
sensitive than the OR-I7 mRNA detection assay shown in Figure 1.3. Additionally, the 
expression level of the OR-I7 receptor may vary from cell to cell, due to differences in the 
development state of each neuron, preventing direct comparison of each cell’s absolute response. 
This is because the OR-I7 transgene is “knocked in” to the genomic location of both copies of 
the olfactory marker protein (OMP), which is turned on late during OSN development. At the 
time of a given experiment, some OSNs may not have very much OR-I7 on their cell surface, 
and may respond weakly or not at all, and the response in those cells may be dominated by the 
endogenous receptor, whose expression begins earlier in the development of the cell and whose 
identity cannot be determined in our experiments. Furthermore, the OR-I7 receptor is primarily 
transported to the cilia, but we lose the cilia during cell preparation (during dissociation of the 
olfactory epithelium tissue into individual cells), and consequently we lose a lot of the OR-I7 
receptor. For these reasons, before comparing the conformationally restricted octanal analogs in 
UBI7 OSNs, we attempted to estimate the percentage of UBI7 OSNs that actually respond to 














B. Expression of OR-I7 in a UBI7 mouse 
 
 
Figure 1.3: Expression of OR-I7 in a wild-type mouse (top, A) and a UBI7 mouse (bottom, B) (Data is provided by 
Dr. Leonardo Belluscio at NIH). Expression of the OR-I7 receptor is highlighted in purple. The red arrowheads 
point to presumed OSNs that express the endogenous OR-I7 receptor. This experiment detects the mRNA of the 
receptor. Darker color indicates higher amount of OR-I7 mRNA. 
 
1.2.4. Testing 1.2 and 1.3 on a UBI7 mouse 
To our knowledge, the calcium imaging method of detecting OR-I7 OSN activation has 
never been tested on UBI7 mice, and therefore it was crucial to determine if the response of the 
expressed OR-I7 receptors could actually be detected by calcium imaging. Octanal, a natural 
product agonist of the OR-I7 receptor, was tested on the OSNs of the UBI7 mouse to check for 
the OR-I7 response. The EC50 (concentration at which 50% of the maximal response is obtained) 
of octanal in OR-I7 receptor, expressed in rat neurons, is 1.8 µM, and by 10 µM octanal the 
receptor response is saturated.5 However, we do not know if this value holds for the mouse OR-
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I7 in the context of the UBI7 mouse, so we tested three concentrations, 3 µM, 10 µM, and 100 
µM.  
Moreover, OR-I7 is known not to be activated by the corresponding alcohol, 1-octanol.4 
Thus, 1-octanol (at 100 µM) was also tested as a control. Activation by octanal and 1-octanol 
could indicate that the response is coming from an endogenous receptor that also happens to 
respond to octanal, and not from transgenic OR-I7. Out of the ~1100 endogenous rodent 
olfactory receptors, there are about 55 octanal receptors16 and in one experiment, 68% of 
receptors activated by octanal were also activated by 1-octanol,17 so there is a high percentage of 
octanal-responding cells that also respond to 1-octanol. We want to ignore these cells because 
they have a high chance of not responding solely through OR-I7, the receptor we intend to study. 
Another consideration we must keep in mind in our calcium imaging experiments is that 
odorants that are applied to the cells earlier in the experiment tend to have slightly higher 
response than odorants applied later, and application of odorants at high concentrations could 
weaken or eliminate the response of odorants applied afterwards at lower concentrations, 
possibly due to desensitization of the receptor. (Desensitization occurs as a feedback mechanism 
to protect the cell from overstimulation.18) To minimize the effects of desensitization, the 
odorants were applied at the lower concentrations first, and the sample of cells was divided into 
four dishes, with the odorants tested at different orders in each dish.  
The solvent, DMSO, was applied to the cell as a negative control. Cells that respond to 
the solvent were not considered odorant-responding cells. Forskolin (10 µM), a molecule that 
generates a cellular response through bypassing the olfactory receptor to activate adenylyl 
cyclase in the signal transduction pathway, was applied at the end of the calcium imaging 
experiment to determine if the signal transduction pathway was still functioning at the end of the 
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experiment and estimate the cell’s maximum response range or full efficacy. (Efficacy describes 
the effect of a ligand on the functional properties of the receptor.19 In the absence of a ligand, 
most receptors exhibit some basal (i.e. ligand-independent) activation of its G-protein. The 
response of a receptor could change depending on the ligand which binds to it. An inverse 
agonist inhibits the basal activity, whereas an antagonist does not change the basal activity but 
prevent other ligands from binding. A full agonist fully activates the receptor (in vitro, for 
example, to the strength of response similar to a saturating amount of forskolin), while a partial 
agonist only activates the receptor at partial efficacy even at saturating concentration (i.e. it 
reaches a plateau below the full response of forskolin).) Cells that did not respond to forskolin 
were excluded from the analysis (regardless of whether these cells responded to the tested 
compounds). The calcium imaging responses of the tested compounds were all normalized to the 
response of 10 µM forskolin and all cells that responded to forskolin were considered viable 













1.3. Results and Discussion: 
1.3.1. Comparison of the UBI7 mouse to wild-type (WT) mice 
1.3.1.1. OR-I7 activation by octanal is detectable in UBI7 OSNs by calcium imaging 
A                                                                                             B 
 
Figure 1.4: Comparison of the calcium imaging response of OSNs from the UBI7 mouse and WT mice. (A) The 
chart compares the percentage of cells that respond to octanal (in general) at 3 µM, 10 µM, and 100 µM for WT 
mice and a UBI7 mouse (Data for the WT mice was supplied by my colleague, Mihwa Na. The response of 1-
octanol was not tested in these experiments.). (B) The chart compares the percentage of cells that respond to 1-
octanol and/or octanal for WT mice and a UBI7 mouse. (The data for the WT cells on Chart A were obtained from 
different experiments than Chart B. The data for the UBI7 cells on Chart A and Chart B were from the same 
experiment.) 
***Note: On Chart A, the percentages were determined from experiments done on 3 WT mice and one UBI7 mouse. 
The percentages were calculated relative to the number of forskolin-responding cells (WT: 9446, UBI7: 1852). On 
Chart B, the sample of cells for the WT mice was collected from a total of 7 mice (11707 viable cells, results given 
in chapter 3), whereas the UBI7 cells were obtained from one mouse (1852 viable cells). (More WT mice were used 
for the experiments to obtain additional odorant-responding cells for analysis. Since a high percentage of UBI7 cells 
responded to octanal, only one UBI7 mouse was needed.)  
 
Transgenic OR-I7 expression in the UBI7 OSNs caused a ~8-fold increase in octanal-
responding cells at 3 µM (WT-1.4%, UBI7-10.8%), a ~6-fold increase in octanal-responding 
cells at 10 µM (WT-2.2%, UBI7-13%), and a ~2.5-fold increase in octanal-responding cells at 
100 µM (WT-5.8%, UBI7-14.6%) compared to wild-type OSNs (Figure 1.4A). UBI7 cells that 
express the OR-I7 receptor should respond to octanal, but so would some small percentage of 
cells via their endogenous receptors. The percentage of UBI7 cells expressing endogenous 
receptors that normally respond to octanal (in addition to the OR-I7 receptor) should be similar 
































































WT @ 60 µM
UBI7 @ 100 µM
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which only express the endogenous receptors. The excess of UBI7 cells responding to octanal 
are therefore likely responding because they express the OR-I7 receptor at a sufficient expression 
level in addition to endogenous receptors that do not respond to octanal (at the given 
concentrations). Based on the difference in percentages between the WT cells and the UBI7 
cells, we could estimate that 87% (10.8%-1.4%/10.8% × 100%) of the octanal-responding UBI7 
cells at 3 µM, 83% (13%-2.2%/13% × 100%) at 10 µM, and 60% (14.6%-5.8%/14.6% × 100%) 
at 100 µM, owe their response to the expression of the OR-I7 receptor and an endogenous 
receptor that does not respond to octanal. 
We obtained similar results when comparing the 1-octanol-positive and 1-octanol-
negative responses in WT and UBI7 cells. As shown on Figure 1.4B, there was a ~6-fold 
increase in UBI7 cells that respond to octanal but not 1-octanol (WT: 1.6%, UBI7: 9.9%). From 
the difference in percentages, we could estimate that 84% (9.9%-1.6%/9.9% × 100%) of the 
octanal-responding cells that do not respond to 1-octanol owe their response to the expression of 
the OR-I7 receptor. There was a ~2.6-fold increase in UBI7 cells that respond to both 1-octanol 
and octanal (WT: 1.8%, UBI7: 4.7%), and a ~2.8-fold decrease in UBI7 cells that respond to 1-
octanol but not octanal (WT: 1.4%, UBI7: 0.5%) compared to WT cells. The increase in cells 
that respond to both 1-octanol and octanal coupled with the decrease in cells that respond to 1-
octanol (and not octanal) suggest that ~62% (4.7%-1.8%/4.7% × 100%) to ~64% (1.4%-
0.5%/1.4% × 100%) of the UBI7 cells which express endogenous receptors that normally 
respond to 1-octanol but not octanal were also expressing OR-I7. (Note: For experiments on WT 
cells in which 1-octanol and octanal were both tested, the concentration used was 60 µM, 
whereas 100 µM was used for UBI7 cells. Figure 1.4B provides a crude comparison between the 
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WT and UBI7 cells, but there would probably be some deviation in the actual percentage 
differences if the same concentrations were compared.) 
The percentage of UBI7 cells estimated to express the OR-I7 receptor and an endogenous 
receptor that do not respond to octanal (at the tested concentration) decreased as the 
concentration of octanal increased (87% at 3 µM, 83% at 10 µM, and 60% at 100 µM). As noted 
above, in rat neurons, the EC50 of octanal is about 1.8 µM and OR-I7 is saturated (reached 
maximum response) by 10 µM.5 Thus, the lowest concentration of octanal tested, 3 µM, may 
possibly already be sufficient to activate most of the mouse UBI7 cells that expressed an 
adequate level of the OR-I7 receptor. Assuming that the OR-I7 receptor was close to saturation 
at 3 µM, higher concentrations of octanal would only activate the same cells that were activated 
at 3 µM. But, as the concentration of octanal increased, various endogenous receptors (some 
broadly tuned perhaps) that do not respond to octanal at low concentration may start responding 
at the higher concentrations, and consequently the percentage of UBI7 cells estimated to respond 
to OR-I7 and an endogenous receptor that do not respond to octanal would drop as the 
concentration of octanal increased above the saturating concentration of 10 µM. Nevertheless, 
the increase in cells that respond to octanal for the UBI7 mouse indicates that OR-I7 was 
expressed at a sufficient level in at least ~60% (at 100 µM) to ~87% (at 3 µM) of the cells that 
respond to octanal, but the UBI7 cells’ responses at the lower concentration are probably more 
representative of the response of OR-I7. 
1.3.1.2. Removal of 1-octanol-responding cells  
UBI7 cells responding to octanal and 1-octanol are suspected to be responding to an 
endogenous octanal receptor that is not OR-I7 or to an endogenous receptor that responds to 1-
octanol co-expressed with the OR-I7 receptor. (As OR-I7 does not respond to 1-octanol,4 the 
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response to 1-octanol unquestionably arise from the endogenous receptor.) For the UBI7 OSNs, 
a total of 96 cells responded to 1-octanol (@ 100 µM). Usually, over half (56% @ 60 µM 
(1.8%/(1.4%+1.8%) × 100%, Figure 1.4B)) of the endogenous 1-octanol-responding cells are 
cells that respond to both 1-octanol and octanal. Thus, out of the 96 cells that responded to 1-
octanol, we could assume that around half of them were expressing endogenous receptors that 
responded to both octanal and 1-octanol based on the data for WT cells. These UBI7 cells may 
also be expressing a detectable level of the OR-I7 receptor, but the response of octanal that was 
stimulated by the OR-I7 receptor would likely be overlapping with the response that was 
produced by the endogenous receptor (that could also respond to octanal in addition to 1-
octanol). We decided to remove these cells from the analysis because the response of the 
endogenous receptor interferes with the OR-I7 response.  
All of the 1-octanol-responding UBI7 cells were excluded from the analysis to enrich for 
cells responding solely through OR-I7 (96 cells excluded, 213 cells remaining). In the process, 
we also removed the other half of the 96 1-octanol-responding cells that express endogenous 
receptors responding only to 1-octanol in addition to a sufficient level of the OR-I7 receptor. 
(Note: There were 9 cells that express endogenous receptors responding only to 1-octanol, but 
the expression of OR-I7 was evidently not sufficient to stimulate a calcium imaging response. 
These cells were removed from the analysis.) While the octanal response of the co-expressed 
OR-I7 receptor would not be affected in these cells, the UBI7 cells that express these 
endogenous receptors were still seen as cells that respond to both 1-octanol and octanal (same as 
the cells that express endogenous receptors that respond to both 1-octanol and octanal). We 
could not distinguish the response of the endogenous receptor and the response of OR-I7 for 
UBI7 cells that responded to both 1-octanol and octanal. By removing all of the 1-octanol-
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responding UBI7 cells, we are in effect removing half of all the octanal responses that are 
produced by endogenous receptors (overlapped with the octanal response produced by detectable 
levels of OR-I7) and increasing the signal from OR-I7. Thus, only the forskolin-responding cells 
that do not respond to 1-octanol were used to analyze the response of the cis- (1.2) and trans-
isomer (1.3). The number of cells that responded to each odorant at 3 µM, 10 µM, and 100 µM 
for each dish of cells tested are given in Figure 1.5. The calcium imaging response of a 
representative cell that responded to forskolin but not 1-octanol is shown on Figure 1.5A. This 
cell responded to octanal and the trans-isomer (1.3) but not to the cis-isomer (1.2) at 3 µM, 10 
µM, and 100 µM. 
1.3.2. Activation of OR-I7 by octanal, 1.2, and 1.3 
1.3.2.1. Trans-isomer is preferred by OR-I7 according to the number of cells activated 
The trans-isomer (1.3) had a similar amount of responding UBI7 cells compared to 
octanal at all three concentrations for Dish 1 and 3 (Figure 1.5). The trans-isomer (1.3) gave 
slightly more responding cells than octanal in Dish 2 and 4, but in these two dishes the trans-
isomer (1.3) was applied before octanal, and since there was a chance that the odorant applied 
later would give a weaker or no response due to desensitization,20 the difference may not be 
significant. 
1.3.2.2. Cis-isomer has weaker response than trans-isomer and octanal 
For all four dishes, the cis-isomer (1.2) activated fewer UBI7 cells compared to both the 
trans-isomer (1.3) and octanal at all three concentrations regardless of the order in which it was 
applied. We concluded that the cis-isomer (1.2) is a less potent OR-I7 agonist compared to 
octanal and the trans-isomer (1.3). Each cell may be expressing the OR-I7 receptor at different 
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levels, so it was not possible to obtain the EC50 value for each odorant, but apparently fewer cells 







Figure 1.5: Response of cells to octanal, 1.2 (cis-isomer), and 1.3 (trans-isomer). (A) The calcium imaging response 
of a representative cell that responded to forskolin, octanal and the trans-isomer (1.3), but not the cis-isomer (1.2) 
nor 1-octanol. (B) Graphs representing the response of all the UBI7 cells that do not respond to 1-octanol (the total 
number of cells analyzed is given in the title of each graph). The odorants are shown in the order in which they were 
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1.3.3. Response strength of octanal, 1.2, and 1.3 








Figure 1.6: Percentage of cells responding to different 
odorant(s) types. 
***All cells that responded to 1-octanol (96 cells) were 
excluded in this analysis. The number of cells 
responding to the odorant(s) in each category at 3, 10 
and 100 µM is given in parentheses. 
 
 
All of the UBI7 cells were assumed to express the OR-I7 receptor, but the expression 
level in some cells (at least 9%, as evident from the cells that respond to only 1-octanol 
(9/(9+87)) ×100%, Figure 1.4B) may not be high enough to be detected by calcium imaging. For 
such cells, only the response of the endogenous receptor would be detected. From comparison of 
the octanal responses for the WT cells and the UBI7 cells, we were also aware that ~13% of the 
UBI7 cells at 3 µM (1.4%/10.8% × 100%, Figure 1.4A), ~17% at 10 µM (2.2%/13% × 100%, 




























































stimulated by the endogenous receptors. When we categorized the responses of the UBI7 cells at 
3 µM, 10 µM, and 100 µM, a minority of cell types were activated as the concentration increased 
from 3 µM to 100 µM (Figure 1.6), which we believe to be the response of the endogenous 
receptor only. Since the OR-I7 receptor was expressed in a majority of the UBI7 cells (~60-87%, 
based on comparison of WT and UBI7 cells, Figure 1.4A), the responses from the categories of 
cells that made up less than 10% of the total cell population (i.e. the cells that respond to 1) the 
cis-isomer (1.2) and octanal only, 2) the cis-isomer (1.2) and the trans-isomer (1.3) only, 3) the 
cis-isomer (1.2) only, and 4) octanal only) were most likely not the response of OR-I7. However, 
the response of all these cells was included in the analysis on Figure 1.5.  
To reduce the chance of including the response of endogenous receptors in the analysis, 
only the cells in the most common categories, the cells that respond to 1) octanal, the cis-isomer 
1.2, and the trans-isomer 1.3 (47.40%-58.22%, Figure 1.6), 2) the trans-isomer 1.3 and octanal 
(17.84%-34.10%, Figure 1.6), and 3) the trans-isomer 1.3 only (8.92%-16.76%, Figure 1.6) were 
now considered. Cells that respond only to the trans-isomer (1.3) and octanal (17.84%-34.10%) 
apparently indicate that the trans-isomer (1.3) and octanal are both more potent OR-I7 agonists 
than the cis-isomer (1.2), and cells that respond only to the trans-isomer (1.3) (8.92%-16.76%) 
suggest that the trans-isomer (1.3) is more potent than both the cis-isomer (1.2) and octanal. 
(Note: The trans-isomer (1.3) was applied before octanal in 3 out of the 4 dishes of cells tested, 
and that may cause the octanal response to be desensitized.) The only category in which the 
relative potency of the three odorants (in relation to each other) remains ambiguous is the cells 
that respond to the cis-isomer (1.2), the trans-isomer (1.3), and octanal (47.40%-58.22%). To 
compare the response strength of the cis-isomer (1.2), the trans-isomer (1.3) and octanal, we first 
looked at the overall average response levels (the response levels, normalized to the response of 
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forskolin, for these cells were averaged; forskolin is considered to activate the cell at 100%), and 




Figure 1.7: Response level of cells (124 total cells by 100 µM) that respond to octanal, the cis-isomer 1.2, and the 
trans-isomer 1.3. The graphs show the average response for all the cells in each dish (total cells on the title of the 
graph) that respond to all three odorants. (Average reponse were normalized to the response of forskolin calculated 
by ‘response of odorant’/ ‘response of forskolin’ × 100%. The calcium imaging response is the ratio of the 
flourescence emission at 340 nm and 380 nm, F340/F380.) 
 
Although these UBI7 cells (82 cells @ 3 µM, 104 cells @ 10 µM, and 124 cells @ 100 
µM) responded to all three odorants, the average response (agonist efficacy) of the cis-isomer 
(1.2) is on average much lower (~2X lower) than the response of the trans-isomer (1.3) and 
octanal for all four dishes regardless of the order of application (Figure 1.7). This evidence 
further supports the idea that the OR-I7 receptor prefers the trans-isomer (1.3) over the cis-
isomer (1.2) of 4-ethylcyclohexylacetaldehyde (1.1) and hence prefers the specific octanal 
conformation between C6-C7 that is mimicked by the trans-isomer (1.3) over the conformation 






























































































































1.3.3.2. The cis-isomer is a partial agonist of OR-I7 
As an agonist of OR-I7, octanal should be able to fully activate the OR-I7 receptor, but 
since the expression level of OR-I7 varied from cell to cell (coupled with the possibility of 
desensitization), octanal may not reach the maximum response level of forskolin in every cell. 
However, the average response of the cis-isomer (1.2) was clearly lower than that of the trans-
isomer (1.3) and octanal (regardless of the order in which it was applied) even at the highest 
concentration, 100 µM (Figure 1.7). Out of the cells that responded to all three odorants (the cis-
isomer (1.2), the trans-isomer (1.3), and octanal), the cis-isomer (1.2) had the lowest response in 
51 out of 82 cells at 3 µM (62.2%, Figure 1.8A, cell #1-51), 73 out of 104 cells at 10 µM 
(70.2%, Figure 1.8B, cell #1-73), and 75 out of 124 cells at 100 µM (60.5%, Figure 1.8C, cell 
#1-75). There exist a minority of cells in which the cis-isomer (1.2) has a 1) similar response 
level to the trans-isomer (1.3) and octanal (14 cells @ 3 µM (17.1%), Figure 1.8A, cell #52-65; 
13 cells @ 10 µM (12.5%), Figure 1.8B, cell #74-86; 13 cells @ 100 µM (10.5%), Figure 1.8C, 
cell #100-112), 2) similar response level as either the trans-isomer (1.3) or octanal (17 cells @ 3 
µM (20.7%), Figure 1.8A, cell #74-82; 17 cells @ 10 µM (16.3%), Figure 1.8B, cell #87-103; 32 
cells @ 100 µM (26%), Figure 1.8C, cell #76-99, 113-120), or 3) higher response than both the 
trans-isomer (1.3) and octanal (0 cell @ 3 µM; 1 cell @ 10 µM (1%), Figure 1.8B, cell #104; 4 
cells @ 100 µM (3%), Figure 1.8C, cell #121-124). However, we point out that any trend 
involving such small minority of cells is likely due not to OR-I7 but to an endogenous receptor, 
which will vary from cell to cell while OR-I7 remains constant. That is, a few endogenous 
receptors may be present that are selective for the cis-isomer (1.2) (and/or the trans-isomer (1.3) 
and/or octanal). Since the OR-I7 receptor was expressed in a majority of the UBI7 cells (at least 
60% of the octanal-responding cells at 100 µM and up to ~87% at 3 µM), we attributed the 
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response of the most general group, the cells in which the cis-isomer (1.2) had the lowest 
response (which constitute 60.5%-70.2% of the total population of cells that respond to 1.2, 1.3, 
and octanal between 3 µM and 100 µM), to be the response of OR-I7. As the response of the cis-
isomer (1.2) was systematically lower than that of octanal and the trans-isomer (1.3), we 
conclude that the cis-isomer (1.2) is a partial agonist of OR-I7: it activates the receptor at partial 
efficacy, but even at high concentration fails to achieve the maximum response. As observed for 
the calcium imaging response of cell C66 (Figure 1.8D), the cis-isomer (1.2) was unable to 

























Figure 1.8: Calcium imaging response of cells that respond to the cis-isomer (1.2), the trans-isomer (1.3) and 
octanal. (A) Relative response of the 82 cells to the cis-isomer (1.2), the trans-isomer (1.3), and octanal at 3 µM. (B) 
Relative response of the 104 cells to the cis-isomer (1.2), the trans-isomer (1.3), and octanal at 10 µM. (C) Relative 
response of the 124 cells to the cis-isomer (1.2), the trans-isomer (1.3), and octanal at 100 µM. Each row represents 
the relative response (normalized to the response of forskolin calculated by ‘response of odorant’/ ‘response of 
forskolin’ × 100%) of one cell to the odorants. The cell was tested in the dish, denoted by D and the dish number, 
designated on the column to the right of the odorants’ responses. (The odorants’ responses were arranged in the 
same order for clarity, but the order of odorant application was different for each dish (Refer to Figure 1.5 or 1.7 for 
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level.) The response of the corresponding cell at each concentration can be identified by the cell ID number given in 
parentheses. Cells that do not respond to all three odorants (1.2, 1.3, and octanal) at the lower concentrations were 
not included in Panel A and B. (D) The calcium imaging response of a representative cell (C66) displaying partial 
activation by the cis-isomer (1.2).  
(Note: Responses lower than 10% of the response of forskolin were usually not considered activating, but for cell 
C74 and C75, the cis-isomer (1.2) did elicit a response higher than 10% at the lower concentrations, but the signal 
probably was desensitized to be under 10% by 100 µM. For these two cells, there was a cis-isomer (1.2) response at 
100 µM, but the response level was lower than 10%. Therefore, these cells were categorized as cells that respond to 
octanal, the cis-isomer (1.2), and the trans-isomer (1.3), instead of as cells that respond only to octanal and the 
trans-isomer (1.3).) 
 
 The cis- (1.2) and trans-isomers (1.3) were also tested using the luciferase assay on 
HEK293 cells transfected with the OR-I7 receptor gene.8 The relative ranking of potency (data 
not shown) was in agreement with our data (although the receptor did not reach saturation at the 
concentrations tested). The cis-isomer (1.2) was found to have a weaker response than the trans-
isomer (1.3). 
Lastly, we note that in a majority of the cells, the response of the trans-isomer (1.3) is the 
same as if not stronger than the response of octanal. As previously mentioned, one of the most 
common group of cells in this experiment are the cells that respond only to the trans-isomer (1.3) 
(Figure 1.6). Response to solely the trans-isomer (1.3) signifies that the trans-isomer (1.3) is 
more potent than both octanal and the cis-isomer (1.2) in these cells. From Figure 1.8A, it could 
already be seen that not only is the response of the trans-isomer (1.3) higher than that of the cis-
isomer (1.2), but it is also higher than the response of octanal in a majority of the cells. 
Comparing the response level of the trans-isomer (1.3) with that of octanal in the second most 
common cell category (the cells that respond to the trans-isomer (1.3) and octanal, but not the 
cis-isomer (1.2)), the trans-isomer (1.3) gave a higher response than octanal in 71% (42 out of 59 
cells) of the cells at 3 µM, 58% (28 out of 48 cells) of the cells at 10 µM, and 42% of the cells 
(16 out of 38 cells) at 100 µM (Figure 1.9). Only in a low percentage of the cells (3% @ 3 µM (1 





Figure 1.9: Calcium imaging response of cells that respond to the trans-
isomer (1.3) and octanal. (A) Relative response of the 59 cells to the 
trans-isomer (1.3) and octanal at 3 µM. (B) Relative response of the 48 
cells to the trans-isomer (1.3) and octanal at 10 µM. (C) Relative 
response of the 38 cells to the trans-isomer (1.3) and octanal at 100 µM. 
Each row represents the relative response (normalized to the response of 
forskolin calculated by ‘response of odorant’/ ‘response of forskolin’ × 
100%) of one cell to the odorants. The cell was tested in the dish, 
denoted by D and the dish number, designated on the column to the right 
of the odorants’ responses. (The odorants’ responses were arranged in 
the same order for clarity, but the order of odorant application was 
different for each dish (Refer to Figure 1.5 or 1.7 for the order of 
application in each dish.), and the order in which the odorants were 
applied may affect the response level.) 
(Note: Responses lower than 10% of the response of forskolin were 
usually not considered activating, but for one cell (row 31) on Panel C 
(@ 100 µM), octanal did elicit a response higher than 10% at the lower 
concentrations, but the signal probably was desensitized to be under 
10% by 100 µM. For this cell, there was an octanal response at 100 µM, 
but the response level was lower than 10%. Therefore, this cell was 
categorized as a cell that responds to octanal and the trans-isomer (1.3), 
instead of a cell that respond only to the trans-isomer (1.3).) 
 
than that of the trans-isomer (1.3). (The rest of the cells (25-
39% from 3-100 µM) gave similar responses to the trans-
isomer (1.3) and octanal (Figure 1.7).) These data support 
the conclusion that the trans-isomer (1.3) is more potent 
than octanal and the geometric relationship between the 
aldehyde group and the last two carbons on the chain of 
octanal is favorably mimicked by the trans-isomer (1.3) 
without the loss of entropy during binding. In other words, 
the conformation of the trans-isomer (1.3) may be favorably 
pre-organized, and resemble the bound conformation of 
octanal in complex with rodent OR-I7. 
 
 




1.3.4. A molecular explanation for our data: The OR-I7 receptor has carbon chain 
conformational sensing ability 
Besides having a shorter chain length when in the chair conformation (cis: 6.9 Å, trans: 
7.8 Å) than the trans-isomer (1.3), the ethyl group on the cis-isomer (1.2) is also at a different 
position from the ethyl group on the trans-isomer (1.3) in relation to the aldehyde group (Figure 
1.10, Figure 1.11A). The trans-isomer (1.3) has higher potency and efficacy than the cis-isomer 
(1.2), so the position of the ethyl group (i.e. the orientation of the C6-C7 bond) on the trans-
isomer (1.3) should be more favorable for activation of the OR-I7 receptor.  
 
A Line Structures and length 
       
        1.2 (chair)                              1.2 (twist-boat)   
            6.9 Å                                          7.5 Å 
 
          1.3 (chair)                          1.3 (twist-boat) 
              7.8 Å                                      6.6 Å 
 






1.2 (chair) 1.2 (twist-boat) 1.3 (chair) 1.3 (twist-boat) 
46.0 kJ/mol 68.5 kJ/mol 39.8 kJ/mol 76.6 kJ/mol 
 
Figure 1.10: Conformations of 1.2 and 1.3. (A) Line structures and lengths of 1.2 and 1.3 in the chair and twist-
boat conformation (the distance from the carbonyl carbon to the carbon on the ethyl group, indicated by the red 
dashed line, was calculated on Avogadro21). (B) 3D Ball and stick model and the minimized energy for 1.2 and 1.3 
in the chair and twist-boat conformation. Energy minimization/optimization was done on Avogadro21 using a 
MMFF94 force field with the cyclohexyl ring fixed in the chair or twist-boat conformation. 
 
However, we noticed that if the cis-isomer (1.2) flips into the higher energy twist-boat 
conformation, the length of the cis-isomer (1.2) (7.5 Å) comes close to the length of the trans-
isomer (1.3) (7.8 Å), and the ethyl group becomes oriented in a similar position as the ethyl 
group of the trans-isomer (1.3) (in the chair conformation) (Figure 1.10A and Figure 1.11B). 
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Our data support the idea that the cis-isomer (1.2) activates the OR-I7 receptor when in the 
twist-boat conformation, but the energy cost required to switch from the chair conformation 
(46.0 kJ/mol, calculated in Avogadro21) to the twist-boat conformation (68.5 kJ/mol, calculated 
in Avogadro21) lowers the potency of the cis-isomer (1.2) and prevents it from achieving full 
efficacy, hence it is a partial agonist of OR-I7. 
A B  
Figure 1.11: Overlapping 3D models. (A) 
3D model of the cis-isomer 1.2 in the chair 
conformation (carbons: yellow; oxygen: 
blue) overlapping with the trans-isomer 1.3 
in the chair conformation (carbons: gray; 
oxygen: red). (B) 3D model of the cis-isomer 
1.2 in the twist-boat conformation (carbons: 
yellow; oxygen: blue) overlapping with the 
trans-isomer 1.3 in the chair conformation 
(carbons: gray; oxygen: red).  
***Molecular modeling and energy 
minimization/optimization were done on 
Avogadro21 using a MMFF94 force field 
with the cyclohexyl ring of the cis-isomer 1.2 
fixed in the twist-boat conformation and the 
cyclohexyl ring of the trans-isomer 1.3 fixed 
in the chair conformation. 
 
  
            Front View      Side View 
 
1.2 (chair conformation) 
overlapping with 1.3 (chair 
conformation) 
 
1.2 (twist-boat conformation) 




 4-Ethylcyclohexylacetaldehyde (1.1) 
(EC50=1.0 µM, as a cis-trans mixture) was 
previously found to have approximately equal 
potency compared to octanal (EC50=1.8 µM), 
suggesting that the OR-I7 receptor tolerates the 
gauche conformation of octanal during activation.5 The cis- (1.2) and trans- (1.3) isomers of 1.1 
mimicked two of the possible conformations that could be adopted by octanal while in the 
gauche conformation. Analog 1.2 and 1.3 have been synthesized and tested on the olfactory 
sensory neurons of a UBI7 mouse that express the OR-I7 receptor in addition to the endogenous 
  
Conformation of 
octanal mimicked by 
the cis-isomer (1.2) 
Conformation of 
octanal mimicked by 




receptors through calcium imaging. Based on the increase in the percentage of cells that respond 
to octanal, we concluded that most of the UBI7 cells (~60% at 100 µM to ~87% at 3 µM) 
expressed a functional level of the OR-I7 receptor. The potency of the trans-isomer (1.3) is 
comparable to (but consistently higher than) that of octanal, whereas the cis-isomer (1.2) was 
found to be a less potent OR-I7 agonist than the trans-isomer (1.3) and octanal. Thus, the 
conformation of the C6-C7 bond of the trans-isomer (1.3) is a better mimic of octanal’s 
conformation during activation of the OR-I7 receptor. The cis-isomer (1.2) could orient its ethyl 
group into a similar position as the trans-isomer (1.3) after converting from the chair to the twist-
boat conformation, but the energy cost for adopting this conformation probably lowers the 
efficacy of the cis-isomer (1.2), making it a partial agonist of the OR-I7 receptor.  
 Since octanal may adopt hundreds of different conformations, its most stable (lowest 
energy) conformation, may not be its actual activating conformation, and thus there may be an 
entropy penalty when octanal binds OR-I7 in a preferred conformation, and this penalty may in 
part explain octanal’s relatively weak potency (EC50: 1.8 µM5). If octanal’s structure could be 
constrained into its activating conformation, the efficacy would most likely rise as the entropy 
loss is reduced, leading to a more favorable ∆G and a more potent OR-I7 agonist. It’s not 
possible to test all of the conformations of octanal to find its optimal activating conformation, but 
the cis- (1.2) and trans-isomer (1.3) represent two of the conformations that could be adopted by 
octanal, and from this study, we can conclude that the conformation of octanal mimicked by the 
trans-isomer (1.3) is more preferable compared to that of the cis-isomer (1.2). While the trans-
isomer (1.3) may not be the actual conformation of octanal when activating OR-I7, it is at least a 
conformation that is acceptable by the OR-I7 receptor and favorable (i.e. a closer to the actual 
bound, activating conformation).  
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 The difference in potency between the cis-isomer (1.2) and the trans-isomer (1.3) 
indicates that the OR-I7 receptor has a preference for the conformation of its ligand during 
activation. As with the OR-I7 receptor, other ORs may exist with preferences for their ligands’ 
conformations. These results are significant because there is no structural biology information 
enlightening how the mammalian odorant receptors bind their ligands. Many odorants have 
flexible carbon chains, while protein-small molecule crystal structures, including the many 
GPCR X-ray structures now available, teach us that attractions like H-bonds fix small molecule 
conformations upon binding. But how can this apply to odorants, which in order to become 
volatile must have few or no H-bonds available for binding? Our results provide experimental 
data supporting the idea that even a flexible hydrophobic carbon chain can adopt a preferred 
conformation upon binding and activating an odorant receptor. It is possible that many other 
odorant receptors function as conformational sensors of odorant carbon chain, and this allows 
them to contribute to the olfactory code and through this, natural selection during evolution. 
Many natural fragrances, such as the santalols, ionones, and the patchoulenes contain 
elaborate carbon ring systems and/or double bonds that place a degree of restriction on the 
conformation of the odorant. Such odorants may be conformationally restricted versions of linear 
compounds that activate the receptors with lower potency and efficacy. 
1.5. Experimental Procedures 
1.5.1. Materials and reagents 
Unless otherwise stated, chemical reagents and solvents were purchased from VWR 
International, Fisher Scientific, or Sigma Aldrich and used without further purification. UBI7 
mouse11, 12 was provided by Dr. Leonardo Belluscio (NIH/NINDS). Octanal was distilled before 
use. Aldehydes were stored at 4°C under vacuum prior to testing. Analytical TLC was performed 
29 
 
on silica gel 60 F254 plates. Flash chromatography22 was performed on Teledyne Isco 
CombiFlash Rf-200 flash chromatography system or manually in glass columns with 230-400 
mesh silica gel. 1H and 13C NMR spectra were recorded on a Varian Mercury 300 spectrometer 
or a Bruker Ultrashield 500 spectrometer. HRMS was performed by Dr. Lijia Yang (CCNY 
Chemistry Department staff) on a Waters LCT XE (TOF) mass spectrometer using electrospray 
ionization (ESI). Infrared (IR) spectra were recorded using Thermo Nicolet 6700 FT-IR 
spectrometer. GC analyses were performed on a Shimadzu GC-2010 gas chromatograph with an 
FID detector using a 15 m × 0.25 mm capillary column with dimethyl polysiloxane as the 
stationary phase. Compound 1.2 and 1.3 were first synthesized and characterized by Yadi Li8 
with helpful advice from Dr. Mark Biscoe on the synthetic routes to the two isomers. Compound 
1.2 was synthesized for this study following his procedures, and compound 1.3 was synthesized 
from 1.3d, provided by Yadi Li. (Note: The literature procedure that was applied for each 
reaction is cited. The procedure may not necessarily be used for the synthesis of the same 
compound as in the literature.) 
General Procedure for Lithium Aluminum Hydride (LAH) reduction5  
The acid or ester (1 equiv.) in diethyl ether was added slowly to lithium aluminum hydride (1.1 
equiv.) in diethyl ether at 0°C. The suspension was stirred at room temperature for 2-3 h and then 
cooled to 0°C. Water (1 mL per g of LAH) was added, followed by 15% sodium hydroxide (1 
mL per g of LAH) and water (3 mL per g of LAH). The solution was stirred for a few minutes at 
room temperature, filtered through a celite pad, washed with diethyl ether, dried, and 





General Procedure for Pyridinium chlorochromate (PCC) oxidation5 
The alcohol (1 equiv.) was added to pyridinium chlorochromate (1.1 equiv.) and silica gel (1 g/g 
of PCC) in dry dichloromethane under inert atmosphere. The suspension was stirred for 2 h and 
then passed through a silica gel pad. The solution was concentrated to give the aldehyde. Flash 
chromatography or distillation was sometimes required to purify the product.  
Ethyl 2-(4-ethylcyclohexylidene)acetate (1.2a). Compound 1.2a was synthesized 
following a literature procedure.5 Ethyl 2-(diethoxyphosphoryl)acetate (8.88 g, 
39.6 mmol) in THF (15 mL) was slowly added to sodium hydride, 57-63% in oil, 
(1.6 g, 40 mmol) in THF (50 mL). The mixture was stirred at room temperature 
for 1 hour and 4-ethylcyclohexanone (5 g, 39.6 mmol) in THF (10 mL) was slowly added so that 
the temperature of the mixture was below 30°C. The solution was stirred for 15 minutes and then 
quenched with water. The aqueous layer was extracted with diethyl ether. The organic layer was 
dried, concentrated, and purified by flash chromatography eluting with hexanes/ethyl acetate 
(19:1) to give 1.2a (2.7 g, 13.8 mmol) as a clear liquid in 35% yield. . 1H NMR (CDCl3) : 5.62 
(s, 1H), 4.16 (q, J = 7.2 Hz, 2H), 3.82 - 3.70 (m, 1H), 2.35 - 2.11 (m, 2H), 2.03 - 1.86 (m, 3H), 
1.50 - 1.21 (m, 6H), 1.18 - 1.01 (m, 2H), 0.99 - 0.84 (m, 3H). 13C NMR (CDCl3) δ: 166.87, 
163.56, 113.00, 59.46, 38.93, 37.31, 34.18, 33.46, 29.00, 28.95, 14.33, 11.60. IR (thin film, KBr 
plates), ν (cm-1): 2932, 2855, 1715, 1649, 1380, 1235, 1186, 1150. Spectral data agree with those 
reported previously.5, 23 
Ethyl 2-(cis-4-ethylcyclohexyl)acetate (1.2b). Compound 1.2a (2 g, 10.2 mmol) in 
THF (10 mL) was slowly added to 1 M L-selectride6, 7 in THF (30.5 mL, 30.5 
mmol) so that the temperature of the mixture was below -70°C. The mixture was 





followed by ethyl acetate (14.4 mL), pH=7 phosphate buffer (0.1 M, 6.4 mL), and 30% hydrogen 
peroxide solution (8.8 mL). The mixture was stirred overnight. The aqueous and organic layers 
were partitioned and the aqueous layer was extracted with ethyl acetate. The combined organic 
layer was extracted with brine, dried, concentrated and purified by chromatography eluting with 
hexanes/ethyl acetate (49:1) to give 1.2b (0.2 g, 1 mmol) as a clear liquid in 10% yield. 1H NMR 
(CDCl3) : 4.20 - 4.09 (m, 2H), 2.29 (d, J = 7.5 Hz, 2H), 2.05 (m, 1H), 1.60 - 1.20 (m, 14H), 
0.98 - 0.81 (m, 3H). 13C NMR (CDCl3) δ: 173.45, 60.08, 39.30, 37.03, 32.54, 28.76, 28.24, 
26.96, 14.30, 11.84. IR (thin film, KBr plates), ν (cm-1): 2960, 2921, 2855, 1736, 1451, 1297, 
1219, 1171, 1123, 1035. HRMS (ESI) [M+Na]+: Calcd for C12H22O2 m/z = 221.1512, found m/z 
= 221.1511. 
2-(cis-4-Ethylcyclohexyl)ethanol (1.2c). Compound 1.2b (0.2 g, 1 mmol) was LAH 
reduced according to the general procedure to obtain 1.2c (0.085 g, 0.54 mmol) as a 
clear liquid in 54% yield. 1H NMR (CDCl3) : 3.75 - 3.66 (m, 2H), 1.69 - 1.42 (m, 
7H), 1.42 - 1.17 (m, 8H), 1.02 - 0.83 (m, 3H). 13C NMR (CDCl3) δ: 61.39, 37.25, 
37.15, 31.76, 28.97, 28.42, 27.01, 11.88. IR (thin film, KBr plates), ν (cm-1): 3331 (broad), 2959, 
2919, 2873, 2853, 1450, 1378, 1062, 1011, 978. HRMS (ESI) [M+Na]+: Calcd for C10H20O m/z 
= 179.1406, found m/z = 179.1432. 
2-(cis-4-Ethylcyclohexyl)acetaldehyde (1.2). Compound 1.2c (0.04 g, 0.26 mmol) was 
PCC oxidized according to the general procedure to obtain 1.2 (0.03 g, 0.19 mmol) as a 
clear liquid in 76% yield. The product contains 95.6% of the cis-isomer 1.2 and 4.4% 
of the trans-isomer 1.3 according to GC analysis. 1H NMR (CDCl3) : 9.78 (t, J = 2.4 
Hz, 1H), 2.41 (dd, J = 2.4, 7.2 Hz, 2H), 2.24 - 2.12 (m, 1H), 1.63 - 1.48 (m, 4H), 1.46 - 1.21 (m, 





11.81. IR (thin film, KBr plates), ν (cm-1): 2960, 2921, 2855, 2711, 1726, 1451, 1378. HRMS 
(ESI) [M+Na]+: Calcd for C10H18O m/z = 177.1250, found m/z = 177.1251. 
(trans-4-Ethylcyclohexyl)methanol (1.3a). (trans-4-Ethylcyclohexyl)carboxylic acid 
(5.7 g, 36 mmol) (purchased from OChem Incorporation) was LAH reduced 
according to the general procedure to obtain 1.3a (5 g, 35 mmol) as a clear liquid in 
97% yield. 1H NMR (CDCl3) δ: 1H NMR (CDCl3) : 3.47 (d, J = 6.2 Hz, 2H), 1.90 - 1.71 (m, 
4H), 1.54 - 1.36 (m, 1H), 1.29 - 0.83 (m, 11H). 13C NMR (CDCl3) δ: 68.83, 40.70, 39.59, 32.26, 
29.96, 29.49, 11.51. IR (thin film, KBr plates), ν (cm-1): 3330 (broad), 2960, 2915, 2852, 1448, 
1379, 1100, 1072, 1036, 1003, 964, 896. 
(trans-4-Ethylcyclohexyl)carbaldehyde (1.3b). Compound 1.3a (3 g, 21 mmol) was 
PCC oxidized according to the general procedure to obtain 1.3b (2.7 g, 19 mmol) as a 
clear liquid in 91% yield. The aldehyde is prone to oxidation in air so it was used 
immediately for the next step without further purification. 
trans-1-Ethyl-4-vinylcyclohexane (1.3c). Compound 1.3c was synthesized based on a 
literature procedure.5 To an ice-cooled mixture of methyl triphenylphosphonium 
bromide (10.33 g, 29 mmol) in dry THF (75 mL) was added 1.6 M n-BuLi solution 
(16.9 mL, 27 mmol). The mixture was stirred at 0°C for 30 minutes, and then cooled to -75°C. 
Compound 1.3b (2.7 g, 19 mmol) in THF (25 mL) was added dropwise. The mixture was stirred 
at -75°C for 3 hours. Ammonium chloride solution was added and the layers were separated. The 
organic layer was extracted with water, brine, and dried. The crude was purified by 
chromatography eluting with pentane to give 1.3c (2.5 g, 18 mmol) as a clear liquid in 95% 






1.65 (m, 3H), 1.39 - 1.01 (m, 6H), 1.01 - 0.70 (m, 6H). 13C NMR (CDCl3) δ: 145.09, 111.79, 
42.15, 39.31, 32.73, 31.84, 30.23, 22.91, 14.39, 11.76. 
2-(trans-4-Ethylcyclohexyl)ethanol (1.3d). Compound 1.3d was synthesized based 
on a literature procedure.5 1 M Borane tetrahydrofuran complex solution in THF (9 
mL, 9 mmol) was added dropwise to a solution of 1.3c (2.5 g, 18 mmol) in THF (50 
mL). After 15 minutes, saturated sodium carbonate solution (6.2 mL) and 30% 
hydrogen peroxide solution (3.68 mL, 36 mmol) were added. The mixture was stirred for 2 
hours. Water (50 mL) was added and the layers were separated. The aqueous layer was extracted 
with diethyl ether. The combined organic layers were washed with brine, dried, and 
concentrated. The crude product was purified by chromatography eluting with 
acetonitrile/dichloromethane/cyclohexane (1:9:10) to give 1.3d (1.2 g, 7.8 mmol) as a clear 
liquid in 43% yield. 1H NMR (CDCl3) : 3.70 (t, J = 6.8 Hz, 2H), 1.86 - 1.65 (m, 4H), 1.57 - 1.44 
(m, 3H), 1.41 - 1.29 (m, 1H), 1.27 - 0.81 (m, 10H). 13C NMR (CDCl3) δ: 60.99, 40.36, 39.49, 
34.46, 33.30, 32.77, 30.00, 11.51. IR (thin film, KBr plates), ν (cm-1): 3323 (broad), 2960, 2916, 
2851, 1448, 1378, 1046. HRMS (ESI) [M+Na]+: Calcd for C10H20O m/z = 179.1406, found m/z = 
179.1431. 
2-(trans-4-Ethylcyclohexyl)acetaldehyde (1.3). Compound 1.3d (0.3 g, 1.92 mmol) 
was PCC oxidized according to the general procedure to give 1.3 (0.17 g, 1.1 mmol) as 
a clear liquid in 57% yield. 1H NMR (CDCl3) : 9.78 (t, J = 2.4 Hz, 1H), 2.31 (dd, J = 
2.3, 6.7 Hz, 2H), 1.93 - 1.72 (m, 5H), 1.29 - 1.18 (m, 2H), 1.16 - 0.85 (m, 8H). 13C 
NMR (CDCl3) δ: 203.07, 51.37, 39.04, 33.17, 32.95, 32.52, 29.87, 11.46. IR (thin film, KBr 
plates), ν (cm-1): 2960, 2919, 2852, 2711, 1726, 1448, 1378. HRMS (ESI) [M+Na]+: Calcd for 





1.5.2. Calcium imaging of mouse olfactory sensory neuron 
Calcium imaging was performed as described previously.5 All animal procedures were approved 
by the City College of New York Institutional Animal Care and Use Committee (IACUC) and 
performed at the City College of New York in compliance with relevant national guidelines and 
regulations. Olfactory epithelium tissues were obtained from a 16 week old UBI7 mouse by my 
colleague, Mihwa Na. The tissues were placed into a conical tube containing an enzyme solution 
made with BSA (0.015 g), collagenase (0.0025 g), and 3 mL of DICAT-free Ringer solution 
containing sodium chloride (145 mM), potassium chloride (5.6 mM), HEPES at pH 7.4 (10 
mM), glucose (10 mM), and EGTA (4 mM). The cells were incubated at 37°C for 1 h in the 
enzyme solution. The tissues were then allowed to settle to the bottle of the conical tube and the 
enzyme solution was replaced with a media containing DMEM/F12-HAM, 10% FBS (Gibco), 
1% Pen/Strep (Gibco), and 1X Insulin-Transferrin-Selenium-X (Gibco). Most of the media was 
removed and the tissues were gently vortexed to dissociate the cells. The cells were applied onto 
four coverslips pre-coated with concanavalin A. The cells were allowed to recover in the media 
containing 0.02 M vitamin C (ascorbic acid) at 37°C for 45 minutes. The media was then 
replaced with 1 mL of Ringer solution (sodium chloride (138 mM), potassium chloride (5 mM), 
HEPES at pH 7.4 (10 mM), calcium chloride (1 mM), magnesium chloride (1.5 mM), and 
glucose (10 mM)) containing Fura-2 (6.25 µL) and pluronic acid (1 µL), and incubated for 
another 45 minutes at room temperature in the dark. The cells were placed in new Ringer 
solution and left at room temperature for 10 minutes. The coverslip containing the cells were 
viewed under a fluorescence microscope and the response was obtained using Metamorph. 
Odorants (400 µL)) were applied for 8 seconds at 2 minutes intervals via syringe in a stream of 
Ringer solution flowing at a rate of 1 mL/min. (The odorants were dissolved in DMSO and then 
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diluted (1000X) with Ringer solution to the desired concentration.) Recordings were made at 340 
nm and 380 nm. The ratio of the fluorescence reading at these two wavelengths (F340/F380) 
corresponds to the amount of intracellular calcium. Forskolin (10 µM) was applied at the end of 
the experiment to activate adenylyl cyclase. The calcium imaging response of the odorants were 





Chapter 2: Olfactory Receptor Antagonism of the OR-I7 Aldehyde Receptor 
2.1. Introduction: 
2.1.1. Role of antagonism in the 
olfactory code 
According to the olfactory 
code, each receptor can be 
activated by multiple odorants, and 
different odorants can activate a 
different set of odorant receptors.1 Hence, the olfactory system identifies odors using a 
combinatorial receptor coding scheme, and each odorant would have a unique olfactory code for 
generating the smell that we experience.1 Most studies have focused on identifying the olfactory 
receptors that could be activated by a specific odorant or the odorants that could activate specific 
receptors, but odorants are also capable of antagonizing ORs that they do not activate. 
Antagonists bind to receptors without activating them and this competitively inhibits agonists 
from binding (Figure 2.1). Therefore, instead of activating all the receptors that can be activated 
by the individual odorants, some receptors would lose their response in a mixture, or have it 
lessened, perhaps to partial agonist levels, due to antagonism. Antagonism may play an 
important role in the olfactory code, but the extent of that role and the structural criteria of 







Figure 2.1: Signal transduction pathway of the olfactory system 
during antagonism of the olfactory receptor.  




2.1.2. Molecular receptive range and antagonism of OR-I7 receptor 







































EC50 (µM) 1.8 - 1736 - 1.0 
IC50 (µM) - 460 124 45 - 
 
Figure 2.2: Agonists and antagonists of the rat OR-I7 receptor. EC50 and IC50 values were obtained from calcium 
imaging of rat OSNs.2 
 
In a previous study, evidence of antagonism was observed in the rat olfactory receptor, 
OR-I7.2 OR-I7 is a receptor specific for aliphatic aldehydes, with octanal, an eight carbon 
aliphatic aldehyde, currently as one of its most potent ligand.3, 4 Only aldehydes capable of 
adopting chain lengths longer than 6.5-6.9 Å could activate OR-I7 at micromolar 
concentrations.2 Removal of the ethyl group on 1.1 (to form 2.2), so that the chain length 
becomes shorter than 6.5 Å, converts the molecule from an agonist to an antagonist of the OR-I7 
receptor. Aldehydes with chain lengths shorter than 6.5 Å inhibited the response of octanal in a 
dose-dependent manner with micromolar potency (IC50 values from 45 to 460 µM when tested 
by calcium imaging, Figure 2.2). Since these antagonists all have chain lengths shorter than 6.5 
Å in their most extended conformation, it was proposed that these odorants bind to the receptor 
via their aldehyde moiety, but were not long enough to reach a hydrophobic pocket needed to 
trigger activation of the OR-I7 receptor. The antagonists’ potencies appear to be improving as 
the number of carbons in the mid-region (region in the receptor between the aldehyde binding 
site and the proposed hydrophobic activation pocket) increases. Hexanal (IC50 = 124 µM), with 
one more carbon than pentanal (2.1) (IC50 = 460 µM), is approximately four times more potent 
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than pentanal (2.1). Cyclohexylethanal (2.2) (IC50 = 45 µM), with two extra carbons compared to 
hexanal, was approximately three times as potent. 
2.2.   Design and synthesis of OR-I7 antagonists 
 
Figure 2.3: Structures of designed OR-I7 antagonists tested in Structure-Activity Relationship (SAR) study. 
 The predicted binding free energies in a homology model for OR-I7 suggest that 
saturated aldehydes with five to eleven carbons may be partially stabilized by hydrophobic 
interactions with amino acid residues.5 Increasing the carbons in the mid-region of the receptor 
may promote additional van der Waal interactions as more hydrophobic surface area from the 
ligand is buried in the binding site, and consequently, the affinity and potency of the antagonists 
may improve. To further test this idea, a structure-activity relationship (SAR) study was 
conducted in which the number of carbons in the mid-region of OR-I7 antagonists, 2.1 and 2.2, 
was gradually increased (Figure 2.3). Analogues 2.3, 2.4, 2.5, 2.6, and 2.7 have increasing 
numbers of carbons, compared to 2.1, by one to five carbons, respectively. Analogues 2.7, 2.8, 
2.9, 2.10, 2.11, and 2.12 have one to four more carbons compared to compound 2.2. While 
increasing the number of carbons, the analogues were designed to maintain chain lengths shorter 
than 6.5 Å to prevent the compounds from reaching the putative hydrophobic activation pocket. 
The described analogues were synthesized and tested in HEK293 cells transfected with the 
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mouse OR-I7 receptor to determine if there is any correlation between the number of carbons 
occupying the mid-region and the antagonist’s potency. 
The target compounds were synthesized from commercially available starting materials. 
Compounds 2.3 and 2.12 were synthesized in one step from the alcohols through PCC oxidation. 
Compounds 2.2 and 2.10 were synthesized in two steps from the ester and carboxylic acid, 
respectively, through LAH reduction followed by PCC oxidation (Scheme 2.1).  
 
Scheme 2.1: Synthesis of 2.2, 2.3, 2.10, and 2.12. 
 
Compound 2.4 was synthesized in four steps from 3-pentanone as previously reported 
(Scheme 2.2).6 3-Pentanone was subjected to a Horner-Wadsworth-Emmons reaction to afford 
the α,β-unsaturated ester 2.4a, which was then hydrogenated to give the saturated ester 2.4b. The 
ester was reduced to the alcohol 2.4c and oxidized into the aldehyde 2.4.  
 
Scheme 2.2: Synthesis of 2.4. 
 
 
Compound 2.5 was also synthesized from 3-pentanone according to an established 
route.7, 8 3-Pentanone reacted with ethyl cyanoacetate to form the α,β-unsaturated cyanoester 
2.5a, which served as the Michael acceptor in the following 1,4 addition reaction with a Grignard 
reagent, formed from magnesium and iodomethane, as the Michael donor, to obtain 2.5b. The 
ester 2.5b was hydrolyzed and decarboxylated to form the nitrile 2.5c, which was then 
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hydrolyzed and reduced to the alcohol 2.5d. The alcohol 2.5d was oxidized to form the aldehyde 
2.5. Compound 2.6 was synthesized in a similar manner but using bromoethane instead of 
iodomethane to form the Grignard reagent. Compound 2.8 and 2.9 were also synthesized through 
the same route but starting with cyclohexanone instead of pentanone (Scheme 2.3). 
 
Scheme 2.3: Synthetic route of 2.5, 2.6, 2.8, and 2.9. 
 
Compound 2.7 was synthesized (Scheme 2.4) starting from crotonaldehyde.9, 10 The 
bicyclic ring of 2.7 was obtained through two Diels-Alder reaction. First, crotonaldehyde was 
subjected to a nucleophilic addition reaction to form 2.7a, which was used as the diene in the 
following Diels-Alder reaction with ethyl acrylate as the dienophile to form 2.7b. Compound 
2.7b was subjected to an elimination reaction to form the ester 2.7c, which would serve as the 
diene in another Diels-Alder reaction with maleic anhydride as the dienophile to form 2.7d. The 
alkene 2.7d was hydrogenated to the alkane 2.7e, which was then hydrolyzed to cleave the 
anhydride into carboxylates 2.7f. The carboxylate groups were decarboxylated to form 2.7g. The 
alkene 2.7g was hydrogenated to reduce the double bond on the ring to form 2.7h. The ester 2.7h 
was LAH reduced to the alcohol 2.7i. The alcohol 2.7i was homologated by an extra carbon via a 
PCC oxidation reaction, followed by a Wittig reaction and a hydroboration-oxidation reaction to 
form the aldehyde 2.7j, the alkene 2.7k, and the alcohol 2.7l, respectively. The alcohol 2.7l was 




Scheme 2.4: Synthesis of 2.7. 
 
Compound 2.11 (Scheme 2.5) was synthesized from (-)-b-pinene. (-)-b-Pinene was 
homologated by an extra carbon via a hydroboration-oxidation reaction followed by a PCC 
oxidation and a Wittig reaction, to form the alcohol 2.11a, aldehyde 2.11b, and alkene 2.11c, 
respectively. The elongated alkene 2.11c was then subjected to another hydroboration-oxidation 
reaction to form the alcohol 2.11d, which was oxidized to the aldehyde 2.11. (It is also possible 
to synthesize compound 2.11 from (-)-b-pinene in one step via a hydroformylation reaction.35, 36) 
 








2.2.1. Evaporation problem associated with luciferase assay 
The initial luciferase assay that our collaborator used (Hiroaki Matsunami lab, Duke 
University) is a protocol that has been employed to measure the activation of specific ORs based 
on the cells’ cAMP level.11 In this assay, odorants are tested in genetically modified HEK293 
cells (Hana3A cells) transfected with the OR-I7 receptor gene. Transfected ORs could not easily 
be expressed on the cell membrane, but RTP1S, a receptor-transporting protein, appears to help 
promote cell surface expression. In the transfected cells, activation of the olfactory receptor 
results in the production of cAMP, which in turn activates a protein kinase A. Protein kinase A 
then activates CREB, cAMP response element binding protein, to induce the expression of the 
luciferase gene, causing an increase in light output so that the response of the receptor can be 
quantified from the luminescence reading. Since gene expression occurs slowly, several hours 
were usually required to see a response. As such, the odorant had to be incubated at 37°C with 
the transfected cell in a 75 µM buffer solution for 2-4 hours. Since the OR-I7 agonist, octanal, is 
an aldehyde that is prone to oxidation in air, the production of octanoic acid over time was 
















Octanal was incubated for 2 hours at 37°C in a water solution to test for oxidation. No 
octanoic acid formed during this time span, but there was an apparent loss of octanal from the 
solution (Figure 2.4A). By the end of two hours, there was less than 20% of the original amount 
of octanal remaining in the water solution (Figure 2.4B). Octanal is volatile and has low 
solubility in water, so we speculated that octanal was evaporating from the water solution during 
the incubation. This was a potential problem because the luciferase assay requires incubation at 
37°C in an aqueous solution for several hours to promote gene expression. However, if octanal 
was evaporating throughout this period, we would not be testing the concentration that was 
initially applied before the incubation, and different odorants undergoing comparison might 
evaporate at different rates. 







Figure 2.4: Disappearance of octanal in 
water. Octanal (75 µL, 0.1 mM) in a 
water solution was incubated at 37 °C for 
2 hours in a 96-well plate. Percentage of 
octanal remaining in the solution was 
monitored by GC/MS. The water sample 
was directly injected into the GC/MS 
without further treatment. The expected 
retention time for oxidized octanal 
(octanoic acid) is approximately 8.5 
minutes. (A) Overlapping GC/MS 
spectrum for octanal after 0 h (black), 1 h 
(blue), and 2 h (red) of incubation. (B) 
Percentage of octanal remaining as a 
function of time. Results were obtained 
from the average of 3 trials. Percentages 
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To verify if evaporation occurs during the luciferase assay carried out by our 
collaborators at Duke University, the amount of octanal was monitored in a mock luciferase 
experiment, which was identical to an actual experiment except that the transfected cells were 
not present. Octanal was incubated for 2 hours at 37°C in a CD293 buffer solution (the medium 
used in the actual luciferase experiment for promoting cell growth) with 2,2-difluorooctanal. 2,2-
Difluorooctanal is an OR-I7 agonist that converts to the gem-diol form when hydrated in water, 
and our collaborators were testing this compound in another project. The two hydroxyl groups on 
the gem-diol were expected to boost the odorant’s hydrophilicity, and consequently its solubility 
in water. In the case of octanal, roughly 40% converts to the gem-diol form in water.12 After two 
hours of incubation at 37°C, the percentage of octanal went down by approximately 70%, while 
the percentage of 2,2-difluorooctanal in the solution remained essentially the same (Figure 2.5A 








Figure 2.5: Disappearance rate of 2,2-difluorooctanal and octanal in CD293 buffer in a mock luciferase reaction. 
2,2-Difluorooctanal and octanal (75 µL, 0.1 mM) in a CD293 buffer solution was incubated at 37 °C for 2 hours in a 
96-well plate. Percentage of odorant remaining in the solution was monitored by GC/MS. The odorants were 
extracted from the CD293 buffer with chloroform as described in the procedure. (A) Overlapping GC/MS spectrum 
at 0 h (black), 1 h (blue), and 2 h (red) of incubation. (B) Percentage of odorant remaining as a function of time. 
Results were obtained from a single trial. Percentages were calculated from the peak area for each odorant. 
 
To prevent octanal from escaping the 96-well plate within the two hours of incubation, 
several different 96-well plate covers designed to seal the plate’s opening were used, including a 
plastic lid with parafilm, crystallization tape, sealing mat, and a silicone mat. However, after 
incubation at 37°C, there was still a decrease in the percentage of octanal remaining in the buffer 
compared to 2,2-difluorooctanal (Figure 2.6).  



































Figure 2.6: Disappearance rate of 2,2-difluorooctanal and octanal in sealed 96-well plates. 2,2-Difluorooctanal and 
octanal (0.1 mM) were incubated at 37 °C for 4 hours in a CD293 buffer solution (300 µL, 200 µL used for sealing 
mat). Results were obtained from a single trial. Percentages were normalized to 2,2-difluorooctanal. 
 
Since the covers were all ineffective in maintaining the percentage of octanal in the 
solution, the odorant may be interacting with the material (polystyrene with poly-D-lysine 
surface) of the 96-well plate in some way, possibly getting attached onto the bottom of the plate, 
designed to adhere to cells. Prior to the incubation with octanal and 2,2-difluorooctanal, 
individual 96-well plates were pre-exposed to one of the following odorants at concentrations of 
either 0.1 or 1 mM: 1) octanal, 2) 2,2-difluorooctanal, and 3) 1-octanol. The 96-well plates 
containing these odorants were incubated at 37°C for four hours and then rinsed with water and 
air-dried prior to the assay. Despite being pre-exposed to the odorants and covered with a sealing 
mat during the incubation, the percentage of octanal was still appreciably reduced by the end of 

































Figure 2.7: Disappearance rate of 2,2-difluorooctanal and octanal after pre-exposure. 2,2-Difluorooctanal and 
octanal (0.1 mM) were incubated at 37 °C for 2 hours in a CD293 buffer solution (200 µL). Results were obtained 
from a single trial. Percentages were calculated from the peak area. 
  
The cover should prevent octanal from escaping into the air and the odorants do not 
appear to be adsorbing onto the plate. Octanal, being hydrophobic, may be vaporizing and 
condensing onto the walls of the 96-well plate despite being locked inside a closed chamber. To 
reduce the surface area inside the 96-well plate for the octanal to condense onto, the volume of 
the buffer solution was increased while maintaining the same concentration. With the higher 
volume, there was an approximately 20% increase in the amount of octanal remaining in the 






















Difluorooctanal - 2 h
Difluorooctanal - 4 h
Octanal - 2 h




Figure 2.8: Disappearance rate of 2,2-difluorooctanal and octanal at higher volume. 2,2-Difluorooctanal and octanal 
(0.1 mM) were incubated at 37 °C for 30-45 minutes in a CD293 buffer solution (75 or 225 µL). Results were 
obtained from a single trial. Percentages were normalized to an internal standard, bromooctane. 
 
Although there would be less evaporation if the temperature was reduced, cooler 
temperature would slow gene expression too much. Instead, we decided to look at whether the 
evaporation rate was the same for other aldehydes besides octanal. While 2,2-difluorooctanal is 
an aldehyde, its ability to almost completely convert to the gem-diol form in water result in 
properties that are exceptionally different to other aldehydes. The evaporation rate of several 
other experimental aldehydes under study in our lab (A1-A11, structures shown on Figure 2.9A) 
with similar lengths as octanal were tested at 37 °C using 75 µL volumes. Overall, all the 
aldehydes have similar disappearance/evaporation rate, with around 30-50% remaining after 30 


































































Figure 2.9: Disappearance rate of other aldehydes. Odorants (0.1 mM) were incubated at 37 °C for 30 minutes in 
CD293 buffer solution (75 µL). (A) Structures of odorants. (B) Results were obtained from a single trial. Results 
were obtained from the peak area. (Aldehydes were provided by Yadi Li.) 
 
 Next, we compared the evaporation rate of a few structural analogs of octanal and 2,2-
difluorooctanal. 2,2-Dimethyloctanal is an aldehyde with opposing electronic properties 
(electron-donating) to that of 2,2-difluorooctanal (fluorine is electron-withdrawing). Whereas the 
electron-withdrawing fluoro groups on 2,2-difluorooctanal shift the equilibrium towards the 
gem-diol form, the electron-releasing methyl groups on 2,2-dimethyloctanal shift the equilibrium 






























that was converted to the gem-diol form and the disappearance of the odorants from the solution, 
we should see a difference in the disappearance rate of 2,2-dimethyloctanal and octanal. 
However, 2,2-dimethyloctanal and octanal appeared to have similar disappearance rate (Figure 
2.10). Moreover, even the disappearance rate of alcohols, 2,2-difluorooctanol and 1-octanol, 
were similar to that of octanal (Figure 2.10). With the exception of 2,2-difluorooctanal, the other 
structural analogs that were tested have similar disappearance rates. Whereas the concentration 
of odorants in the solution may be changing over time, the ratio of the odorants to each other 
should be fairly similar at all time. In this sense, the disappearance of the odorants through time 
would not be such a significant problem for the purpose of comparing the activity of odorants 












Figure 2.10: Disappearance rate of structural analogs. Odorants (0.1 mM) were incubated at 37 °C for 4 hours in 
CD293 buffer solution (300 µL). (A) Results were obtained from the average of 3 trials. Bromooctane was used as 
an internal standard. (B) Structures of odorants. (Odorants were provided by Yadi Li.) 
 
While structurally analogous compounds are expected to leave the solution at similar 































Expression of the luciferase gene required incubation of the odorant solutions at 37 °C for 
several hours. However, it did not appear possible to prevent volatile odorants from escaping the 
solution during this timeframe, and using cooler temperatures and volumes close to the capacity 
of the 96-well plate chambers were impractical. To limit the disappearance of the odorants, the 
time of the experiment need to be lowered.  
2.2.2. Glosensor cAMP assay 
To shorten the reaction time, our collaborators adopted the Glosensor assay to determine 
the cAMP level in real time without the need for any reporter gene expression. In this assay, 
HEK293 cells were transfected with the OR-I7 receptor and a mutated form of the firefly 
luciferase gene fused with a cAMP binding region. Binding with cAMP promotes an immediate 
increase in light output so that the response of the receptor can be quantified from the 
luminescence reading in less than 15 minutes and as early as 5 minutes. Additionally, the 
odorants do not need to be incubated at elevated temperature.  
When an agonist binds to the receptor, activation of the signal transduction pathway leads 
to an increase in the cAMP level and subsequently a boost in the light output by the GloSensor 
reporter. To test for antagonism, the agonist (i.e. octanal) was co-applied with various 
concentrations of each of the designed OR-I7 antagonists. The luminescence reading of the 
binary mixture should be lower than the reading of octanal alone if the co-applied compound is 
actually an antagonist that is competing with octanal for the binding site.  
Selected odorants (octanal, 2.1, and 2.2) have been tested using this assay with HEK293 
cells transfected with the rat OR-I7 receptor and the mouse OR-I7 receptor (results not shown). 
The mouse OR-I7 receptor was better expressed in the cells and the Glosensor assay gave more 
consistent response using the mouse ortholog. For that reason, the synthesized compounds were 
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tested in the mouse OR-I7 receptor although prior testing using calcium imaging was done using 
the rat OR-I7 receptor.2 There are 15 amino acid differences between the rat and mouse OR-I7 
receptor, but both are aliphatic aldehyde receptors that behave similarly.13  
2.3.  Results and Discussion 








Figure 2.11: Relative cAMP response of agonist and 
antagonist of OR-I7. HEK293 cells transfected with the 
mouse OR-I7 receptor were exposed to varying 
concentrations of odorant. The cAMP-induced response 
was monitored for 24 minutes after odorant(s) addition. 
(A) Time course plot for increasing concentration of 
octanal, an agonist of the OR-I7 receptor. (B) Time 
course plot for increasing concentration of 
cyclohexylethanal (2.2), an antagonist of OR-I7. (C) 
Time course plot for 5 µM octanal co-applied with 
increasing concentration of 2.2. The average response 
between 3.5 min and 7 min (between dashed lines) was 
used to create a dose-response curve, shown on Figure 
2.12 and 2.13. (Data was provided by Jianghai Ho, 
Matsunami lab.) 
 
The compounds were tested individually for agonist activity. If the compound is an 
agonist of the OR-I7 receptor, such as octanal, there would be an increase in response as the 
concentration of the odorant increased (Figure 2.11A). If the compound is not an agonist of OR-
I7, such as 2.2, which is an antagonist of the receptor, there would be no change in the relative 
response as a function of concentration (Figure 2.11B). However, when an agonist is co-applied 
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with an antagonist, the response of the agonist is suppressed as the concentration of the 
antagonist increase (Figure 2.11C). 













































Figure 2.12: Response of analogues 2.1, 2.3, 2.4, 2.5, 
2.6 and 2.7. (A) Activation Dose-Response Curves. 
Each compound was applied to HEK293 cells 
expressing mouse OR-I7. The cAMP production was 
monitored and the average response between 3 and 7.5 
min is shown versus the compound’s concentration. 
The responses were compared to that of octanal, a 
known agonist of OR-I7. (B) Inhibition Dose-Response 
Curves. Each set of compounds was tested for the 
ability to antagonize mouse OR-I7. Cells were treated 
with varying concentrations of the synthesized 
compounds co-applied with 5 µM of octanal. (C) IC50 
values generated from the dose-response curves. (Data 
was provided by Jianghai Ho, Matsunami lab.) 
 
Aside from octanal, and consistent with previous findings on aliphatic aldehyde shorter 
than 7 Å,2 none of the compounds showed any activity as an agonist up to 100 µM (Figures 
2.12A, 2.13A, and 2.14A). Since the compounds are all shorter than 6.5-6.9 Å, they should not 











































Figure 2.13: Response of analogues 2.2, 2.7, 2.8, 2.9, 
and 2.12. (A) Activation Dose-Response Curves. Each 
compound was applied to HEK293 cells expressing 
mouse OR-I7. The cAMP production was monitored 
and the average response between 3 and 7.5 min is 
shown versus the compound’s concentration. The 
responses were compared to that of octanal, a known 
agonist of OR-I7. (B) Inhibition Dose-Response 
Curves. Each set of compounds was tested for the 
ability to antagonize mouse OR-I7. Cells were treated 
with varying concentrations of the synthesized 
compounds co-applied with 5 µM of octanal. (C) IC50 
values generated from the dose-response curves. (Data 
was provided by Jianghai Ho, Matsunami lab.) 
 
2.3.3. Effect of carbon numbers on antagonism 
All of the tested odorants antagonized the response of octanal to some extent (Figure 
2.12, 2.13, & 2.14), but there does not appear to be any apparent correlation between the number 
of carbons in the mid-region and the antagonist’s potency. In Set A (i.e. compounds on Figure 
2.12), there was an improvement in potency after adding one carbon from 2.1 (IC50=150 µM) to 
2.3 (IC50=32 µM), but the potency decreased as more carbons were added onto 2.4, 2.5, and 2.6. 
In Set B (i.e. compounds on Figure 2.13), the activities of 2.7 (IC50=0.37 µM) and 2.12 (IC50=1.0 
µM) were comparable to that of 2.2 (IC50=0.82 µM), but the additional carbons on the rings of 
2.7 and 2.12 did not significantly improve the activity compared to 2.2. Analogues 2.8 and 2.9, 
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with 1 and 2 extra carbons on the ring, were weaker antagonists than 2.2. Similarly, the 
analogues (2.10 and 2.11) in Set C (i.e. compounds on Figure 2.14), which contained 1 or 3 more 





























Figure 2.14: Response of analogues 2.2, 2.10, and 2.11. 
(A) Activation Dose-Response Curves. Each compound 
was applied to HEK293 cells expressing mouse OR-I7. 
The cAMP production was monitored and the average 
response between 3 and 7.5 min is shown versus the 
compound’s concentration. The responses were 
compared to that of octanal, a known agonist of OR-I7. 
(B) Inhibition Dose-Response Curves. Each set of 
compounds was tested for the ability to antagonize 
mouse OR-I7. Cells were treated with varying 
concentrations of the synthesized compounds co-applied 
with 5 µM of octanal. (C) IC50 values generated from the 
dose-response curves. (Data was provided by Jianghai 
Ho, Matsunami lab.) 
 
2.3.4. Effect of cyclic ring on strength of antagonism 
Adding more carbons to the mid-region did not improve the antagonists’ activity, but the 
cyclic aldehydes appeared to have higher potency than the acyclic aldehydes. The acyclic 
aldehydes (2.1, 2.3, 2.4, 2.5, and 2.6) in Set A, showed weaker antagonist activity than the 2.2.2-
bicyclic aldehyde, 2.7. The improvement in activity from 2.1 (IC50=460 µM) to 2.2 (IC50=45 





2.3.5. Effect of protruding groups on antagonism  
The reintroduction of acyclic groups onto the cyclohexyl ring system, such as the methyl 
group on 2.8 and the ethyl group on 2.9, resulted in lower activity compared to 2.2, which 
contains no groups on its ring. The acyclic groups, which aren’t long enough to reach the 
activation pocket, might be clashing sterically with amino acid residues lining the binding site of 
the receptor, and thus interfere with binding or interactions within the mid-region. In Set B 
(Figure 2.13), 2.7 and 2.9 both contain the same number of carbons, but having the ethyl group 
of 2.9 “tied back” onto the bicyclic ring of 2.7, may possibly prevent it from sterically clashing 
with amino acid residues. In Set C, 2.11 (IC50=13 µM), containing the two methyl groups on the 
ring system, have weaker activities compared to the other compounds tested in this set, 2.10 
(IC50=7.9 µM) and 2.2 (IC50=0.41 µM). Ring systems that contain a globular shape, such as 2.2 
(IC50=0.82 µM), 2.7 (IC50=0.37 µM) and 2.12 (IC50=1.0 µM), have the highest antagonist 
potency in this experiment, followed by 2.10 (IC50=7.9 µM). 
2.3.6. Effect of orientation 
Out of the four aldehydes containing rigid, cyclic systems (2.2, 2.7, 2.10, and 2.12), 2.10 
was the least potent antagonist of OR-I7. Compound 2.10 was ~8 to 20 times less potent than the 
other aldehydes containing a globular structure and no protruding groups. To search for a 
possible explanation for this difference, the four globular aldehydes were each modeled in their 
most stable conformation (Figure 2.15). The orientations of the aldehydes in the receptor pocket 
may have some influence on the potency of the antagonists. Comparing the orientations of the 
four aldehydes, the ring systems for 2.2, 2.7, and 2.12 are all situated downwards from the 
aldehyde group, whereas the ring for 2.10 is projected out of the page, sideways to the aldehyde 
group. In effect, the cyclohexyl rings of 2.2, 2.7, and 2.12, may all be seen as a full hexagonal 
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shape on the model (Figure 2.15) with the aldehyde group placed at the same position, whereas 
the cyclohexyl ring of 2.10 is contracted by the 2.2.1-bridgehead to form the cyclopentyl rings. 
The ring system of 2.10 contained a mix of cyclohexyl and cyclopentyl rings, while 2.2, 2.7, and 
2.12, all consisted only of cyclohexyl ring(s). The cyclopentyl ring on 2.10 may be less 
preferable for the OR-I7 receptor or the particular orientations resulting from the different ring 
systems led to interactions with different residues on the receptor modulating the antagonists’ 






 2.2 2.7 2.10 2.12 
 
Length (Å) 5.4 5.0 4.9 5.4 
IC50 (µM) 0.82 0.37 7.9 1.0 
 
Figure 2.15: 3D Structural models of 2.2, 2.7, 2.10, and 2.12. The structures of the aldehydes were drawn in their 
most extended conformation. The energy was minimized using MM2 on ChemBio3D Ultra 12.0. The length was 
measured from the carbonyl carbon to the furthest carbon (highlighted in yellow). The structures were oriented with 
the aldehyde group at the same position. 
 
2.3.7. Effect of antagonist’s size 
The size of the antagonist occupying the mid-region of the receptor appears to have 
minimal effect on the potency of the compound. The switch from the small cyclohexyl ring of 
2.2 to the larger adamantyl ring of 2.12 resulted in similar IC50 values (2.2: 0.82 µM; 2.12: 1.0 
µM). Large groups in the mid-region may be tolerated but not necessary for antagonizing the 
receptor, since 2.2 with a smaller ring system is just as potent as 2.12. Likewise, while the 
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Figure 2.16: Homology model of the mouse OR-I7 
receptor bound by selected antagonists. Homology 
model is based on the inactive β2-adrenergic receptor. 
The antagonists are colored orange (carbons) and red 
(oxygen). Possible interactions with amino acid residues 
are indicated by dashed lines. (Models were provided by 




the molecules from binding to and antagonizing the response of the receptor. The mid-region 
seems able to accommodate a wide variety of compact organic ring systems, and as long as they 
do not extend beyond 7 Å, they remain antagonists and do not activate the receptor. 
2.3.8. Homology model of the mouse OR-I7 receptor bound by selected antagonists 
 To better evaluate the interactions between the designed antagonists and the OR-I7 
receptor, homology models were constructed with the antagonists bound to the receptor. (Models 
were constructed by another collaborator, Victor Batista, at Yale University.) Correlating the 
antagonist’s IC50 value with its optimal position in the receptor pocket may aid in explaining the 
observed differences between the potency of the tested antagonists. As shown on Figure 2.16, the 
two weaker OR-I7 antagonists, pentanal (2.1) and 2.6 are predicted to form a H-bond with the 
Tyr257 residue, whereas the stronger antagonists, 2.9 (~10X as potent) and 2.2 (>100X as 
potent), are predicted to form a H-bond with the Lys164 residue. Thus, interaction with the 
Lys164 residue appears to improve the antagonists’ potency. In previous homology models, 
agonists of the OR-I7 receptor, including octanal, were also found to interact with the Lys164 
residue.5 However, in another model, the gem-diol form of octanal, which was expected to form 
when octanal becomes hydrated in water, prefers to interact with the Tyr257 residue possibly 
through hydrogen bonding, and based on interaction energy calculations, the gem-diol is better 
accommodated (by 2-6 kcal/mol) in the OR-I7 receptor than the aldehyde.12 As a result, the 
agonist, octanal, could potentially H-bond with either the Lys164 residue or the Tyr257 residue 
via the gem-diol form.  
In order to antagonize the response of octanal, the antagonist needs to compete with 
octanal for the binding site. When comparing the IC50 values of the weaker antagonists (2.1 and 
2.6) and the stronger antagonists (2.2 and 2.9) with the residues to which they are interacting 
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with in the homology model (Figure 2.16), binding with the Lys164 residue appears more 
effective in inhibiting the response of octanal than binding with the Tyr257 residue. But 
conversely, the most potent antagonist, 2.7, interacts with the Tyr257 residue instead of the 
Lys164 residue. If interaction with the Tyr257 residue is indeed less favorable compared to the 
Lys164 residue, then the 2.2.2-bicyclic ring of 2.7 may possibly be stabilizing the molecule 
through additional van der Waals interactions, or the extra interaction with the Ser260 residue, 
not seen for the other modeled antagonists, may be further strengthening the binding. Otherwise, 
binding to either residue may be just as effective in antagonizing the response of the OR-I7 
receptor, since the agonist, octanal, could bind at either residue.12, 13 The results may also 
indicate that ligands can tumble in the orthosteric binding pocket. 
Based on the homology models (Figure 2.16), by increasing the carbons in the mid-
region, not only the size of the molecules differs, but the orientations of the molecule in the 
receptor pocket also shifted to accommodate the extra carbons. For instance, 2.2, 2.7, and 2.9 all 
contain a cyclohexyl ring within their structure, but the ring is oriented at different positions for 
the three molecules. Thus, while the aldehyde group on the antagonists were only seen to bind 
onto one of two residues, the hydrophobic portion of the molecule are all involved in fairly 
diverse interactions due to the differences in their orientations, which may affect the stability of 








2.3.9. Attempt to synthesize 2.13 
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EC50 (µM) - (1.0) - ? 
IC50 (µM) 0.82 - 0.37 ? 
 
Figure 2.17: Agonists and antagonists of the OR-I7 receptor. (A) Structures of agonists and antagonists of the OR-
I7 receptor. Chain lengths are calculated on ChemBio3D Ultra 12.0. EC50 values were obtained from calcium 
imaging of rat OR-I7.2 IC50 values were obtained from cAMP detection assay of mouse OR-I7. (B) 3D model of 
2.13 (carbons: purple, oxygen: blue) overlapping with the trans-isomer of 1.1 (carbons: gray, oxygen: red) in the 
chair conformation. 
 
The 2.2.2-bicyclo aldehyde 2.7 was the only antagonist found to be slightly more potent 
than the original cyclohexyl aldehyde 2.2. Attaching an ethyl group onto 2.2, so that the chain 
length exceeds 7 Å (forming 1.1 in chapter 1), transforms 2.2 from an antagonist to an agonist of 
OR-I7.2 Similarly, attachment of an ethyl group onto the ring of 2.7 (forming 2.13, Figure 
2.17A) may switch antagonist 2.7 into an agonist. Since 2.7 is a better antagonist than 2.2, 2.13 
may also be a better agonist than 1.1.  
As speculated in chapter 1, the cis-isomer 1.2 may be activating the OR-I7 receptor in the 
twist-boat conformation. In this conformation, the position of the ethyl group on the cis-isomer 
1.2 is closer to the position of the ethyl group on the trans-isomer 1.3. However, there would be 
an energy barrier to convert the cis-isomer 1.2 from the chair conformation to the less favorable 
twist-boat conformation. One way to reduce the energy barrier is to pay the cost during synthesis 
by locking the cis-isomer (1.2) in the boat conformation using a 2.2.2-bicyclic ring, resulting in 
2.13. The position of the ethyl group on 2.13 is closer to the position of the ethyl group on the 
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trans-isomer (1.3) (Figure 2.17B). There will be no conformational flexibility in the mid-region, 
and the aldehyde and ethyl groups should be locked in what we speculate would be a favorable 
geometric relationship for OR-I7 binding. 
 As an extension to this study, we attempted to synthesize compound 2.13 for analysis. 
Compound 2.13 would test for whether the extension of the length of 2.7 would transform the 
molecule from an inhibitor to an activator of the OR-I7 receptor, and the potency of 2.13 would 
give us feedback as to whether the cis-isomer 1.2 (in chapter 1) activates the OR-I7 receptor in 
the boat conformation. Our prediction is that despite the boat conformation in this ring system, 
the compound should be just as potent as the trans-isomer (1.3). Compound 2.13 is not 
commercially available and has never been synthesized before, but there are literature procedures 
for the synthesis of similar molecules, such as 2.13a (Scheme 2.6).14, 15 The alkene 2.13a, had 
been synthesized from the dialdehyde 2.13b via a Wittig reaction, and 2.13b had been 






Once 2.13a is 
synthesized, there are 
various ways to transform 
2.13a to 2.13. For 
instance, 2.13a could be 
subjected to a 
hydroboration-oxidation 
to functionalize both or 
either one of the alkenes 
into hydroxyl group(s) 
resulting in 2.13d and/or 
2.13e (Scheme 2.6C). 
The remaining alkene on 
2.13e could be reduced to 
form 2.13g, and oxidation 
of the hydroxyl group of 
2.13g would give the 
product 2.13. From 
2.13d, one of the 
hydroxyl groups could be 
reacted to an alkyl group 
through a deoxygenation reaction or by reduction of the tosylate 2.13f to arrive at 2.13g, which 







Scheme 2.6: Synthesis of 2.13. (A) Retrosynthesis of 2.13. (B) Synthesis route 
for 2.13a. (C) Synthesis route for 2.13 from 2.13a. Reactions that are found in the 





A. Route 1 
 
B. Route 2 
 
 
C. Route 3 
 
Scheme 2.7: Synthetic routes to arrive at 2.13c. Reactions that are found in the literature are indicated by solid 




Before arriving at 2.13a, it is necessary to first synthesize 2.13c (available from 
commercial sources at ~$1000/5g). Once compound 2.13c is obtained, it could be used to 
synthesize 2.13a, and from 2.13a, the desired product 2.13 could be synthesized. A few possible 
routes have been found in the literature to synthesize 2.13c (Scheme 2.7). The first route 
(Scheme 2.7A) is the scheme originated by Holtz et. al. to synthesize 2.13c from diethyl 
succinate.16 The second route (Scheme 2.7B) follows the scheme used by Della et. al. to 
synthesize 2.13o from dimethyl cyclohexane-1,4-dicarboxylate.17 This route can also be used to 
synthesize compound 2.14 (this structure was first suggested by Dr. Ryan Murelli) from 2.14a, 
which would also be effective in locking the cis-isomer (1.2) in the boat conformation via the 
2.2.1-bicyclo ring. 
 
Retrosynthesis of compound 2.14 from 2.14a 
 
The third route (Scheme 2.7C) is based on the scheme used by Chapman et. al. to synthesize 
2.13o from cyclohexane-1,4-dicarboxylic acid.18 The ester 2.13o could afterwards be reduced to 
the alcohol 2.13c. 
At present, routes 1 and 2 have been attempted to synthesize 2.13c at reduced scale in our 
lab. For both routes, difficulties occurred during the step to produce the 2.2.2-bicyclic ring 
(Route 1: 2.13i, Route 2: 2.13o). Following both procedures (at reduced scale), multiple products 




Scheme 2.8: Possible transition state from 2.13n to 2.13o. 
 
The challenge in forming the 2.2.2-bicyclic ring may mainly arise from a slow intramolecular 
substitution reaction. To form the 2.2.2-bicyclic ring, the intermediate would need to shift from 
the chair conformation to the sterically hindered, less stable, boat conformation (Scheme 2.8). 
Meanwhile, the elimination side-products could form and intermolecular reactions could occur 
between the intermediates/side products.  
 The scale of the reaction may also be affecting the yield. Literature procedures16, 17, 19 
usually perform these reactions at multi-gram scale, whereas these reactions have only been 
attempted in our lab at small scale. Some steps in the reactions involve keeping the temperature 
of the reaction stabilized and crystallization of the product. At the larger scale it would be easier 
to maintain the temperature of the reaction as well as promote the formation of crystals. 
2.4.   Conclusions 
Several aldehyde analogues with chain lengths shorter than 6.5 Å were synthesized. None 
of these aldehydes can activate the OR-I7 receptor. This was in accordance with previous 
studies2 suggesting that the distance from the aldehyde group to the most distant carbon needs to 
be more than 6.9 Å in order to bridge two important contact points or pockets. The synthesized 
short aldehydes all inhibited the response of octanal, demonstrating that the aldehydes could 
compete with octanal for the binding site. The tested acyclic odorants (2.1, 2.3, 2.4, 2.5, and 2.6) 
have weaker antagonist potency than the compact, unbranched cyclic odorants (specifically 2.7), 
and cyclic odorants that contained acyclic, protruding groups (2.8, 2.9, and 2.11) were weaker 
antagonist than the rigid, cyclic odorants (2.2, 2.7, and/or 2.12). The OR-I7 receptor appears to 
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prefer rigid, cyclic groups in the mid-region, but all twelve of the synthesized odorants could 
antagonize the response of octanal to some extent (IC50=0.37 µM to 150 µM), suggesting that the 
mid-region accommodates aldehydes of different shapes and sizes. To summarize, the response 
of the OR-I7 receptor could be inhibited by odorants containing an aldehyde functional group, 
with an extended conformation of less than 6.9 Å, and preferably a rigid, cyclic structure. 
Although the tested odorants were all aldehydes with chain lengths shorter than 6.5 Å, they differ 
in many aspects, such as structural conformation, size, and flexibility. Yet, they were all able to 
antagonize the OR-I7 receptor. It has been established that each olfactory receptor can be 
activated by multiple odorants, and each odorant activates multiple receptors, but it’s noteworthy 
that as with OR-I7, each receptor may also be antagonized by multiple odorants. Similarly, since 
each odorant could activate multiple olfactory receptors, they may also be antagonizing multiple 
olfactory receptors, as part of their contribution to the olfactory code. 
2.5.   Experimental Procedures 
Unless otherwise stated, chemical reagents and solvents were purchased from VWR 
International, Fisher Scientific, or Sigma Aldrich and used without further purification. CD293 
medium was purchased from Life Technologies. Tetrahydrofuran (THF) was dried prior to use. 
Octanal and pentanal (2.1) were freshly distilled. Aldehydes were stored as a DMSO solution at 
4°C in flame-sealed ampules under vacuum prior to testing. Analytical TLC was performed on 
silica gel 60 F254 plates. Flash chromatography20 was performed on Teledyne Isco CombiFlash 
Rf-200 flash chromatography system. Melting points were measured on a Laboratory Devices 
Mel-Temp apparatus. 1H and 13C NMR spectra were recorded on a Varian Mercury 300 
spectrometer or a Bruker Ultrashield 500 spectrometer. HRMS was performed by Dr. Lijia Yang 
(CCNY Chemistry Department staff) on a Waters LCT XE (TOF) mass spectrometer using 
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electrospray ionization (ESI). Infrared (IR) spectra were recorded using Thermo Nicolet 6700 
FT-IR spectrometer. GC/MS analysis was performed on Shimadzu GCMS QP-2010. (Note: The 
literature procedure that was applied for each reaction is cited. The procedure may not 
necessarily be used for the synthesis of the same compound as in the literature.) 
General Procedure for Lithium Aluminum Hydride (LAH) reduction2  
The acid or ester (1 equiv.) in diethyl ether was added slowly to lithium aluminum hydride (1.1 
equiv.) in diethyl ether at 0°C. The suspension was stirred at room temperature for 2-3 h and then 
cooled to 0°C. Water (1 mL per g of LAH) was added, followed by 15% sodium hydroxide (1 
mL per g of LAH) and water (3 mL per g of LAH). The solution was stirred for a few minutes at 
room temperature, filtered through a celite pad, washed with diethyl ether, dried, and 
concentrated to give the alcohol. Flash chromatography was sometimes required to purify the 
product. 
General Procedure for Pyridinium chlorochromate (PCC) oxidation2 
The alcohol (1 equiv.) was added to pyridinium chlorochromate (1.1 equiv.) and silica gel (1 g/g 
of PCC) in dry dichloromethane under inert atmosphere. The suspension was stirred for 2 h and 
then passed through a silica gel pad. The solution was concentrated to give the aldehyde. Flash 
chromatography or distillation was sometimes required to purify the product.  
General Procedure for Hydrogenation Reaction2 
The alkene was hydrogenated in ethyl acetate with a catalytic amount of Pd/C for 3 h using a 
balloon filled with hydrogen gas. The solution was filtered through celite and concentrated to 
give the alkane. 
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2-Cyclohexylethanol (2.2a). Ethyl cyclohexylacetate (2 g, 11.7 mmol) was LAH 
reduced according to the general procedure to obtain the alcohol 2.2a (1.5 g, 11.7 
mmol) as a clear liquid in 99% yield. 1H NMR (CDCl3) δ: 3.68 (t, J = 6.7 Hz, 2H), 
1.78 - 1.59 (m, 5H), 1.51 - 1.11 (m, 7H), 1.02 - 0.84 (m, 2H). 13C NMR (CDCl3) δ: 60.89, 40.39, 
34.22, 33.38, 26.57, 26.29. IR (thin film, KBr plates) ν (cm-1): 3332 (broad), 2922, 2852, 1448, 
1051, 1011, 978. Spectral data match those reported previously.2  
Cyclohexylacetaldehyde (2.2). Compound 2.2a (200 mg, 1.56 mmol) was PCC 
oxidized according to the general procedure to obtain the aldehyde 2.2 (140 mg, 1.11 
mmol) as a clear liquid in 71% yield. 1H NMR (CDCl3) δ: 9.75 (s, 1H), 2.29 (dd, J = 
1.9, 6.9 Hz, 2H), 1.97 - 1.57 (m, 6H), 1.40 - 0.84 (m, 5H). 13C NMR (CDCl3) δ: 203.00, 51.38, 
33.22, 32.68, 26.04, 25.97. IR (thin film, KBr plates) ν (cm-1): 2925, 2853, 2712, 1725, 1449, 
1408, 1297, 1193, 1020, 900. Spectral data match those reported previously.2 
3-Methylpentanal (2.3). 3-Methyl-1-pentanol (2 g, 19.6 mmol) was PCC oxidized 
according to the general procedure. The product was purified by distillation to give 2.3 
(450 mg, 4.5 mmol) as a clear liquid in 23% yield as a mixture of stereoisomers. 1H 
NMR (CDCl3) δ: 9.80 - 9.72 (m, 1H), 2.46 - 2.31 (m, 1H), 2.21 (ddd, J = 2.5, 7.8, 16.1 Hz, 1H), 
1.97 (qd, J = 6.8, 13.3 Hz, 1H), 1.45 - 1.17 (m, 2H), 1.02 - 0.78 (m, 6H). 13C NMR (CDCl3) δ: 
203.19, 50.69, 29.74, 29.51, 19.52, 11.30. IR (thin film, KBr plates), ν (cm-1): 2964, 2932, 2878, 
2822, 2717, 1728, 1463, 1381, 1209, 1141, 1021, 946, 875, 776. Spectral data match those 
reported previously.21-23 
Ethyl 3-ethylpent-2-enoate (2.4a). Compound 2.4a was synthesized according 
to a literature procedure.6 Triethyl phosphonoacetate (7.8 g, 34 mmol) in THF 







mmol) in THF (10 mL) at 0°C. The suspension was stirred for 1 h and then 3-pentanone (3 g, 34 
mmol) in THF (12.5 mL) was slowly added. The solution was stirred for an hour and quenched 
with water. The solution was extracted with diethyl ether, and the organic layer was dried and 
concentrated. The crude was purified by flash chromatography eluting with hexanes/diethyl ether 
(99:1) to give 2.4a (1.58 g, 10.1 mmol) as a yellowish liquid in 29% yield. 1H NMR (CDCl3) δ: 
5.59 (s, 1H), 4.14 (q, J = 6.7 Hz, 2H), 2.61 (q, J = 7.4 Hz, 2H), 2.18 (q, J = 7.4 Hz, 2H), 1.27 (t, 
J = 6.6 Hz, 3H), 1.06 (t, J = 7.4 Hz, 6H). 13C NMR (CDCl3) δ: 167.30, 166.65, 113.71, 59.44, 
30.74, 25.44, 14.33, 13.04, 12.02. IR (thin film, KBr plates) ν (cm-1): 2972, 2936, 2877, 1717, 
1645, 1463, 1380, 1307, 1273, 1205, 1148, 1105, 1040, 868. Spectral data match those 
previously reported.24 
Ethyl 3-ethylpentanoate (2.4b). Compound 2.4a (1.48 g, 9.47 mmol) was 
hydrogenated according to the general procedure to give 2.4b (1.35 g, 8.53 
mmol) as a clear liquid in 90% yield. 1H NMR (CDCl3) δ: 4.12 (q, J = 7.1 Hz, 
2H), 2.22 (d, J = 6.9 Hz, 2H), 1.74 (p, J = 6.4 Hz, 1H), 1.42 - 1.18 (m, 7H), 0.87 (t, J = 7.4 Hz, 
6H). 13C NMR (CDCl3) δ: 173.76, 60.08, 38.56, 37.93, 25.85, 14.28, 10.82. IR (thin film, KBr 
plates) ν (cm-1): 2962, 2926, 2857, 1738, 1461, 1374, 1178, 1097, 1034. Spectral data match 
those previously reported.25  
3-Ethylpentan-1-ol (2.4c). Compound 2.4b (1.25 g, 7.9 mmol) was LAH reduced 
according to the general procedure and purified by flash chromatography eluting with 
hexanes/ethyl acetate (49:1) to give 2.4c (480 mg, 4.13) as a clear liquid in 52% 
yield. 1H NMR (CDCl3) δ: 3.64 (t, J = 7.2 Hz, 2H), 1.93 - 1.63 (br. s., 1H), 1.63 - 1.40 (m, 2H), 





25.50, 10.78. IR (thin film, KBr plates), ν (cm-1): 3331 (broad), 2961, 2925, 2874, 1461, 1379, 
1062. 
3-Ethylpentanal (2.4). Compound 2.4c (100 mg, 0.875 mmol) was PCC oxidized 
according to the general procedure to obtain 2.4 (32 mg, 0.280 mmol) as a clear liquid 
in 33% yield. 1H NMR (CDCl3) δ: 9.77 (t, J = 2.3 Hz, 1H), 2.33 (dd, J = 2.5, 6.6 Hz, 
2H), 1.84 (td, J = 6.5, 12.8 Hz, 1H), 1.46 - 1.25 (m, 4H), 0.88 (t, J = 7.4 Hz, 6H). 13C NMR 
(CDCl3) δ: 203.43, 47.84, 35.88, 26.15, 10.92. IR (thin film, KBr plates), ν (cm-1): 2964, 2935, 
2878, 2714, 1727, 1461, 1412, 1382, 1337, 1246, 1136, 1096, 1021. 
Ethyl 2-cyano-3-ethylpent-2-enoate (2.5a). Compound 2.5a was 
synthesized based on a literature procedure.7 Ethyl cyanoacetate (56.5 g, 0.5 
mol), 3-pentanone (51.7 g, 0.6 mol), ammonium acetate (3.85 g, 0.05 mol), 
and acetic acid (6 g, 0.1 mol) were added to benzene (50 mL) in a round bottom flask connected 
to a Dean-Stark apparatus. The solution was refluxed for 6 h and then washed three times with 
water. The organic layer was dried and concentrated. The product was purified by distillation to 
give 2.5a (58.5 g, 0.32 mol) as a clear liquid in 64.6% yield. 1H NMR (CDCl3) δ: 4.26 (q, J = 7.2 
Hz, 2H), 2.78 (q, J = 7.4 Hz, 2H), 2.57 (q, J = 7.4 Hz, 2H), 1.34 (t, J = 7.2 Hz, 3H), 1.13 (t, J = 
7.4 Hz, 3H), 1.19 (t, J = 7.7 Hz, 3H). 13C NMR (CDCl3) δ: 184.19, 161.70, 115.62, 104.01, 
61.68, 31.40, 26.51, 14.08, 12.65, 12.38. IR (thin film, KBr plates), ν (cm-1): 2981, 2941, 2879, 
2223, 1731, 1602, 1465, 1368, 1245, 1270, 1211, 1099, 1022, 912, 857, 817. 
Ethyl 2-cyano-3-ethyl-3-methylpentanoate (2.5b). Compound 2.5b was 
synthesized based on literature procedures.8, 26 Iodomethane (11.3 g, 80 
mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings 






Copper chloride (100 mg, 1 mmol) was added, and 2.5a (9.06 g, 50 mmol) in diethyl ether (10 
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric 
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The 
combined organic layer was dried and concentrated. The resulting residue was purified by flash 
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.5b (4.3 g, 21.8 mmol) as a 
clear liquid in 43.6% yield. 1H NMR (CDCl3) δ: 4.32 - 4.20 (m, 2H), 3.45 (s, 1H), 1.64 - 1.39 
(m, 4H), 1.39 - 1.22 (m, 3H), 1.08 (s, 3H), 0.98 - 0.82 (m, 6H). 13C NMR (CDCl3) δ: 165.57, 
116.22, 62.32, 46.26, 40.47, 29.60, 28.91, 21.79, 14.06, 7.90, 7.75. IR (thin film, KBr plates), ν 
(cm-1): 2972, 2884, 2247, 1742, 1465, 1389, 1369, 1328, 1244, 1192. 
3-Ethyl-3-methylpentanenitrile (2.5d). Compound 2.5d was synthesized based on a 
literature procedure.8 Compound 2.5b (4 g, 20 mmol) was added to a solution 
containing 85% potassium hydroxide (5.8 mL), water (25.4 mL), and ethanol (5 
mL). The solution was refluxed for 6 h and then concentrated. The resulting residue was refluxed 
for 4 h in 20% sulfuric acid (31 mL). The solution was cooled to room temperature and extracted 
with diethyl ether. The organic layer was dried and concentrated. A catalytic amount of copper 
powder (70 mg) was added to the resulting residue (2.5c) and the suspension was slowly heated 
to 170°C. The suspension was then allowed to cool back to room temperature and was purified 
by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.5d (1.26 g, 10.1 
mmol) as a yellowish liquid in 50% yield. 1H NMR (CDCl3) δ: 2.20 (s, 2H), 1.40 (q, J = 7.2 Hz, 
4H), 0.98 (s, 3H), 0.84 (t, J = 7.6 Hz, 6H). 13C NMR (CDCl3) δ: 118.57, 35.68, 30.88, 27.65, 
23.65, 7.95. IR (thin film, KBr plates), ν (cm-1): 2969, 2941, 2883, 2243, 1463, 1425, 1385. 
3-Ethyl-3-methylpentan-1-ol (2.5f). Compound 2.5d was hydrolyzed based on a 





with sulfuric acid (8.1 mL) and water (9.8 mL) for 6 h. The solution was cooled to room 
temperature, diluted with water, and extracted with diethyl ether. The organic layer was dried 
and concentrated. The resulting residue 2.5e was LAH reduced according to the general 
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give 
2.5f (650 mg, 5 mmol) as a clear liquid in 56.8% yield. 1H NMR (CDCl3) δ: 3.77 - 3.57 (m, 2H), 
1.90 (s, 1H), 1.75 - 1.38 (m, 2H), 1.38 - 1.02 (m, 4H), 1.02 - 0.66 (m, 9H). 13C NMR (CDCl3) δ: 
59.50, 41.12, 34.46, 31.36, 24.23, 7.89. IR (thin film, KBr plates) ν (cm-1): 3333 (broad), 2963, 
2938, 2880, 1463, 1380. 
3-Ethyl-3-methylpentanal (2.5). Compound 2.5f (100 mg, 0.77 mmol) was PCC 
oxidized according to the general procedure to give 2.5 (58 mg, 0.45 mmol) in 59% 
yield. 1H NMR (CDCl3) δ: 9.84 (t, J = 3.3 Hz, 1H), 2.24 (d, J = 3.3 Hz, 2H), 1.38 (q, J 
= 7.4 Hz, 4H), 1.00 (s, 3H), 0.85 (t, J = 7.4 Hz, 6H). 13C NMR (CDCl3) δ: 204.05, 52.00, 36.33, 
31.81, 24.33, 7.91. IR (thin film, KBr plates), ν (cm-1): 2967, 2882, 2732, 1721, 1463, 1382. 
HRMS (ESI) [M+H]+: Calcd for C8H16O m/z = 129.1274, found m/z = 129.1266. 
Ethyl 2-cyano-3,3-diethylpentanoate (2.6b). Compound 2.6b was 
synthesized based on literature procedures.8, 26 Bromoethane (8.7 g, 80 
mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings 
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes. 
Copper chloride (100 mg, 1 mmol) was added, and 2.5a (9.06 g, 50 mmol) in diethyl ether (10 
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric 
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The 
combined organic layer was dried and concentrated. The resulting residue was purified by flash 





clear liquid in 42% yield. 1H NMR (CDCl3) δ: 4.31 - 4.20 (m, 2H), 3.49 - 3.43 (m, 1H), 1.65 - 
1.41 (m, 6H), 1.38 - 1.25 (m, 3H), 0.99 - 0.84 (m, 9H). 13C NMR (CDCl3) δ: 165.74, 116.67, 
62.32, 44.43, 43.12, 27.59, 13.98, 7.90. IR (thin film, KBr plates), ν (cm-1): 2972, 2944, 2885, 
2246, 1741, 1602, 1459. 
3,3-Diethylpentanenitrile (2.6d). Compound 2.6d was synthesized according to a 
literature procedure.8 Compound 2.6b (4.2 g, 20 mmol) was added to a solution 
containing 85% potassium hydroxide (6.1 mL), water (26.7 mL), and ethanol (5.25 
mL). The solution was refluxed for 6 hours and then concentrated. The resulting residue was 
refluxed for 4 h in 20% sulfuric acid (32.6 mL). The solution was cooled to room temperature 
and extracted with diethyl ether. The organic layer was dried and concentrated. A catalytic 
amount of copper powder (80 mg) was added to the resulting residue (2.6c) and the suspension 
was slowly heated to 170°C. The suspension was then allowed to cool back to room temperature 
and was purified by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.6d 
(1.32 g, 9.5 mmol) as a yellowish liquid in 47% yield. 1H NMR (CDCl3) δ: 2.19 (s, 2H), 1.44 - 
1.31 (m, 6H), 0.82 (t, J = 7.4 Hz, 9H). 13C NMR (CDCl3) δ: 118.49, 38.10, 27.87, 24.80, 7.54. IR 
(thin film, KBr plates), ν (cm-1): 2968, 2943, 2882, 2245, 1735, 1461, 1425, 1383. 
3,3-Diethylpentan-1-ol (2.6f). Compound 2.6d was hydrolyzed according to a 
literature procedure.27 Compound 2.6d (1.1 g, 7.9 mmol) was refluxed in a solution 
of sulfuric acid (8.1 mL) and water (9.8 mL) for 6 h. The solution was cooled to 
room temperature, diluted with water, and extracted with diethyl ether. The organic layer was 
dried and concentrated. The resulting residue 2.6e was LAH reduced according to the general 
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give 





1.56 - 1.40 (m, 3H), 1.29 - 1.13 (m, 6H), 0.83 - 0.71 (m, 9H). 13C NMR (CDCl3) δ: 59.28, 38.08, 
36.79, 27.99, 7.46. IR (thin film, KBr plates) ν (cm-1): 3323 (broad), 2964, 2939, 2880, 1464, 
1378, 1036. 
3,3-Diethylpentanal (2.6). Compound 2.6f (100 mg, 0.69 mmol) was PCC oxidized 
according to the general procedure to give 2.6 (44 mg, 0.31 mmol) in 45% yield. 1H 
NMR (CDCl3) δ: 9.83 (t, J = 3.3 Hz, 1H), 2.24 (d, J = 3.0 Hz, 2H), 1.45 - 1.32 (m, 6H), 
0.92 - 0.76 (m, 9H). 13C NMR (CDCl3) δ: 204.03, 49.23, 40.98, 28.55, 7.52. IR (thin film, KBr 
plates), ν (cm-1): 2967, 2882, 2733, 1721, 1462, 1381, 1300, 1155, 1093, 1028. 
 (1E)-N,N-diethylbuta-1,3-dien-1-amine (2.7a). Compound 2.7a was synthesized 
according to a literature procedure.10 Crotonaldehyde (8 g, 0.114 mol) in toluene (15 
mL) was added to a solution of diethylamine and potassium carbonate at 4°C. The 
solution was allowed to come to room temperature and was stirred for 4 h. The product was 
purified by distillation to give 2.7a as a yellow liquid (6.5 g, 52 mmol) in 45% yield. 1H NMR 
(CDCl3) δ: 6.35 - 6.17 (m, 2H), 5.03 (dd, J = 10.7, 13.2 Hz, 1H), 4.76 - 4.64 (m, 1H), 4.50 - 4.40 
(m, 1H), 3.05 (q, J = 7.2 Hz, 4H), 1.19 - 0.90 (m, 6H). Spectral data match those previously 
reported.10 
Ethyl 2-(diethylamino)cyclohex-3-ene-1-carboxylate (2.7b). Compound 
2.7b was synthesized according to a literature procedure.10 To 2.7a (6.5 g, 52 
mmol) in toluene (11.2 mL) was added ethyl acrylate (5.66 g, 56.5 mmol). 
The solution was stirred for 5 days in the dark under argon. The solution was diluted with diethyl 
ether and extracted three times with 2 M HCl. The combined aqueous layer was extracted twice 
with diethyl ether. The pH of the aqueous solution was raised to 10 by adding 6 M NaOH. The 






and concentrated to give 2.7b (9.8 g, 43 mmol) as a yellowish liquid in 84% yield. 2.7b was used 
for the next step without further purification. 1H NMR (CDCl3) δ: 5.90 (br. s., 1H), 5.83 - 5.55 
(m, 1H), 4.13 (dd, J = 6.9, 12.4 Hz, 2H), 3.77 - 3.51 (m, 1H), 2.75 - 2.36 (m, 5H), 2.30 - 2.10 (m, 
1H), 2.05 (br. s., 1H), 1.99 - 1.83 (m, 1H), 1.80 (br. s., 1H), 1.42 - 1.11 (m, 3H), 1.10 - 0.77 (m, 
6H). Spectral data match those previously reported.10 
Ethyl cyclohexa-1,3-diene-1-carboxylate (2.7c). Compound 2.7c was synthesized 
according to a literature procedure.10 Compound 2.7b (9.8 g, 43 mmol) was added to 
acetic acid (48 mL) and refluxed for 2 h. The reaction was quenched with ice water 
and extracted three times with diethyl ether. The combined organic layer was washed with water, 
saturated sodium bicarbonate, and brine, dried, and concentrated. The resulting residue was 
purified by flash chromatography, eluting with hexanes/ethyl acetate (49:1) to give 2.7c (5 g, 33 
mmol) as a yellowish liquid in 75.5% yield. 1H NMR (CDCl3) δ: 6.95 (br. s., 1H), 6.16 - 5.94 (m, 
2H), 4.26 - 4.09 (m, 2H), 2.50 - 2.31 (m, 2H), 2.31 - 2.13 (m, 2H), 1.35 - 1.18 (m, 3H). Spectral 
data match those previously reported.10 
Ethyl 3,5-dioxo-4-oxatricyclo[5.2.2.02,6]undec-8-ene-1-carboxylate (2.7d). 
Compound 2.7d was synthesized according to a literature procedure.9  Compound 
2.7c (5 g, 33 mmol) was mixed with maleic anhydride (3.3 g, 33 mmol) and 
stirred for 30 minutes at 100°C and 30 minutes at 170°C. The product was 
purified by flash chromatography eluting with dichloromethane to give 2.7d (7.78 g, 31 mmol) 
as a white solid (m.p. 85-86°C) in 94.6% yield. 1H NMR (CDCl3) δ: 6.73 (d, J = 8.5 Hz, 1H), 
6.38 - 6.30 (m, 1H), 4.40 - 4.28 (m, 2H), 3.68 (d, J = 8.5 Hz, 1H), 3.29 (br. s., 1H), 3.20 (d, J = 





171.92, 171.89, 170.67, 132.23, 132.08, 61.84, 46.99, 45.84, 44.69, 32.34, 28.18, 23.76, 14.13. 
Analytical data match those previously reported.9 
Ethyl 3,5-dioxo-4-oxatricyclo[5.2.2.02,6]undecane-1-carboxylate (2.7e). 
Compound 2.7d (7.78 g, 31 mmol) was hydrogenated according to the general 
procedure to give 2.7e (7.4 g, 29 mmol) as a white solid (m.p. 81-83°C) in 94% 
yield. Compound 2.7e was used for the next step without further purification. 1H 
NMR (CDCl3) δ: 4.22 (q, J = 6.3 Hz, 2H), 3.69 (d, J = 10.2 Hz, 1H), 3.19 (d, J = 10.5 Hz, 1H), 
2.30 (br. s., 1H), 1.96 - 1.71 (m, 6H), 1.71 - 1.45 (m, 2H), 1.28 (t, J = 7.0 Hz, 3H). 13C NMR 
(CDCl3) δ: 173.85, 173.03, 171.66, 61.42, 45.53, 44.42, 40.36, 29.09, 26.70, 24.16, 22.65, 21.23, 
14.09. Analytical data match those previously reported.9 
Ethyl bicycle[2.2.2]oct-2-ene-1-carboxylate (2.7g). Compound 2.7g was 
synthesized according to a literature procedure.9 Compound 2.7e (7.4 g, 29 mmol) 
and potassium carbonate (11.67 g, 65 mmol) were refluxed in water for 2 h. The 
solution was acidified to pH 1 with 10% HCl. The solution was extracted with ethyl acetate. The 
organic layer was dried and concentrated to give 2.7f (7 g, 26 mmol) as a white solid (m.p. 135-
138°C), which was used for the next step without further purification. Compound 2.7f (7 g, 26 
mmol) was added to acetonitrile (233 mL). Pyridine (2.8 g, 36 mmol) was added followed by 
lead acetate (11.66 g, 26 mmol). The solution was refluxed for 3 h and then filtered through a 
silica pad. The product was purified by flash chromatography eluting with hexanes/ethyl acetate 
(19:1) to give 2.7g (1.41 g, 7.8 mmol) as a clear liquid in 27% yield (in 2 steps from 2.7e). 1H 
NMR (CDCl3) δ: 6.47 - 6.39 (m, 1H), 6.36 - 6.27 (m, 1H), 4.18 (q, J = 7.2 Hz, 2H), 2.57 (br. s., 





134.27, 132.41, 60.44, 43.95, 29.71, 29.34, 25.56, 14.26. IR (thin film, KBr plates) ν (cm-1): 
2945, 2910, 2868, 1731, 1455, 1390, 1366, 1317, 1288, 1249. 
Ethyl bicyclo[2.2.2]octane-1-carboxylate (2.7h). Compound 2.7g (1.41 g, 7.8 
mmol) was hydrogenated according to the general procedure to give 2.7h (1.37 g, 
7.5 mmol) as a clear liquid in 96% yield. Compound 2.7h was used for the next 
reaction without further purification. 1H NMR (CDCl3) δ: 4.07 (q, J = 7.2 Hz, 2H), 1.78 - 1.65 
(m, 6H), 1.58 (d, J = 7.4 Hz, 7H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ: 178.25, 60.02, 
38.19, 28.04, 25.41, 23.79, 14.21. IR (thin film, KBr plates) ν (cm-1): 2945, 2921, 2866, 1726, 
1457, 1365, 1336, 1243. 
Bicyclo[2.2.2]oct-1-ylmethanol (2.7i). Compound 2.7h (1.37 g, 7.5 mmol) was LAH 
reduced according to the general procedure to give the alcohol 2.7i (1 g, 7.13 mmol) 
in 95% yield as a white solid (m.p. 60-61°C). Compound 2.7i was used for the next 
reaction without further purification. 1H NMR (CDCl3) δ: 3.21 (s, 2H), 1.68 - 1.46 (m, 7H), 1.46 
- 1.08 (m, 7H). 13C NMR (CDCl3) δ: 72.04, 32.44, 27.72, 25.71, 24.60. 
Bicyclo[2.2.2]octane-1-carbaldehyde (2.7j). Compound 2.7i (1 g, 7.13 mmol) was 
PCC oxidized according to the general procedure to give aldehyde 2.7j, which was 
used for the next step without further purification. 1H NMR (CDCl3) δ: 9.40 (s, 1H), 1.79 - 1.51 
(m, 13H). Spectral data match those reported previously.15 
1-Ethenylbicyclo[2.2.2]octane (2.7k). Compound 2.7k was synthesized based on a 
literature procedure.28 To methyl triphenylphosphonium bromide (5.4 g, 15 mmol) in 
THF (30 mL) at 0°C was added potassium butoxide (1.7 g, 15 mmol). The suspension was 
stirred for 1 h and then aldehyde 2.7j in THF (7 mL) was slowly added. The reaction was stirred 







aqueous phase was extracted with diethyl ether. The combined organic layer was dried, 
concentrated and purified by flash chromatography eluting with hexanes to give the alkene 2.7k. 
1H NMR (CDCl3) δ: 5.72 - 5.64 (m, 1H), 4.85 - 4.77 (m, 2H), 1.63 - 1.51 (m, 7H), 1.51 - 1.40 
(m, 6H). Spectral data agree with those reported previously.15 
2-(Bicyclo[2.2.2]oct-1-yl)ethanol (2.7l). Compound 2.7l was subjected to a 
hydroboration-oxidation reaction.29 Compound 2.7k was dissolved in THF and 
cooled to 0°C. 1 M Borane tetrahydrofuran complex solution in THF (2.4 mL, 2.4 
mmol) was slowly added and the solution was stirred for 1 h at room temperature. The solution 
was cooled to 0°C and water (500 µL) was added followed by 3 M NaOH (750 µL) and 30% 
hydrogen peroxide (750 µL). The solution was stirred at room temperature for 2 h. The reaction 
was quenched with water and the layers were separated. The aqueous layer was extracted with 
diethyl ether and the combined organic layer was dried and concentrated. The product was 
purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give the alcohol 2.7l 
(330 mg, 2.17 mmol) in 30% yield (over 3 steps from 2.7i). 1H NMR (CDCl3) δ: 3.83 - 3.63 (m, 
2H), 1.64 - 1.32 (m, 15H), 1.28 (br. s., 1H). 13C NMR (CDCl3) δ: 59.49, 44.86, 31.15, 29.24, 
26.17, 24.17. IR (thin film, KBr plates) ν (cm-1): 3331 (broad), 2930, 2859, 1455, 1352, 1265. 
Bicyclo[2.2.2]oct-1-ylacetaldehyde (2.7). Compound 2.7l (100 mg, 0.65 mmol) was 
PCC oxidized according to the general procedure to the aldehyde 2.7 (70 mg, 0.46 
mmol) as a clear liquid in 71% yield. 1H NMR (CDCl3) δ: 9.84 - 9.79 (m, 1H), 2.12 (d, 
J = 3.0 Hz, 2H), 1.65 - 1.47 (m, 13H). 13C NMR (CDCl3) δ: 203.78, 55.19, 31.31, 30.70, 25.98, 
24.11. IR (thin film, KBr plates), ν (cm-1): 2937, 2862, 2728, 1721, 1456, 1409, 1268. HRMS 





Ethyl cyano(cyclohexylidene)acetate (2.8a). Compound 2.8a was 
synthesized based on a literature procedure.7 Ethyl cyanoacetate (56.5 g, 0.5 
mol), cyclohexanone (58.9 g, 0.6 mol), ammonium acetate (3.85 g, 0.05 
mol), and acetic acid (6 g, 0.1 mol) were added to benzene (50 mL) in a round bottom flask 
connected to a Dean and Stark apparatus. The solution was refluxed for 6 h and then washed 
three times with water. The organic layer was dried and concentrated. The product was purified 
by distillation to give 2.8a (60.6 g, 0.31 mol) as a clear liquid in 63% yield. 1H NMR (CDCl3) δ: 
4.26 (q, J = 7.0 Hz, 2H), 2.97 (t, J = 5.8 Hz, 2H), 2.70 - 2.60 (m, 2H), 1.85 - 1.57 (m, 6H), 1.34 
(t, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ: 180.03, 162.03, 115.63, 102.06, 61.72, 36.91, 31.59, 
28.59, 28.26, 25.65, 14.09. IR (thin film, KBr plates) ν (cm-1): 2939, 2861, 2224, 1729, 1601, 
1447, 1367, 1201. Spectral data agree with those previously reported.30 
Ethyl cyano(1-methylcyclohexyl)acetate (2.8b). Compound 2.8b was 
synthesized based on the literature procedures.8, 26 Iodomethane (11 g, 77 
mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings 
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes. 
Copper chloride (100 mg, 1 mmol) was added, and 2.8a (9.66 g, 50 mmol) in diethyl ether (10 
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric 
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The 
combined organic layer was dried and concentrated. The resulting residue was purified by flash 
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.8b (10.4 g, 49.7 mmol) as a 
yellowish liquid in 99% yield. 1H NMR (CDCl3) δ: 4.32 - 4.19 (m, 2H), 3.45 (s, 1H), 1.62 - 1.37 
(m, 10H), 1.31 (t, J = 7.0 Hz, 3H), 1.14 (s, 3H). 13C NMR (CDCl3) δ: 165.26, 115.88, 62.20, 





2933, 2861, 2247, 1742, 1601, 1448, 1388, 1370, 1325. Spectral data match those previously 
reported.26 
 (1-Methylcyclohexyl)acetonitrile (2.8d). Compound 2.8d was synthesized based on 
a literature procedure.8 Compound 2.8b (5.2 g, 25 mmol) was added to a solution 
containing 85% potassium hydroxide (7.5 mL), water (33 mL), and ethanol (6.5 
mL). The solution was refluxed for 6 hours and then concentrated. The resulting residue was 
refluxed for 4 h in 20% sulfuric acid (40.3 mL). The solution was cooled to room temperature 
and extracted with diethyl ether. The organic layer was dried and concentrated. A catalytic 
amount of copper powder (70 mg) was added to the resulting residue (2.8c) and the suspension 
was slowly heated to 170°C. The suspension was then allowed to cool back to room temperature 
and was purified by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.8d 
(2.2 g, 16 mmol) as a yellowish liquid in 64% yield. 1H NMR (CDCl3) δ: 2.25 (s, 2H), 1.63 - 
1.31 (m, 10H), 1.07 (s, 3H). 13C NMR (CDCl3) δ: 118.44, 36.95, 33.01, 30.33, 25.75, 25.24, 
21.88. IR (thin film, KBr plates) ν (cm-1): 2929, 2855, 2242, 1742, 1453, 1422, 1384. 
2-(1-Methylcyclohexyl)ethanol (2.8f). Compound 2.8d was hydrolyzed based on a 
literature procedure.27 Compound 2.8d (1.89 g, 13.8 mmol) was refluxed in a solution 
with sulfuric acid (14 mL) and water (16.8 mL) for 6 h. The solution was cooled to 
room temperature, diluted with water, and extracted with diethyl ether. The organic layer was 
dried and concentrated. The resulting residue 2.8e was LAH reduced according to the general 
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give 
2.8f (710 mg, 5 mmol) as a yellowish liquid in 36% yield. 1H NMR (CDCl3) δ: 3.75 - 3.65 (m, 





38.15, 32.16, 26.40, 25.39, 21.97. IR (thin film, KBr plates) ν (cm-1): 3330 (broad), 2925, 2851, 
1453, 1043, 1019. 
 (1-Methylcyclohexyl)acetaldehyde (2.8). Compound 2.8d (100 mg, 0.70 mmol) was 
PCC oxidized according to the general procedure to give 2.8 (62 mg, 0.44 mmol) in 
63% yield. 1H NMR (CDCl3) δ: 9.86 (t, J = 3.3 Hz, 1H), 2.29 (d, J = 3.0 Hz, 2H), 1.55 
- 1.31 (m, 10H), 1.08 (s, 3H). 13C NMR (CDCl3) δ: 203.96, 54.53, 38.18, 33.69, 26.01, 25.77, 
21.78. IR (thin film, KBr plates), ν (cm-1): 2928, 2853, 2729, 1721, 1453, 1380. 
Ethyl cyano(1-ethylcyclohexyl)acetate (2.9b). Compound 2.9b was 
synthesized based on literature procedures.8, 26 Bromoethane (8.7 g, 80 
mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings 
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes. 
Copper chloride (50 mg, 0.5 mmol) was added, and 2.8a (9.06 g, 50 mmol) in diethyl ether (10 
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric 
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The 
combined organic layer was dried and concentrated. The resulting residue was purified by flash 
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.9b (3.6 g, 16.2 mmol) as a 
clear liquid in 32% yield. 1H NMR (CDCl3) δ: 4.25 (q, J = 7.2 Hz, 2H), 3.61 (s, 1H), 1.76 - 1.40 
(m, 12H), 1.32 (t, J = 7.0 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3) δ: 165.56, 116.26, 
62.29, 45.57, 40.50, 32.54, 32.37, 26.66, 25.39, 21.31, 21.28, 14.08, 7.42. IR (thin film, KBr 
plates) ν (cm-1): 2935, 2865, 2246, 1741, 1456, 1387, 1369, 1323. HRMS (ESI) [M+Na]+: Calcd 
for C13H21NO2 m/z = 246.1464, found m/z = 246.1471. 
 (1-Ethylcyclohexyl)acetonitrile (2.9d). Compound 2.9d was synthesized based on a 






containing 85% potassium hydroxide (5.1 mL), water (22.2 mL), and ethanol (4.38 mL). The 
solution was refluxed for 6 h and then concentrated. The resulting residue was refluxed for 4 h in 
20% sulfuric acid (27.1 mL). The solution was cooled to room temperature and extracted with 
diethyl ether. The organic layer was dried and concentrated. A catalytic amount of copper 
powder (60 mg) was added to the resulting residue (2.9c) and the suspension was slowly heated 
to 170°C. The suspension was then allowed to cool back to room temperature and was purified 
by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.9d (1.4 g, 9.3 
mmol) as a clear liquid in 59% yield. 1H NMR (CDCl3) δ: 2.28 (s, 2H), 1.58 - 1.36 (m, 12H), 
0.92 - 0.81 (m, 3H). 13C NMR (CDCl3) δ: 118.49, 35.38, 34.65, 30.00, 26.07, 25.80, 21.52, 7.36. 
IR (thin film, KBr plates) ν (cm-1): 2966, 2929, 2857, 2243. HRMS (ESI) [M+Na]+: Calcd for 
C10H17N m/z = 174.1253, found m/z = 174.1266. 
2-(1-Ethylcyclohexyl)ethanol (2.9f). Compound 2.9d was hydrolyzed based on a 
literature procedure.27 Compound 2.9d (1.26 g, 8.3 mmol) was refluxed in a solution 
of sulfuric acid (9.3 mL) and water (11.2 mL) for 6 hours. The solution was cooled to 
room temperature, diluted with water, and extracted with diethyl ether. The organic layer was 
dried and concentrated. The resulting residue 2.9e was LAH reduced according to the general 
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give 
2.9f (690 mg, 4.4 mmol) as a yellowish liquid in 53% yield. 1H NMR (CDCl3) δ: 3.71 - 3.60 (m, 
2H), 1.61 - 1.47 (m, 2H), 1.47 - 1.20 (m, 13H), 0.79 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3) δ: 
59.15, 39.20, 35.79, 34.37, 29.67, 26.47, 21.60, 7.42. IR (thin film, KBr plates) ν (cm-1): 3329 




(1-Ethylcyclohexyl)acetaldehyde (2.9). Compound 2.9d (100 mg, 0.64 mmol) was 
PCC oxidized according to the general procedure to give 2.9 (70 mg, 0.45 mmol) in 
71% yield. 1H NMR (CDCl3) δ: 9.84 (t, J = 3.3 Hz, 1H), 2.31 (d, J = 3.3 Hz, 2H), 1.53 - 
1.35 (m, 12H), 0.90 - 0.80 (m, 3H). 13C NMR (CDCl3) δ: 204.15, 49.99, 36.47, 35.80, 30.58, 
26.10, 21.48, 7.48. IR (thin film, KBr plates), ν (cm-1): 2928, 2856, 2726, 1720, 1456, 1381. 
HRMS (ESI) [M+Na]+: Calcd for C10H18O m/z = 177.1255, found m/z = 177.1275. 
2-(Bicyclo[2.2.1]hept-2-yl)ethanol (2.10a). 2-Norbornaneacetic acid (1 g, 6.5 mmol) 
was LAH reduced according to the general procedure to the alcohol 2.10a (780 mg, 
5.6 mmol) in 86% yield as the exo (cis) product. 1H NMR (CDCl3) δ: 3.61 (t, J = 6.7 
Hz, 2H), 2.18 (br. s., 1H), 1.94 (br. s., 1H), 1.66 - 1.26 (m, 8H), 1.23 - 0.96 (m, 4H). 13C NMR 
(CDCl3) δ: 61.66, 41.14, 39.94, 38.34, 38.10, 36.55, 35.31, 30.07, 28.76. IR (thin film, KBr 
plates) ν (cm-1): 3330 (broad), 2948, 2869, 1455, 1313, 1053, 1030, 986. Spectral data match 
those previously reported.31-33 
Bicyclo[2.2.1]hept-2-ylacetaldehyde (2.10). Compound 2.10a (100 mg, 0.71 mmol) 
was PCC oxidized according to the general procedure to the aldehyde 2.10 (72 mg, 
0.52 mmol) in 73% yield as the exo (cis) product. 1H NMR (CDCl3) δ: 9.71 (t, J = 1.9 
Hz, 1H), 2.45 - 2.19 (m, 3H), 2.00 - 1.89 (m, 2H), 1.61 - 1.42 (m, 3H), 1.34 - 1.01 (m, 5H). 13C 
NMR (CDCl3) δ: 202.58, 51.07, 41.11, 37.93, 36.69, 35.86, 35.21, 29.77, 28.50. IR (thin film, 
KBr plates), ν (cm-1): 2950, 2870, 2818, 2716, 1724. 
(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methanol (2.11a). Compound 2.11a was 
synthesized from a hydroboration-oxidation reaction.29 (-)-b-Pinene (10 g, 73.4 
mmol) was dissolved in THF (160 mL) and 1M borane tetrahydrofuran complex 







temperature. The solution was cooled to 0°C and water (7.4 mL) was slowly added to quench the 
reaction followed by 3M NaOH (10 mL) and 30% hydrogen peroxide (10 mL). The solution was 
stirred at room temperature for 2 h and then water (100 mL) was added. The layers were 
separated and the aqueous layer was extracted with diethyl ether. The combined organic layer 
was dried, concentrated, and the product was purified by flash chromatography eluting with 
hexanes/ethyl acetate (49:1) to give the alcohol 2.11a (6.8 g, 44 mmol) as a clear liquid in 60% 
yield. 1H NMR (CDCl3) δ: 3.67 - 3.51 (m, 2H), 2.42 - 2.31 (m, 1H), 2.25 (t, J = 7.4 Hz, 1H), 2.06 
- 1.82 (m, 5H), 1.56 - 1.29 (m, 2H), 1.29 - 1.14 (m, 3H), 1.01 - 0.88 (m, 4H). 13C NMR (CDCl3) 
δ: 67.85, 44.49, 42.88, 41.49, 38.66, 33.15, 27.98, 26.00, 23.34, 18.77. IR (thin film, KBr plates) 
ν (cm-1): 3330 (broad), 2948, 2869. 
6,6-Dimethylbicyclo[3.1.1]heptanes-2-carbaldehyde (2.11b). Compound 2.11a (6.8 g, 
44 mmol) was PCC oxidized according to the general procedure to the aldehyde 2.11b 
which was purified by flash chromatography eluting with hexanes/ethyl acetate (19:1) 
to give 2.11b (2.1 g, 13.8 mmol) as a clear oil in 31% yield. 1H NMR (CDCl3) δ: 9.76 (s, 1H), 
2.79 - 2.69 (m, 1H), 2.58 - 2.50 (m, 1H), 2.44 - 2.19 (m, 2H), 1.98 - 1.79 (m, 4H), 1.30 - 1.16 (m, 
4H), 0.71 (s, 3H). Spectral data match those previously reported.34  
2-Ethenyl-6,6-dimethylbicyclo[3.1.1]heptanes (2.11c). Compound 2.11c was 
synthesized based on a literature procedure.2 1.6 M Butyllithium in hexane (16.8 mL, 
26.9 mmol) was added to a solution of methyltriphenyl phosphonium bromide (12.3 g, 34.4 
mmol) in THF at 0°C. After 30 minutes, the solution was cooled to -75°C and 2.11b (3.5 g, 23.0 
mmol) was slowly added. The solution was stirred for 3 h at -75°C. The reaction was quenched 
with ammonium chloride solution and the organic layer was dried and concentrated. The product 





in 24% yield. 1H NMR (CDCl3) δ: 6.05 - 5.92 (m, 1H), 4.96 - 4.82 (m, 2H), 2.71 (br. s., 1H), 
2.32 (br. s., 1H), 1.97-1.88 (m, 5H), 1.65 (d, J = 9.4 Hz, 1H), 1.19 (s, 3H), 1.03 - 0.92 (m, 3H). 
2-(6,6-Dimethylbicyclo[3.1.1]hept-2-yl))ethanol (2.11d). Compound 2.11c was 
subjected to a hydroboration-oxidation reaction.29 Compound 2.11c (800 mg, 5.32 
mmol) was dissolved in THF (12.8 mL) and 1 M borane tetrahydrofuran complex 
solution in THF (5.0 mL, 5 mmol) was slowly added. The solution was stirred for 1 h at room 
temperature. The solution was cooled to 0°C and water was slowly added to quench the reaction 
followed by 3 M NaOH (0.8 mL) and 30% hydrogen peroxide (1 mL, 8.82 mmol). The solution 
was stirred at room temperature for 2 h and then quenched with water. The layers were separated 
and the aqueous layer was extracted with diethyl ether. The combined organic layer was dried, 
concentrated, and the product was purified by flash chromatography eluting with hexanes/ethyl 
acetate (9:1) to give the alcohol 2.11d in 67% yield. 1H NMR (CDCl3) δ: 3.65 (dt, J = 3.4, 6.8 
Hz, 2H), 2.33 (d, J = 7.2 Hz, 1H), 2.11 (d, J = 7.4 Hz, 1H), 2.02 - 1.78 (m, 4H), 1.68 (q, J = 7.1 
Hz, 2H), 1.59 - 1.31 (m, 2H), 1.18 (s, 3H), 1.04 - 0.80 (m, 5H). 13C NMR (CDCl3) δ: 61.71, 
46.40, 41.43, 40.74, 38.71, 37.47, 33.63, 28.18, 26.44, 23.25, 22.35. IR (thin film, KBr plates) ν 
(cm-1): 3325 (broad), 2935, 2907, 1468, 1383, 1366. 
 (6,6-dimethylbicyclo[3.1.1]hept-2-yl)acetaldehyde (2.11). Compound 2.11d (100 mg, 
0.6 mmol) was PCC oxidized according to the general procedure to the aldehyde 2.11 
(24 mg, 0.14 mmol) in 24% yield (95.5% cis product by GC/MS). 1H NMR (CDCl3) δ: 
9.71 (t, J = 2.1 Hz, 1H), 2.70 - 2.30 (m, 4H), 2.14 - 1.79 (m, 6H), 1.52 - 1.39 (m, 1H), 1.19 (s, 
3H), 1.06 - 0.85 (m, 5H). 13C NMR (CDCl3) δ: 203.39, 52.51, 46.78, 41.55, 39.16, 35.53, 33.89, 
28.42, 26.62, 23.66, 22.51. IR (thin film, KBr plates), ν (cm-1): 2984, 2941, 2909, 2869, 2814, 





2-(1-Adamantyl)ethanal (2.12). 2-(1-Adamantyl)ethanol (200 mg, 1.1 mmol was 
PCC oxidized according to the general procedure to the aldehyde 2.12 (140 mg, 0.79 
mmol) in 71% yield. This compound was noticed to have a camphoraceous odor. 1H 
NMR (CDCl3) δ: 9.87 (t, J = 3.2 Hz, 1H), 2.13 (d, J = 3.0 Hz, 2H), 1.99 (br. s., 3H), 1.78 - 1.59 
(m, 12H). 13C NMR (CDCl3) δ: 203.59, 57.25, 42.73, 36.65, 33.34, 28.49. IR (thin film, KBr 
plates), ν (cm-1): 2903, 2848, 2728, 1721, 1450, 1406, 1362, 1346. Spectral data match those 
previously reported.37, 38 
Mouse OR-I7 HEK293 Glosensor Assay (from collaborator Jianghai Ho experiments in 
Matsunami Lab, Duke University Medical Center) 
The GloSensor cAMP Assay System (Promega) was used according to manufacturer’s 
instructions with slight modifications as previously described.2 A plasmid encoding Rho-tagged 
mouse OR-I7 (80 ng/well) was transfected into the Hana3A cell line in 96-well plate format 
along with plasmids encoding the human receptor trafficking protein, RTP1S (10 ng/well), type 
3 muscarinic acetylcholine receptor (M3-R) (10 ng/well), and pGloSensor TM-22F (10 ng/well). 
Then, 18 to 24 h following transfection, cells were loaded with 2% GloSensor reagent for 2 h 
and treated with compounds in a total volume of 74 µL. Luminescence was measured using a 
Polarstar Optima plate reader (BMG) with a time interval of 90 seconds per well. Data was 
analyzed and IC50s were estimated using Prism 5.0 and Microsoft Excel. Responses over t=3-7.5 
minutes were summed, base-lined, normalized, and plotted versus odorant concentration (Figures 
2.12, 2.13, and 2.14).   
Homology Model Construction and Ligand Docking (Experiments done in the lab of Victor 





General procedure for evaporation assay 
These experiments were mock experiments, done without the transfected cells, but otherwise 
identical to our collaborator’s lab at Duke University. The solute evaporation was monitored to 
learn whether there were different odorant evaporation rates in the biological testing. The 
odorant was diluted with DMSO to 1.0 M, and the 1.0 M DMSO solution was diluted with 
CD293 buffer (or water) to 0.1 mM. Designated volumes of the 0.1 mM solution were 
transferred into 96-well plates and incubated at 37˚C for the designated timespan. The 96-well 
plate was then placed on top of ice and the odorant solutions were pooled. An aliquot of the 
pooled solution was extracted with an equal volume of chloroform or a 0.1 mM 1-bromooctane 
solution in chloroform as an internal standard. The layers were separated and the organic layer 
was diluted with 2.0 mL of chloroform, dried with magnesium sulfate and analyzed by GC/MS. 
GC/MS analyses were obtained on a Shimadzu GC/MS-QP2010 instrument. Temperature 
program for GC analysis was as follows: Injection temperature = 250˚C; held at 65˚C for 1 
minute, heated from 65˚C to 80˚C at 5˚C/minute, held at 80˚C for 1 minute, heated from 80˚C to 
120˚C at 15˚C/minute, held at 120˚C for 1 minute, heated from 120˚C to 200˚C at 40˚C/minute, 
and held at 200˚C for 3 minutes. The amount of odorant in the solution was determined relative 
to the peak area or relative to 2,2-difluorooctanal or 1-bromooctane (as an internal standard). The 
percentage of odorant remaining over time was compared to a sample that was extracted prior to 
the incubation, designated as time = 0 minute. 
Pre-exposure assay 
For the experiment requiring pre-exposure to the odorants, 400 µL of the following solution in 
water was separately added into the 96-well plates prior to the experiment: water, 0.1 mM 
octanal, 0.1 mM 1-octanol, 0.1 mM 2,2-difluorooctanal, 1 mM octanal, 1 mM 1-octanol. The 
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solutions were incubated at 37°C for 4 hours uncovered. Afterwards, the solutions were 
discarded, and the well plates were rinsed three times with water and left to dry overnight. 
During the experiment, 200 µL of 0.1 mM octanal and 2,2-difluorooctanal was added to the well 
plates. The 96-well plates were covered with sealing mats (ThermoScientific, catalog #4411-11) 




Chapter 3: Olfactory Receptor Antagonism in the Mammalian Olfactory System 
3.1. Introduction 
3.1.1. Combinatorial receptor coding 
Olfaction is one of the major senses used to analyze the physical environment. Rodents 
have about 1100 olfactory receptor genes and humans have about 390 olfactory receptor genes, 
plus many pseudogenes.1 Each odorant can activate multiple olfactory receptors and each 
olfactory receptor can be activated by multiple odorants, suggesting that each odorant has a 
specific combinatorial olfactory code for generating its unique smell.1 An odor was generally 
believed to be linked to the activation of a set of receptors by specific odorant(s), but mixtures 
have long been noted to elicit lower response than the individual components,2 suggesting the 
possibility of odorants to act as inhibitors as well as activators. Recently, odorants were 
identified that antagonized olfactory receptors through binding to the receptors without 
activating them.3-5 These antagonists inhibit the action of agonists. Thus, in a mixture, some 
receptors may have their response modulated due to antagonism, and the original olfactory code 
of the individual odorants might become much more complex, but currently, it is uncertain 
whether antagonism is an important contributor to the olfactory code in natural product mixtures 
and whole animals.  


















Octanal, an eight-carbon, aliphatic aldehyde, activates the aldehyde receptor OR-I7 when 
applied alone, but its response has been shown to decrease when co-applied with citral3 and 
cyclohexylethanal,5 both now considered antagonists of the OR-I7 receptor. Octanal’s olfactory 
code, and consequently its smell, would presumably be modified in a mixture with these 
compounds. Similarly, the response of eugenol (100 µM) in the mOR-EG receptor was 
eliminated in a mixture containing high concentration (1 mM) of methyl isoeugenol.4 For each of 
these rodent receptors, the antagonists were structurally similar to the agonist, which may mean 
they act at the orthosteric site. Octanal differs from cyclohexylethanal by only its extended chain 
length, and eugenol differs from methyl isoeugenol by the functional groups on the phenyl ring 
and the position of a double bond. Antagonism had also been seen in human olfactory receptors. 
The human receptor, OR1G1, could be activated by several odorants, with 9-carbons being the 
optimal chain length, and the agonist-induced response was inhibited by several shorter 6-
carbons odorants.6 These findings demonstrated that the response of odorants can be antagonized 
at the receptor, and structural variations in chain length and functional group, can change an 
agonist into an antagonist. In these cases, where the structure of the antagonist is related to the 
structure of the agonist (activating odorant ligand), it is assumed that the antagonist targets the 
same or overlapping binding site as the activating ligand, though this does not need to be the case 
as allosteric antagonists are known for other GPCRs.7  
While the aforementioned receptors are one of the many receptors that are activated by 
octanal and eugenol, they cannot be representative of the whole receptor set that generate the 
smell of each of these odorant. Octanal at 30 µM was found to activate 144 cells (6%) out of 
2301 cells from rats,3 and eugenol at 100 µM could activate 95 cells (3%) out of 3000 cells4 in 
previous experiments. Since each mature olfactory sensory neuron (OSN) express only one 
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olfactory receptor,8, 9 it’s possible that octanal’s and eugenol’s olfactory code involve several 
olfactory receptors. However, antagonizing the response of a single receptor may be sufficient to 
change the odorant’s smell. Currently, little is known about the degree at which antagonism 
affects the olfactory code and there is limited information on the determinants of antagonism in 
olfactory receptors. One way to study antagonism is to look at all (or a sampling of) the ORs in 
the mammalian olfactory system. Activation of an OR leads to an increase in the intramolecular 
calcium level, allowing a large repertoire of olfactory receptors to be screened and profiled at 
once via calcium imaging. Since each olfactory sensory neuron expresses only one olfactory 
receptor,8, 9 the response of an OR can be determined, with and without an antagonist, by 
studying the calcium level of olfactory sensory neurons.  
 Designated Agonist Tested as Antagonist 

































Cyclohexylethanoic acid (3.6) 
 
Table 3.1: Agonists and antagonists tested in OSNs. In Exp. A, 1-octanol (3.1) was treated as the agonist. In Exp. 
B, octanal (3.2) was treated as the agonist. In Exp. C, octanoic acid (3.3) was treated as the agonist. The 
individual odorants were first applied alone and then co-applied with the agonist. 
 
3.1.3. Factors causing mixture suppression  
In a mixture, reduced activation, compared to the individual components, may be 
attributed to other factors besides competition with the agonist for the active site. Other than 
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competing with the agonist for the orthosteric or active site, an odorant may also inhibit the 
receptor through binding to an allosteric site, another site on the receptor besides the orthosteric 
site. Additionally, an odorant may cause reduction in activity by activating alternative pathways. 
For instance, ORs have been found to display phosphoinositide 3-kinase (PI3K)-dependent 
antagonism with odorant pairs.10 Activation of PI3K would stimulate the production of 
phosphatidylinositol (3,4,5) triphosphate (PIP3) which negatively regulates the sensitivity of the 
ion channel and thereby reduce the signal of the receptor. However, the activation of two 
functionally distinct targets is expected to require very different ligands. The orthosteric and 
allosteric sites usually bind to structurally distinct molecules, and PI3K-dependent antagonism 
was achieved by odorant pairs with few structural similarities. For instance, the only structural 
similarity between citral and 1-octanol, which could be inhibited by citral in a PI3K-dependent 
manner,10 was their extended carbon chain, whereas their degree of saturation, functional groups, 
and the number of carbons are all different. In summary, very little is known about the structural 
attributes that distinguish an agonist from an antagonist in the orthosteric site of a receptor. It is 
expected that they will share some structural features, but it’s not clear what these features are. 
3.1.4. Experimental design: Length vs. functional group 
In this chapter, we aim to uncover the relative importance of the functional group 
(alcohol, aldehyde, or carboxylic acid) and of the carbon chain (linear vs. cyclic 8-carbon chain) 
in a presumed orthosteric antagonist. To reduce the possibility of an odorant modifying the 
response of a receptor through an allosteric site or a separate pathway, there should be minimal 
structural differences between the two odorants tested in the binary mixtures. The odorants in our 
study were designed to only differ from each other by either their chain length or their functional 
group. When the chain length is changed, the number of carbons is kept constant, but they are 
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conformationally restricted in a cyclohexyl ring. Thus, any decline in activity would most likely 
be linked to these structurally-related odorants competing for the same binding site on the 
receptor rather than stimulating distant sites or pathways. Accordingly, these two variations, 
chain length and functional group, were simultaneously evaluated as possible determinants of 
antagonism. In this study, the degree of antagonism elicited by binary mixtures in olfactory 
sensory neurons was analyzed (Table 3.1).   
The first experiment (please refer to Table 3.1) focused on all of the receptors that can be 
activated by 1-octanol (3.1). In the activated cells, 1-octanol (3.1) was applied as a binary 
mixture with octanal (3.2), octanoic acid (3.3), or cyclohexylethanol (3.4). Octanal (3.2) and 
octanoic acid (3.3) have the same number of carbons and unconstrained chain length as 1-octanol 
(3.1), but a different functional group. These mixtures tested the functional group as a decisive 
factor for antagonism. Cyclohexylethanol (3.4) has the same number of carbons and functional 
group as 1-octanol (3.1) but a shorter chain length. The mixture of the two tested for chain length 
as the source of antagonism. Since the structure of 1-octanol (3.1) is similar to that of octanal 
(3.2), octanoic acid (3.3), and cyclohexylethanol (3.4) (with the exception of the functional group 
or chain length), any antagonism seen, would most likely arise from competition for the 
orthosteric site, rather than from binding to a distinct allosteric site. The second experiment was 
conducted in a similar manner, except the designated agonist was switched from 1-octanol (3.1) 
to octanal (3.2). Octanal (3.2) was tested in a mixture with 1-octanol (3.1) or octanoic acid (3.3) 
to look at functional group and with cyclohexylethanal (3.5) to look at carbon chain length or 
shape as the determinant of antagonism. The same was done with octanoic acid (3.3) as the 
agonist. Octanoic acid (3.3) was tested in binary mixtures with 1-octanol (3.1) or octanal (3.2) to 
study the effect of functional group and cyclohexylethanoic acid (3.6) to study the effect of chain 
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length on antagonism. The response of endogenous ORs to the individual compounds and their 
binary mixtures in live mouse olfactory sensory neurons was obtained through calcium imaging. 
The odorant vehicle, or solvent, DMSO, was first applied to the cell as a negative control. 
Cells that respond to the solvent were not considered odorant-responding cells. Individual 
odorants were applied to the cells at the beginning of the experiment and again at the end of the 
experiment. Cells that failed to respond at the beginning or end (possibly due to sensitization or 
desensitization of the receptor) were not considered as an odorant-responding cell. Cells that 
gave irregular responses (i.e. noisy responses or a response when no odorant was applied) were 
not considered odorant-responding cells. Forskolin was applied at the end of the calcium imaging 
experiment to determine if the signal transduction pathway was still functioning. Forskolin is a 
molecule that bypasses the olfactory receptor to activate adenylyl cyclase. All cells that 
responded to forskolin were considered viable cells regardless of whether they responded to the 
odorants (viable cells may respond to functional groups and carbon chain other than the ones that 
were tested in this experiment). During calcium imaging screens with individual organic 
odorants, it is common to activate between 0 - 8% of the set of forskolin-responding cells (about 
2000 cells per mouse).  
 Different ORs will probably be activated and antagonized at different ligand 
concentrations. Since we cannot test all concentrations, 60 µM was the concentration chosen for 
this study. The odorant responses were in all cases normalized to the response of forskolin. 
Responses (of individual odorants) that were consistently lower than 10% of the response of 
forskolin were omitted. An inhibitory, and possibly antagonistic, response was defined as a 70-




3.2. Results and Discussion: 
The rodent olfactory system consists of around 1100 ORs,1 and the response profiles of 
over 10,000 viable cells (forskolin responding cells) were obtained and analyzed in total. 
Although the identity of the OR expressed in each cell was unknown, we aim to profile a 
majority of the olfactory receptor types through analyzing 10-fold the number of receptors. 
Olfactory sensory neurons were exposed to 60 µM of each odorant and then binary mixtures that 
contain the designated agonist and one other odorant at 60 µM. If the odorant is not an antagonist 
for the receptor expressed in an observed cell, then there should be no reduction in the response 
of the binary mixtures compared to the response of the agonist, but if the odorant is antagonizing 
the response of the agonist, the binary mixture will display a reduction in signal (Figure 3.1).  
 
Figure 3.1: Calcium imaging response of cells. A baseline was drawn from the DMSO response to the forskolin 
response and a line was drawn between the two peak signals of the designated agonist, applied before and after the 
binary mixtures. The height of the binary mixture response, x, and the height between the binary mixture response 
and the interpolated agonist response, y, were measured. To calculate the percent antagonism (signal reduction), y 
was divided by ‘x+y’ and multiplied by 100%. Only cells that show at least 70% reduction from the agonist 
response to the binary mixture response were considered to be inhibited.  (The odorant designated as the antagonist 




Figure 3.2: Percent activation and percent 
antagonism. Each row represents the relative 
response of one cell to the four odorants. The 
response of the cell to the designated agonist in 
each experiment is shown in the first column. The 
response of the cell to the other three odorants 
tested in the experiment is shown in the following 
three columns. The response of the agonist in each 
cell was antagonized by the odorant(s) whose 
compound number is bolded in the last column. The 
percentage of antagonism (% reduction of the 
agonist’s response) is given in parentheses. 
 
In order to be considered an antagonist, the 
molecule must not respond to the cell on 
its own (partial agonists could also lower 
the response of full agonists). 
3.2.1. Summary of antagonism   
The response of the agonist was 
reduced by at least 70% in 38 total cells 
(out of 11707 viable cells tested) (Figures 
3.2, 3.3). In the first experiment with 1-
octanol (3.1) as the agonist, 125 cells 
responded to 1-octanol (3.1) (out of 3830 
viable cells). Out of these 125 cells, 
antagonism was seen in 7 cells (5.6%). 
Octanoic acid (3.3) was the inhibitor in 2 
cells (1.6%), cyclohexylethanol (3.4) was 
the inhibitor in 4 cells (3.2%), and 1 cell 
(0.8%) was inhibited by both octanoic acid 






































second experiment with octanal (3.2) as the agonist, 82 cells were activated by octanal (out of 
3478 viable cells). Out of these 82 cells, inhibition was seen in 31 cells (37.8%). Two cells 
(2.4%) were inhibited by 1-octanol (3.1), 12 cells (14.6%) were inhibited by octanoic acid (3.3), 
12 cells (14.6%) were inhibited by 3.5, 1 cell (1.2%) was inhibited by both 3.1 and 3.5, 3 cells 
(3.7%) were inhibited by both 3.3 and 3.5, and 1 cell (1.2%) was inhibited by both 3.1 and 3.3. 
In the experiment with octanoic acid (3.3) as the agonist, 39 cells (out of 4399 cells) were 
activated by octanoic acid (3.3), but inhibition was never seen in any of these cells. Out of the 
three tested agonists, 3.1, 3.2, and 3.3, the cells activated by octanal (3.2) were the most 
susceptible to inhibition by one or more of the other compounds tested, being inhibited in 37.8% 
of the cells, followed by 1-octanol (3.1), which was inhibited in 5.6% of the cells, and cells 
activated by octanoic acid (3.3) was the least susceptible to inhibition (These data are 




Figure 3.3: Summary of antagonized cells. In Exp. A, there were 3830 forskolin responding cells, 125 1-octanol-
responding cells, and 7 1-octanol-responding cells that were antagonized by one or more of the three other 
compounds (designated antagonists). In Exp. B, there were 3478 forskolin responding cells, 82 octanal-responding 
cells, and 31 octanal-responding cells that were antagonized. In Exp. C, there were 4399 forskolin responding cells, 
39 octanoic acid-responding cells, and zero antagonized cell.  
 
3.2.2. Competitive Inhibition 
We limited our study to only a few structurally similar molecules, so that antagonism 
would most likely arise from competitive inhibition, but there would always be the chance that 
reduction in activity was due to other types of inhibition, in addition to the initiation of inhibitory 
G-protein pathways. To ask if some of the cells showing a reduction in response were due to an 
antagonist competitively inhibiting the active site, additional experiments were conducted to test 
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for competitive inhibition.4, 11, 12 We note that in all of our experiments, the identity of the OR 
expressed by the cells is unknown. Due to the nature of the experimental apparatus, we cannot 
inspect the data during the experiment and change to a different type of experiment on the same 
day. Consequently, after finding evidence for inhibition (Figure 3.2 and 3.3) we planned a new 
experiment specifically searching for evidence of pharmacologic antagonism. To determine if the 
inhibition was competitive, first the concentration of the antagonist was gradually increased, and 
then the concentration of the agonist was gradually increased. We should see a reduction in the 
agonist’s response as more antagonists compete with the agonist for the binding site, and we 
should see the agonist’s response recovering as more agonist is applied to compete with the 
antagonist for the binding site. 
Thus, in a new experiment, where one odorant was kept constant and the other varied by 
dose, out of 1775 forskolin responding cells, 8 cells (0.45%; compared to 0.46% in Experiment 
B) were found to show dose-dependent inhibition by a compound designated as an antagonist. 
As seen for one of the 8 cells in Figure 3.4A, the concentration of the agonist, octanal, was kept 
constant at 60 µM, while the concentration of the antagonist, 3.5, increased from 30 to 300 µM. 
The response of the agonist, octanal (3.2), was gradually reduced as higher concentrations of the 
antagonist, cyclohexylethanal (3.5), were applied. Conversely, in a separate experiment, an 
example of which is shown in Figure 3.4B, the concentration of the antagonist, 3.5, was kept 
constant at 60 µM, while the concentration of the agonist, octanal (3.2), increased from 30 to 300 
µM. Out of 1473 cells, the response of octanal was rescued in 2 cells (0.14%; compared to 
0.46% in Experiment B). In these cells, the response of the agonist, octanal (3.2), was lower 
when co-applied with 3.5. As the concentration of octanal (3.2) increased, the response of 
octanal (3.2) was recovered. 
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In comparison, the percentage of cells that were antagonized by 3.5 in these two 
experiments (0.45% and 0.14%) was lower than that in Experiment B (0.46%). Since a higher 
concentration (up to 300 µM compared to only 60 µM in Experiment B) of the antagonist, 3.5, 
was applied, we expected a higher percentage of cells to be antagonized. Due to experimental 
limitations, we have no control over the types of receptors that were sampled in each experiment, 
and the cells that were collected per experiment probably account for less than 1% of the total 
population of cells in the olfactory epithelium, so each of our experiment entail a stochastic 
sampling, that is, we cannot be sure the same receptors show up in every sampling. Furthermore, 
only a low number of cells were antagonized in each separate experiment so that the inclusion or 
omission of 1 or 2 cells as an antagonized cell would lead to a significant change in the 
percentages. Differences between experiments are inevitable, but we hope to converge to some 












Figure 3.4: Cells showing competitive inhibition. (A) Dose-dependent inhibition of octanal (3.2) by 
cyclohexylethanal (3.5). (B) Response of octanal (3.2) in the absence and presence of cyclohexylethanal (3.5). 
 
3.2.3. Trends between the ability to activate, to antagonize, and to be antagonized (Based 
on analysis of data from Experiments A, B, and C) 
Octanal (3.2), an aldehyde, activated the highest percentage of forskolin-positive cells 
(3.323%) (in agreement with previous work3, 13), followed by 1-octanol (3.1) (3.152%), an 
alcohol, and lastly octanoic acid (3.3), a carboxylic acid (0.880%) (Figure 3.5). This ordering 
holds true for their shorter cyclic counterparts as well, with 3.5, an aldehyde, activating the 
highest percentage of cells (1.67%), followed by 3.4 (0.52%), an alcohol, and 3.6 (0.21%), a 
carboxylic acid (Table 3.2). Although octanal (3.2) activated the most cells, it was also 
antagonized in the highest number of cells (31 cells, 37.8%, compared to 5.6% for octanol and 
0% for octanoic acid). Octanoic acid activated the fewest cells, but was antagonized in the least 
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number of cells (0 cells). Thus, the cells that were activated by the highest-activating odorant 
(octanal) were also the most susceptible to antagonism and vice versa (i.e. the cells that were 
activated by the least-activating odorant (octanoic acid) were the least susceptible to 
antagonism). However, since antagonism could only be seen for cells that were activated, it’s not 
entirely unexpected for the agonist that activated the highest percentage of cells to also be 
inhibited the most. One might also state that odorant GPCRs appear to like to bind aldehydes 
more than alcohols and acids, and binding may lead to activation or antagonism. 
In the tested binary mixtures (3.1&3.2, 3.1&3.3, and 3.2&3.3), antagonism was always 
observed to some extent. In the case of the binary mixtures containing 3.1 and 3.2, 3.2 never 
inhibited the response of 3.1, but 3.1 could inhibit the response of 3.2 in 4 cells (4.9%). For 
binary mixtures containing 3.1 and 3.3, 3.1 never inhibited the response of 3.3, whereas 3.3 
inhibited the response of 3.1 in 3 cells (2.4%). For binary mixtures of 3.2 and 3.3, 3.2 never 





Figure 3.5: Status of each odorant in the 11,707 cells as 1) designated agonist, 2) designated antagonist, and 3) an 
agonist whose response is inhibited (susceptibility to antagonism). The percentages are all relative to the total 
11,707 cells tested. 
 
The response to octanoic acid (3.3), when it was tested as the designated agonist, was 
never inhibited by any of the other odorants, but octanoic acid (3.3) was able to inhibit the 
response of the other odorants in several cells. (The odorants were diluted in solutions buffered 
to pH = 7.3. The odorants do not change the pH of the solution, eliminating the possibility that 
inhibition occurred due to change in the pH.) With the same chain length, but a different 
functional group, octanoic acid (3.3) inhibited the response of a total of 3 (out of 125) 1-octanol-
responding cells and 16 (out of 82) octanal-responding cells. In comparison, octanal (3.2) did not 
inhibit the response of any odorant, and antagonism by 1-octanol (3.1) was substantially lower, 
comprising of only 4 (out of 82) octanal-responding cells and 0 (out of 39) octanoic acid-
responding cells. In these experiments, the ability of one odorant to act as the antagonist 
appeared to be the reverse of their susceptibility to be antagonized (Figure 3.5). Octanal (3.2), 
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which did not inhibit the response of any cell, was antagonized in a total of 31 cells (out of 82), 
whereas octanoic acid (3.3), which antagonized a total of 19 cells, was never antagonized in any 
cell (out of 39). 1-Octanol (3.1) antagonized 4 cells and was antagonized in 7 cells. Hence, the 
best antagonist is the worst at being antagonized and vice versa. 
Although octanal (3.2) activated the most cells, it was never observed to inhibit the 
response of any cell activated by the other odorants tested. As the least activating odorant of the 
three functional groups tested, octanoic acid (3.3) was actually found to be the best inhibitor. 
Concurrently, octanal (3.2) is known to have a strong, citrus, fruity odor, whereas octanoic acid’s 
rancid smell is much fainter in comparison (though perhaps in part due to its higher boiling point 
and lower vapor pressure). In regards to the olfactory code, this characteristic of octanoic acid 
(3.3) suggest that weakly activating odorants might be triggering signal transduction in very few 
ORs, but they could still be binding to many receptors. Odorants with a faint smell may activate 
few receptors, but they may nevertheless be effective in masking the odor of highly activating, 
strong odorants. This speculative statement is suggested by our data.  
3.2.4. Effect of chain length and functional group on activation and antagonism 
Multiple ORs were seen to be inhibited by the linear carbon chain odorants and/or the 
shorter cyclic analog (Figure 3.2 and 3.3). The molecular features of chain length and functional 
group probably play a role in determining antagonism in ORs other than OR-I7 and mOR-EG 
(mentioned above), but overall, in our limited study, neither emerged as the clearly more 
important antagonist structural feature since the number of cells antagonized by each category, 
antagonists with a different chain type, linear or cyclic, (16 out of 38 antagonized cells) and 
antagonists with different functional groups (17 out of antagonized 38 cells), were similar (the 
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remaining 5 cells were antagonized by both antagonists with different chain length and 
antagonists with different functional group). 
However, cells that responded to only one odorant, and therefore only one of the three 
functional groups tested, were more commonly antagonized by the cyclic odorant bearing the 
same functional group (13 out of 20 antagonized cells, Figure 3.2, top: C1-C3, C4-C5, C7-C11, 
C14, C19-C20) than were antagonized by the linear odorants bearing a different functional group 
(5 out of 20 antagonized cells, Figure 3.2, top: C6, C12, C15, C17-C18 (the two remaining 
antagonized cells, C13 and C16, were inhibited by both a cyclic odorant bearing the same 
functional group and a linear odorant bearing a different functional group)). These types of cells 
appear to be selective for the odorant’s functional group, with antagonism or activation being 
determined by structural features of the carbon chain (in our study, the number of carbons in the 
chain did not vary). 
A majority of the antagonized cells that responded to more than one odorant (11 out of 18 
antagonized cells, Figure 3.2, bottom: C21-C22, C25-C26, C28-C33, C35) were inhibited by 
only octanoic acid (3.3). Since these cells could bind with multiple odorants, binding to these 
cells conceivably relies on the odorants’ affinity to the active site. These cells may be 
antagonized by octanoic acid (3.3) due to the higher affinity of octanoic acid for the binding site, 














Figure 3.6: Response of functional group-specific cells. (A) Response pattern of functional group-specific cells. (B) 
Proposed binding pockets of linear and cyclic odorant specific receptor. 
 
For all cells that are specific for functional groups, the response of the linear odorants 
was never higher than that of their cyclic counterpart. Cells which were specific for functional 
groups usually responded more strongly for the shorter, cyclic odorant. Within the group of cells 
that responded to both the linear and cyclic odorant bearing the same functional group, cells 
which responded more strongly for the linear odorant were never encountered though equipotent 
examples were observed (Figure 3.6A). The responses of the linear odorant were either the same 
as or lower than the response of the cyclic odorant. Since the linear and cyclic odorants contain 
the same number of carbons and the same functional group, but differ in their size and chain 
length, the cells that showed similar responses for the linear and cyclic odorants probably have 
little preference for the size or chain length. Conversely, the cells showing higher responses for 
the cyclic odorant probably prefer its more compact, rotationally restricted shape.  
The more flexible, linear odorants can adopt a conformation with a similar size and 
length as the cyclic odorants (Figure 3.6B). While the response of the linear odorant would be 
weaker due to unfavorable conformational entropy loss and/or steric clashes with amino acids in 
the receptor, it might still elicit a response in cells that prefer the cyclic odorant. No cells were 
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observed in which the response of the linear odorant was higher (at the same concentration) than 
the response of the cyclic odorant, but there should be cells that prefer the size and length of the 
linear odorant. In contrast to the flexible linear odorant, the constrained cyclic odorant could not 
adopt the chain length of the longer linear odorants (Figure 3.6B). As with the OR-I7 receptor, 
the cyclic odorant might act as an antagonist in this type of cell, binding to the receptor but not 
activating it due to failure to reach both the aldehyde and small hydrophobic activation pockets 
at the same time.5 Notably, there were as many cells that responded to only the linear odorant but 
were inhibited by only the cyclic odorant (3 for 1-octanol, Figure 3.2: C1-C3; 10 for octanal, 
Figure 3.2: C4-C5, C7-C11, C14, C19-C20; not applicable to octanoic acid) as the number of 
cells that responded to only the linear and cyclic odorants with the same functional group (2 for 
1-octanol, Figure 3.6A:C39-C40; 9 for octanal, Figure 3.6A: C41-C49). These inhibited cells 
may be cells that were more selective for the chain length of the linear odorant. As with the OR-
I7 receptor, the cyclic odorant was able to compete with the linear odorant for the binding site, 





3.2.4.2. Gem-diol vs. carboxylate 
Cells that responded to octanal (3.2) and 
octanoic acid (3.3) displayed a similar response 
pattern as the cells that responded to the linear and 
cyclic odorants bearing the same functional group. 
For all cells that responded to both octanal (3.2) and 
octanoic acid (3.3), the response of octanal (3.2) 
was never higher than the response of octanoic acid 
(3.3) (for C55-C56, the response of octanal and 
octanoic acid were both over 90% when normalized 
to forskolin, but the response of octanoic acid was 
noticeably higher (data not shown); the response of 
octanal was less than 70% of the response of 
octanoic acid in both C55 and C56) (Figure 3.7A). 
At equilibrium in the buffer solution (pH ~ 7.3), 
octanal (3.2) is partially hydrated to the gem-diol 
form and octanoic acid (3.3) would be fully 
deprotonated to a carboxylate. The carboxylate may be able to form stronger hydrogen bonding 
or carboxylate ionic interactions15, 16 with the OR compared to the gem-diol (Figure 3.7B), 
causing all the cells to produce a weaker response towards octanal (3.2).  
The higher affinity that the carboxylate may have for the receptors might explain why 
octanoic acid (3.3) was the best antagonist out of the three functional groups tested. Octanoic 






Figure 3.7: Cells responding to only octanal and 
octanoic acid. (A) Response pattern of all cells 
that respond to octanal (3.2) and octanoic acid 
(3.3). (B) Hydrolyzed form of octanal and 




never seen to inhibit the response of octanoic acid (3.3). It is worth mentioning that in several 
cells that initially responded to both octanal (3.2) and octanoic acid (3.3) individually (octanal 
giving the lower response), the cells stopped responding to octanal (3.2) by the end of the 
experiment, but they still responded to octanoic acid (3.3) (these cells were excluded from the 
final data due to their inconsistent response to octanal, which consequently lowered the actual 
percentage of octanal and octanoic acid responding cells). Exposure of the receptor to a strong 
ligand, octanoic acid (3.3), may possibly be desensitizing the response of the weaker ligand, 
octanal (3.2).  
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3.1 (1.32%)*  3.1 & 3.2 (1.44%)*  3.1, 3.2, & 3.3 (0.09%)*  3.1, 3.2, 3.3, & 3.4 (0.08%)A  
3.2 (1.31%)*  3.1 & 3.3 (0.00%)* 3.1, 3.2, & 3.4 (0.24%)A  3.1, 3.2, 3.3, & 3.5 (0.00%)B  
3.3 (0.57%)*  3.1 & 3.4 (0.05%)A  3.1, 3.2, & 3.5 (0.37%)B 3.1, 3.2, 3.3, & 3.6 (0.05%)C 
3.4 (0.52%)A  3.1 & 3.5 (0.12%)B  3.1, 3.2, & 3.6 (0.00%)C  
3.5 (1.67%)B 3.1 & 3.6 (0.00%)C 3.1, 3.3, & 3.4 (0.05%)A  
3.6 (0.21%)C 3.2 & 3.3 (0.13%)*  3.1, 3.3, & 3.5 (0.00%)B  
 3.2 & 3.4 (0.16%)A  3.1, 3.3, & 3.6 (0.00%)C  
  3.2 & 3.5 (0.29%)B 3.2, 3.3, & 3.4 (0.00%)A  
  3.2 & 3.6 (0.00%)C 3.2, 3.3, & 3.5 (0.00%)B  
  3.3 & 3.4 (0.00%)A 3.2, 3.3, & 3.6 (0.00%)C  
  3.3 & 3.5 (0.00%)B    






















*Tested in Experiments A, B, and C; ATested in Experiment A; BTested in Experiment B; CTested in Experiment C 
 
Table 3.2: Percentage of cells that were activated by 60 µM of odorant(s). The responses of 11707 viable cells were 
analyzed. Four odorants were tested in each experiment. The response to 1-octanol (3.1), octanal (3.2), and octanoic 
acid (3.3) was tested in every cell. All responses were normalized to the response of forskolin at 10 µM. To 
calculate the percentages, the number of cells activated by the indicated odorant(s) was divided by the total number 
of forskolin responding cells and multiplied by 100%. 
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3.2.5.1 Narrowly vs. broadly tuned cells 
 Cells that were specific for one odorant among the small set of related compounds tested 
here (these cells will be referred to as ‘narrowly tuned’ cells) were more common than cells that 
responded to more than one odorant (these cells will be referred to as ‘broadly tuned’ cells, 
though in the literature broadly tune usually means capable of being activated by a wide variety 
of functional groups and carbon chain shapes) (Table 3.2). Of the total 11707 viable cells tested 
at 60 µM, 5.6% responded to only one of the four odorants tested, 2.3% responded to two out of 
four odorants, 0.75% responded to three odorants and 0.13% responded to all four odorants. The 
percentage of responding cells were similar in the individual experiments (Figure 3.8 - 
Experiment A, with 1-octanol (3.1) tested as the agonist, Experiment B, with octanal (3.2) tested 
as the agonist, and Experiment C, with octanoic acid (3.3) tested as the agonist). Over half of the 
odorant-responding cells, responded to only one out of the four odorants tested, suggesting that 
most cells distinguish between these three closely related functional groups.  
 
Figure 3.8: Percentage of OSNs responding to 1, 2, 3, or 4 odorants in each experiment. In Experiment A, 1-octanol 
(3.1) was tested as the agonist. There were 3830 forskolin-responding cells. In Experiment B, octanal (3.2) was 
tested as the agonist. There were 3478 forskolin-responding cells. In Experiment C, octanoic acid (3.3) was tested as 



























The highest number of antagonized cells (20 cells) came from the ‘narrowly tuned’ cells 
that responded to only one of the four odorants. The number of antagonized cells gradually went 
down for the less common cell types - cells responding to two odorants (11 antagonized cells) 
and cells responding to three odorants (7 antagonized cells). Since the “narrowly tuned” cells 
were most common, these cells should statistically have a higher chance of being antagonized 
compared to the less common cell types. 
In Figure 3.2, the cells showing antagonism were divided into two groups, those that are 
‘narrowly tuned,’ responding to only one odorant, in this case the agonist (Fig. 3.2, top), and 
those that respond to more than one odorant, including the agonist (Fig. 3.2, bottom). Among the 
cells that responded to only one out of the four odorants tested, a majority of the cells were 
antagonized by the cyclic odorant of the same functional group (13 out of 20 antagonized cells), 
whereas among cells that responded to more than one odorant, a majority were antagonized by 
octanoic acid (3.3) (11 out of 18 cells showing antagonism). The total number of cells inhibited 
by antagonists with a shorter chain length than the agonist (16 cells) was similar to the number of 
cells inhibited by antagonists with a different functional group from the agonist (17 cells), but 
chain length appeared to be a more common determinant of antagonism among ‘narrowly tuned’ 
cells, whereas functional group, specifically the carboxyl group of 3.3, appeared to be a more 
common determinant among ‘broadly tuned’ cells. 
Of the ‘broadly tuned’ cells that showed antagonism, the odorant that was antagonized in 
each cell was never the one that stimulated the highest response. Consequently, the response of 
the designated agonist was never inhibited in a ‘broadly tuned’ cell wherein the agonist gave the 
strongest signal. In these antagonized cells, the agonist had the same or a weaker signal than the 
other odorants that could activate those cells (Figure 3.2, bottom). The agonist may possibly 
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have a similar or lower efficacy and/or affinity for these receptors, and consequently its response 
would be easier to antagonize in these cells, just as it was more difficult to antagonize the 
response of octanoic acid (3.3), which was expected to have a higher affinity for the receptors 
due to ionic interactions with charged amino acids in addition to hydrogen bonding. 
3.2.5.2. 1-Octanol and octanoic acid responding cells 
 
Figure 3.9: Cells that respond to 1-octanol (3.1) and octanoic acid (3.3), but not octanal (3.2). 
Among the antagonized cells, there were no cells that could bind to 1-octanol (3.1) and 
octanoic acid (3.3) (as an antagonist), without also binding to octanal (3.2). In other words, cells 
responding to the alcohol and acid appeared obligated to also bind the aldehyde. This may relate 
to how a receptor recognizes and distinguishes these functional groups. The cells that respond 
only to 1-octanol (3.1) (Fig. 3.2, top) were only antagonized by the cyclic alcohol (3.4), and the 
cells that were antagonized by octanoic acid (3.3) (Fig. 3.2, bottom) responded to octanal (3.2) in 
addition to 1-octanol (3.1). Hence, none of the antagonized cells were able to bind with only 1-
octanol (3.1) and octanoic acid (3.3).  
114 
 
In related work published by 
Araneda et al. in 2004, no cells 
were found to respond only to 1-
octanol (3.1) and octanoic acid 
(3.3), without also responding to 
octanal (3.2) at 30 µM and 300 
µM.3 However, this observation 
was based on the response of less 
than 150 cells that responded to 1-
octanol (3.1), octanal (3.2), and/or 
octanoic acid (3.3). Under our 
experimental conditions, we 
analyzed over 500 cells that 
responded to 1-octanol (3.1), 
octanal (3.2), and/or octanoic acid 
(3.3) at 60 µM out of the 11,707 
cells that responded to forskolin. Of 
these cells, there were two cells that 
responded to 1-octanol (3.1) and 
octanoic acid (3.3), but not octanal 
(3.2), (Figure 3.9). Aside from the 
difference in relative intensity 














Figure 3.10: Categories of hypothetical receptors. (A) Receptor 
that is selective for alcohols. (B) Receptor that is selective for the 
carbonyl group. (C) Receptor that is selective for the hydroxyl group. 
(D) Receptor that is selective for molecules containing a single 
hydroxyl group.  
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likely expressed the same receptor, suggesting that there is at least one olfactory receptor in the 
mouse genome that can bind 1-octanol (3.1) and octanoic acid (3.3) but not octanal (3.2). In this 
case, it occurs in 0.017% of all viable cells (roughly 1 out of 5000 cells). Due to experimental 
limitations, it was not possible to look at every single cell, and thus every receptor, in the 
olfactory epithelium, but the more cells that are analyzed the closer we would be to analyzing all 
the olfactory receptors. 
Theoretically, given a constant carbon chain shape, distinguishing the alcohol and 
carboxyl group from the aldehyde group should be difficult. A receptor that is specific for 
alcohols would bind with 1-octanol (3.1) and the gem-diol form of octanal (3.2) (Figure 3.10A). 
A receptor that is specific for the carbonyl group would bind with the aldehyde form of octanal 
(3.2) and octanoic acid (3.3) (Figure 3.10B). A receptor that is specific for the hydroxyl group 
(or hydrogen donors) would be expected to bind only 1-octanol (3.1) and octanoic acid (3.3), but 
because octanal (3.2) forms a significant amount of the gem-diol form,17-19 such a receptor could 
bind to all three functional groups (Figure 3.10C). For a receptor to interact with 1-octanol (3.1) 
and octanoic acid (3.3) but not octanal (3.2), either the concentration of the gem-diol form 
(present at equilibrium in roughly half the amount of octanal (3.2) applied) was not high enough 
to activate the receptor selective for hydrogen donors (1-octanol (3.1), octanal (3.2), and octanoic 
acid (3.3) were all tested at the same concentration (60 µM), so the fraction of octanal (3.2) that 
became hydrated to the gem-diol would be considerably lower compared to the concentration of 
1-octanol and octanoic acid present) (i.e. the receptor depicted on Figure 3.10C), or the receptor 
could only accommodate one hydroxyl group, whereas there is two present on the gem-diol form 




3.2.5.3. 1-Octanol and octanal responding cells 
The percentage of cells that responded selectively to one odorant was always observed in 
our experiment to be higher than the percentage of cells responding to more than one odorant, 
with one exception: cells that respond to both 1-octanol (3.1) and octanal (3.2). The percentage 
of cells responding to this pair of odorants (1.44%) was comparable to or even higher than the 
percentage of cells that responded to single odorants, with the percentage of cells responding to a 
single odorant being highest for 1-octanol (1.32%) and octanal (1.31%). Cells responding to the 
other pairs of odorants were noticeably lower (Table 3.2, column 2), with the percentage of the 
next most common cell type (aldehyde-specific cells responding only to 3.2 and 3.5, 0.29%) 
being around 5-fold lower. Much of the cells appeared to be unable to distinguish between the 
alcohol and aldehyde group.3, 13 Of all the cells that responded to octanal (390 cells), 53% (205 
cells) were found to also respond to 1-octanol at 60 µM (49%3 and 68%19 of octanal-responding 
cells were found to also respond to 1-octanol in rat OSNs at 30 µM). The high percentage of 
cells responding to alcohol 3.1 and aldehyde 3.2 might be attributed to the gem-diol form of 
aldehyde 3.2. It was previously found that 42% of cells that appear to require (i.e. specific for) 
the aldehyde group for activation responded to the gem-diol form.19 The gem-diol form differs 
from the aldehyde form in terms of geometry, hydrogen bonding, and dipole strength and 
direction to such an extent that it could be considered a different functional group. The hydration 
equilibrium constant (KH) for aliphatic aldehydes is around 0.83 at 25°C,17-19 so accordingly, 
approximately 45% of the aldehyde is converted to the gem-diol in water at equilibrium. Since 
aldehydes convert to the gem-diol form in approximately a one to one ratio in the presence of 
water, some of the cells activated by octanal (3.2) may possibly be activated by its gem-diol 
form. Cells that responded to both 1-octanol (3.1) and octanal (3.2) may express receptors that 
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are specific for the hydroxyl group of alcohols (Figure 3.10A). A portion of the 1-
octanol/octanal-responding cells may be responding to 1-octanol (3.1) and the gem-diol form of 
octanal (3.2). At the same time, for cells where octanal (3.2) was antagonized, it might actually 
be the gem-diol form that was antagonized by the antagonists with the different chain length 
and/or functional group. 
3.3. Conclusions 
In this study, limited to the main oxygen functional groups with different oxidation states 
(alcohol, aldehyde, and carboxylic acid) with either an eight carbon linear chain or an eight 
carbon shorter chain with a cyclohexyl ring, a few notable trends were observed regarding 
antagonism. There did not appear to be a clear preference for either chain type or functional 
group type as the determinant of inhibition, but octanoic acid (3.3) inhibited the highest 
percentage of cells out of the three functional groups tested. Carboxylic acids may have higher 
affinity for ORs compared to aldehyde and alcohol possibly due to strong hydrogen bonding and 
charge-charge interactions. While octanoic acid (3.3) inhibited the response of the most cells 
compared to 1-octanol (3.1) and octanal (3.2), it was also the weakest activator, activating the 
lowest percentage of cells. In comparison, although octanal (3.2) did not inhibit the response of 
any cells, it was the best activator, suggesting a possible inverse-correlation between the ability 
of an odorant to activate versus inhibit ORs. None of the functional group-specific receptors 
responded more strongly to the linear odorant compared to the cyclic odorant, suggesting that 
chain length/shape may be a dominant feature of functional group-selective ORs. When an 
odorant contains a chain below a certain length (number of carbons), it may bind but fail to 
satisfy some distal steric requirement for activation, and becomes an antagonist. A relatively 
small set of odorants were tested in this study to ensure the viability of the cells by the end of the 
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experiment. In order to confirm the observed trends, a larger set of odorants would need to be 
tested. 
In this study, agonism appears to be more common than antagonism, but in comparison to 
agonism, it’s more difficult to identify all the cells that were antagonized. Activation of a cell is 
determined from the rise in the calcium level, but since there would be no change in the calcium 
level when a ligand binds but not activate a receptor, it is not possible to check for antagonism 
(i.e. binding) if an agonist of the receptor was not present. In this study, we only see antagonism 
in the cells that were activated by one of the odorants designated as an agonist. Each odorant 
might be binding a higher percentage of cells than what was observed, but evidence of 
antagonism was only limited to the cells in which an agonist was applied. In addition, only one 
concentration (60 µM) was used for the agonist and antagonist. Even though the response of the 
agonist might not be inhibited at 60 µM by an antagonist, it may be inhibited if a higher 
concentration was applied, and in designing such experiments, it is not clear what concentrations 
are the most physiologically relevant. To ensure that the reduction in signal was due to 
antagonism and not signal fluctuation, only cells showing over 70% reduction in activity were 
considered to be antagonized (we did not want to mistake response-to-response variation for 
antagonism), but there may also be cells that were antagonized, and suppressed by less than 70% 
at the tested concentration. Thus, we used a stringent criterion for calling antagonism. 
The percentage of antagonism in cells may be underestimated in this study, but still, 
antagonism was seen in several cells and as long as antagonism occurs, the original olfactory 
code of the odorant would be modified. All of the tested binary mixtures (3.1&3.2, 3.1&3.3, and 
3.2&3.3; not applicable to the mixtures containing the cyclic odorants because antagonism of the 
cyclic odorant by the linear odorant was not tested in all possible combinations, but signs of 
119 
 
antagonism were already seen for 3.1&3.4 and 3.2&3.5) displayed some degree of antagonism. 
In each pair of odorants, one of the two odorants would serve as the antagonist, while the other 
acted as the agonist. Unlike rodents, humans are predicted by their genomic DNA to have only a 
few hundred olfactory receptors, but we may be exposed to hundreds of different odorants at 
once. As more receptors become activated, everything would be expected to eventually converge 
to the same smell if antagonism, or some other kind of mixture suppression,2 were not at work in 
the mixture. Mixtures clearly do not all converge to the same smell. Antagonism of the receptors 
may possibly act as a fine tuning mechanism to produce the smell that we experience, with our 
larger brains sorting out the greater combinatorial complexity of signals generated in the nose.     
3.4. Experimental Procedures 
Materials and reagents 
Unless otherwise stated, chemical reagents and solvents were purchased from VWR 
International, Fisher Scientific, or Sigma Aldrich and used without further purification. C57BL/6 
mice were purchased from Charles River Laboratories. Octanal (3.2) was distilled before use. 1-
Octanol (3.1) and octanoic acid (3.3) were purified by flash chromatography prior to testing. 
Aldehydes were stored at 4°C under vacuum prior to testing. Analytical TLC was performed on 
silica gel 60 F254 plates. Flash chromatography20 was performed on Teledyne Isco CombiFlash 
Rf-200 flash chromatography system. 1H and 13C NMR spectra were recorded on a Varian 
Mercury 300 spectrometer or a Bruker Ultrashield 500 spectrometer. Infrared (IR) spectra were 
recorded using Thermo Nicolet 6700 FT-IR spectrometer. (Note: The literature procedure that 
was applied for each reaction is cited. The procedure may not necessarily be used for the 
synthesis of the same compound as in the literature.) 
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2-Cyclohexylethanol (3.4) (Compound 2.2a in chapter 2). Compound 3.4 was 
synthesized according to a literature procedure.5 Ethyl cyclohexylacetate (2 g, 11.7 
mmol) in diethyl ether (10 mL) was added slowly to lithium aluminum hydride (0.49 
g, 13 mmol) in diethyl ether (40 mL) at 0°C. The suspension was stirred at room temperature for 
2 h and then cooled to 0°C. Water (0.5 mL) was added, followed by 15% sodium hydroxide (0.5 
mL) and water (1.5 mL). The solution was stirred for a few minutes at room temperature, filtered 
through a celite pad, washed with diethyl ether, dried, and concentrated. The crude was purified 
by flash chromatography eluting with ethyl acetate/hexanes (1:9) to obtain the alcohol 3.4 (1.5 g, 
11.7 mmol) as a clear liquid in 99% yield. 1H NMR (CDCl3) δ: 3.68 (t, J = 6.7 Hz, 2H), 1.78 - 
1.59 (m, 5H), 1.51 - 1.11 (m, 7H), 1.02 - 0.84 (m, 2H). 13C NMR (CDCl3) δ: 60.89, 40.39, 34.22, 
33.38, 26.57, 26.29. IR (thin film, KBr plates) ν (cm-1): 3332 (broad), 2922, 2852, 1448, 1051, 
1011, 978. Spectral data match those reported previously.5  
Cyclohexylacetaldehyde (3.5) (Compound 2.2 in chapter 2). Compound 3.5 was 
synthesized according to a literature procedure.5 The alcohol 3.4 (200 mg, 1.56 mmol) 
was added to pyridinium chlorochromate (370 mg, 1.7 mmol) and silica gel (370 mg) 
in dry dichloromethane (10 mL) under inert atmosphere. The suspension was stirred for 2 h and 
then passed through a silica gel pad. The solution was concentrated to give the aldehyde 3.5 (140 
mg, 1.11 mmol) in 71% yield. 1H NMR (CDCl3) δ: 9.75 (s, 1H), 2.29 (dd, J = 1.9, 6.9 Hz, 2H), 
1.97 - 1.57 (m, 6H), 1.40 - 0.84 (m, 5H). 13C NMR (CDCl3) δ: 203.00, 51.38, 33.22, 32.68, 
26.04, 25.97. IR (thin film, KBr plates) ν (cm-1): 2925, 2853, 2712, 1725, 1449, 1408, 1297, 





Cyclohexylethanoic acid (3.6). Compound 3.6 was synthesized based on a 
literature procedure.21 Ethyl cyclohexylacetate (936 mg, 5.5 mmol) was placed in 1 
M NaOH (90% methanol in water, 30 mL) and stirred for 3 h. The mixture was 
concentrated and water (25 mL) was added. The solution was acidified with 5 M HCl (6 mL) and 
extracted with ethyl acetate (3 × 20 mL). The organic layer was washed with brine, dried, and 
concentrated. The crude was purified by flash chromatography eluting with ethyl acetate/hexanes 
(1:9) to give the carboxylic acid 3.6 (560 mg, 3.9 mmol) in 72% yield. 1H NMR (CDCl3) δ: 
11.57 (s, 1H), 2.23 (d, J = 6.3 Hz, 2H), 1.91 - 1.52 (m, 6H), 1.44 - 1.08 (m, 3H), 1.08 - 0.69 (m, 
2H). 13C NMR (CDCl3) δ: 179.55, 41.90, 34.66, 32.97, 26.09, 26.00. IR (thin film, KBr plates) ν 
(cm-1): 3029 (broad), 2925, 2853, 1707, 1449, 1411, 1297. Spectral data match those reported 
previously.22, 23 
Calcium imaging of mouse olfactory sensory neuron 
Calcium imaging was performed as described previously.5 All animal procedures were approved 
by the City College of New York Institutional Animal Care and Use Committee (IACUC) and 
performed at the City College of New York in compliance with relevant national guidelines and 
regulations. Dissociated olfactory epithelium tissue was obtained from 6-8 weeks old C57B/6 
mice by my colleague, Mihwa Na. The tissues were placed into a 15 mL Corning conical 
polypropylene centrifuge tube containing an enzyme solution made with BSA (0.015 g), 
collagenase (0.0025 g), and 3 mL of DICAT-free Ringer solution containing sodium chloride 
(145 mM), potassium chloride (5.6 mM), HEPES at pH 7.4 (10 mM), glucose (10 mM), and 
EGTA (4 mM). The cells were incubated at 37°C for 1 h in the enzyme solution. The tissues 
were then allowed to settle to the bottle of the conical tube and the enzyme solution was replaced 




Insulin-Transferrin-Selenium-X (Gibco). Most of the media was removed and the tissues were 
gently vortexed to dissociate the cells. The cells were allowed to adhere to coverslips pre-coated 
with the protein concanavalin A. The cells were allowed to recover in the media containing 0.02 
M vitamin C (ascorbic acid) at 37°C for 45 minutes. The media was then replaced with 1 mL of 
Ringer solution (sodium chloride (138 mM), potassium chloride (5 mM), HEPES at pH 7.4 (10 
mM), calcium chloride (1 mM), magnesium chloride (1.5 mM), and glucose (10 mM)) 
containing Fura-2 (6.25 µL) and pluronic acid (1 µL), and incubated for another 45 minutes at 
room temperature in the dark. The cells were placed in new Ringer solution and left at room 
temperature for 10 minutes. The coverslip containing the cells were viewed under a fluorescence 
microscope and the response was obtained using Metamorph. Odorants were applied via in-line 
syringes hooked up to a manifold for 8 seconds at 2 minutes intervals and the antagonist was 




Chapter 4: Small molecular activators of the pre-mRNA 3’ cleavage reaction 
Parts of this chapter have been published in Bioorganic and Medicinal Chemistry, 22 (2), Liu, 
M.; Nagre, N. N.; Ryan, K., Structurally diverse low molecular weight activators of the 
mammalian pre-mRNA 3’ cleavage reaction, 834-841.   
4.1.  Introduction 
 Eukaryotic pre-messenger RNA (pre-mRNA) undergoes multiple processing steps prior 
to translation, and each of these steps provides the cell with an opportunity for gene expression 
regulation.1 The pre-mRNA 3’ cleavage step, a site-specific RNA hydrolysis reaction that 
specifies where the polyadenylate (poly(A)) tail will be added to the mRNA, can take place at 
different locations near the 3’ end of a nascent mRNA, downstream of the translation stop codon. 
This variability leads in many genes to alternative mRNA isoforms with different 3’ untranslated 
regions (3’UTRs) between the stop codon and the poly(A) tail.2, 3 The pre-mRNA 3’ cleavage 
step can influence the stability of the mature mRNA because many 3’UTRs contain destabilizing 
sequences and miRNA binding sites, the loss of which, when 3’ cleavage occurs relatively close 
to the stop codon, may slow turnover and allow escape from repression.2, 4-6 Shorter 3’UTRs 
resulting from alternative polyadenylation in some oncogenes have been correlated with cellular 
proliferation and may contribute to oncogenesis.7, 8 The 3’ cleavage and polyadenylation 
reactions are coupled in vivo but can be studied separately in vitro. Natural product inhibitors of 
the pre-mRNA polyadenylation step have recently been found.9, 10 However, low molecular 
weight compounds that influence the 3’ cleavage step in cells are not yet available, but would 
enable new experimental inquiries into the multi-protein complex that carries out 3’ cleavage, 
and might provide a chemical tool to influence alternative polyadenylation. 
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 We previously found in vitro evidence that a kinase-phosphatase pair may exert influence 
over the 3’ cleavage reaction.11 Considering this possibility led us to propose that creatine 
phosphate, long known to stimulate the in vitro reaction at high concentration,12, 13 might do so 
by acting as a serendipitous inhibitor of an unknown 3’ cleavage-suppressing protein 
phosphatase. This model led to experiments identifying two protein phosphatase 2C (PP2C, 
a.k.a. PPM1) family inhibitors that stimulated 3’ cleavage in place of creatine phosphate.14 In 
humans, the PPM1 superfamily consists of at least eighteen different Mg2+- or Mn2+-dependent 
Ser/Thr phosphatases defined by shared sequence homology.15-18 In plants, the PPM1 family is 
greatly expanded, with at least 80 family members in Arabidopsis.19 The in vitro 3’ cleavage 
reaction is carried out in the presence of excess EDTA, where free Mg2+ and Mn2+ 
concentrations are very low. Thus, if a PPM1 family member is involved in vitro, it would likely 
act in a manner that does not require its metal-dependent enzymatic activity, perhaps acting 
allosterically or by influencing the multi-protein 3’ cleavage factor complexes.  
While progress in other major protein phosphatase families has benefited from the 
identification of natural product inhibitors,20 inhibitor discovery for the PPM1 family has been 
slower. The inhibitors we previously identified as 3’ cleavage activators had been discovered 
using the PPM1A family member.21 They had micromolar potency against PPM1A and only 
modest selectivity for the PPM1 family over the other major protein phosphatase families.21 By 
analogy with the toxin inhibitors of the other protein phosphatase families, we expect PPM1 
inhibitors to show a measure of family-specific activity, enabling 3’ cleavage activation even if 
PPM1A is not the actual family member involved in pre-mRNA 3’ cleavage. Here, we have 
tested more potent PPM1 inhibitors for pre-mRNA 3’ cleavage activity, and carried out 
structure-activity relationships for two previously identified 3’ cleavage activators. Though we 
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are not yet able to identify the protein targeted by these small molecules, our results strengthen a 
model in which a PPM1 family member or related protein acts to suppress 3’ cleavage in vitro.  
4.2. Results and Discussion 
4.2.1. Pre-mRNA 3’ cleavage activation by a potent PPM1D cyclopeptide inhibitor 
Cyclic phosphopeptides based on substrates of the PPM1D family member, also known 
as Wip1, are among the most potent inhibitors of any PPM1 family phosphatase.22, 23 We used 
one of these, cyclic peptide 38 (cp38, Fig. 4.1A),22 in place of 50 mM creatine phosphate in the 
in vitro pre-mRNA 3’ cleavage reaction. This peptide inhibits PPM1D with a Ki of 150 nM.22 In 
the 3’ cleavage assay, a standard in vitro pre-mRNA 3’ cleavage substrate adapted from the 
simian virus 40 (SV40) late poly(A) signal24 is exposed to partially purified 3’ cleavage factors 
from HeLa cell nuclear extract.11, 13, 25, 26 Cleavage of the radiolabeled substrate into its 5’ and 3’ 
fragments can be observed and quantitated following resolution on a denaturing polyacrylamide 
gel. In the absence of creatine phosphate, or other activator, this reaction is inefficient. In all 
experiments presented here, the amount of cleavage brought about by an activator (5’ 
fragment/(5’ fragment+uncleaved SV40L RNA)) is normalized to that brought about by 50 mM 
creatine phosphate (R.C., or relative cleavage in figures). As shown in Fig. 4.1B, at 200 nM, 
cp38 activated a level of RNA cleavage comparable to that produced by 50 mM creatine 
phosphate. Removal of cp38’s serine and tyrosine phosphate groups with calf intestinal alkaline 
phosphatase (CIP) prior to cleavage, led to complete loss of activation, while removal of only the 
tyrosine phosphate, using a tyrosine-specific phosphatase, did not reduce activity. (Residual CIP 
activity was inhibited11 before cp38 was added to the in vitro reaction to prevent possible 
dephosphorylation of the cleavage factor proteins.) A repeat of this experiment is shown on 
Figure 4.1D. Cyclopeptide cp38 is therefore 1000-fold more potent than the most potent 3’ 
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cleavage activator previously identified,14 and phosphorylation of its serine, which is required for 
PPM1 inhibition,23 is required to activate pre-mRNA 3’ cleavage. PPM1D is present at very low 
levels in HeLa cells,27 an observation that lead us to suppose that cp38 is likely not working 
through this PPM1 family member, but may instead be a family-specific inhibitor that activates 
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Figure 4.1: Pre-mRNA in vitro 3’ cleavage activation by PP2C inhibitors. (A) Structure of cyclic peptide cp38 and 
(S)-(+)-abscisic acid (ABA). (B) Denaturing gel analysis of SV40L pre-mRNA 3’ in vitro cleavage reactions 
activated by cp38. Creatine phosphate (CP) or cp38 was added, with or without pre-treatment with CIP (calf 
intestinal alkaline phosphatase), mock CIP (CIP buffer only) or tyrosine phosphatase (YOP). Residual CIP activity 
was completely removed before mixing cp38 with cleavage factor proteins.11 Relative cleavage (R.C. = [5’ 
fragment/(5’ fragment + uncleaved RNA)]X100) was normalized to CP, which is set to R.C. = 1.00. (C) Denaturing 
gel analysis of in vitro cleavage using ABA in place of CP. DMSO lane corresponds to reaction without ABA. (D) 
Repeat of pre-mRNA 3’ cleavage reaction using cp38 as activator. (E and F) Repeat of pre-mRNA 3’ cleavage 
reaction using ABA as activator. 
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4.2.2. Pre-mRNA 3’ cleavage activation by abscisic acid 
To further test the hypothesis that a PPM1 family member acts to suppress 3’ cleavage, 
we used the isoprenoid plant hormone (S)-(+)-abscisic acid (ABA). This natural product is a 
potent inhibitor of the group A plant PPM1 enzymes.28 It works by forming a ternary complex 
with the PPM1 enzyme and a co-receptor from the PYR/PYL/RCAR family of ABA receptors.28, 
29 For example, ABA inhibits the plant PPM1s ABI1 and ABI2 with IC50 values of 60 nM and 70 
nM, respectively, when RCAR1 is present.29 ABA is bound mainly by the PYR/PYL/RCAR 
receptor, but also makes contact with the PPM1.30, 31 In the absence of a PYR/PYL/RCAR co-
receptor, ABA can directly inhibit some plant PP2C/PPM1 enzymes in vitro, though with much 
lower potency. For example, ABA reduces ABI2 phosphatase activity in vitro by about 15% at 
ABA concentrations above 3 M.29 We found no pre-mRNA 3’ cleavage activation when 
nanomolar concentrations of ABA were used in place of creatine phosphate (not shown). 
However, at and above 100 M ABA, approximately 10%-15% of the normal 3’ cleavage 
activity was observed (cf. 50 mM creatine phosphate) (Fig. 4.1C). Two repeats of this 
experiment are shown on Figures 4.1E and 4.1F. We consider two possible interpretations of this 
result. First, the absence of activation at nanomolar ABA concentration may indicate that there 
are no conserved mammalian proteins that can act in the manner of the plant PYR/PYL/RCAR 
co-receptors, though ABA is found in animal cells.32 A BLAST search did not reveal any human 
RCAR homologs. Second, homology between the plant and human PPM1 proteins may be 
sufficient to conserve the direct but much less potent inhibition of PPM1 family members. In 
either case, though its cleavage activation efficiency was low, compared to our first generation 
compounds, ABA is a relatively potent 3’ cleavage activator. This result adds to the 
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accumulating though circumstantial evidence that a PPM1 family member can influence pre-
mRNA processing. 
4.2.3. Structure-activity study of arginine β-naphthylamide: Aryl group and side chain 
Prior to the present work, compound 4.1 (Fig. 4.2A) was identified as a 3’ cleavage 
activator through a limited structure-activity relationship study undertaken using commercially 
available compounds related to our initial lead, leucine β-naphthylamide, a weak PPM1A 
inhibitor.14 To search for a more potent activator than 4.1, we synthesized a series of analogs in 
which the naphthalene ring was altered (Fig. 4.2A, 4.2-4.4) or the guanidino group was alkylated 





















Figure 4.2: Structure-activity study of compound 4.1, previously found to activate pre-mRNA 3’ cleavage in vitro. 
(A) Analogs included changes to the naphthyl group and the arginine side-chain of 4.1. (B) In vitro 3’ cleavage 
results for duplicate cleavage reactions using the indicated analogs in place of 4.1, all at 1 mM. R. C., relative 




The synthesis of compounds 4.2-4.6 (Scheme 4.1, A and B) was accomplished by coupling the 
relevant aryl amine to the suitably protected arginine, ornithine or lysine, followed by 







Scheme 4.1: (A and B) Synthesis of the arginine--naphthylamide analogs used in Fig. 4.2. (C) Synthesis of 
morpholine analog 4.7 used in Fig. 4.3. 
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We evaluated each of the compounds shown in Fig. 4.2A for their ability to activate in vitro 3’ 
cleavage at 1 mM in place of, and compared to, 50 mM creatine phosphate. The results of 
duplicate reactions are shown in four independent 3’ cleavage reactions in Fig. 4.2, B-E. 
Changes to the naphthalene ring and guanidino group of 4.1 led to loss of activity (compounds 
4.2, 4.3, 4.4, 4.5), and the guanidino group could not be replaced by trimethylammonium 
(compound 4.1 vs. 4.6), even though both groups have a positive charge.  
4.2.4. Arginine β-naphthylamide modified at the -position retains potency 
In previous work we found that acetylation of the -amino group of leucine -
naphthylamide led to some loss of that compound’s 3’ cleavage activity, as well as a significant 
decrease in solubility, a point of practical importance due to the high activator concentrations 
needed for activity. In view of the poor results changing the naphthyl and guanidino groups of 
lead compound 4.1, we decided to modify the -amino group. To minimize a reduction in 
solubility we chose the morpholine group for its high water solubility (compound 4.7, Fig. 4.3, 
and Scheme 4.1C). Unlike the other changes, this modification retained activity. A representative 
in vitro 3’ cleavage comparison of 4.7 with 4.1 over 25 to 200 M (as usual, in place of, and 
compared to, creatine phosphate) is shown in Fig. 4.3B. Corroborating experiments are shown on 
Figure 4.3C and 4.3D. Compound 4.7 proved to be slightly more potent than lead compound 4.1, 
and to have a similar maximum relative cleavage (Fig. 4.3B). While only slightly more potent 
than 4.1, the activity of compound 4.7 indicates that modifications of the alpha amine can be 
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Figure 4.3: Structure and 3’ cleavage activity of a morpholine-modified arginine--naphthylamide analog. (A) 
Structure of 4.7. (B) Side by side comparison of 4.1 and 4.7 in an SV40L pre-mRNA 3’ in vitro cleavage reaction. 
R. C., relative cleavage, as defined in Fig. 4.1, with activation by 50 mM creatine phosphate (CP) set to 1.00. (C 
and D) Repeats of pre-mRNA 3’ cleavage reaction. 
 
4.2.5. Structure-activity study on phosphocholine 
We previously identified phosphocholine as a pre-mRNA 3’ cleavage activator. Like 
creatine phosphate, it activates 3’ cleavage over the 10-50 mM range.14 Its ability to inhibit 
PPM1 family proteins is unknown. Phosphocholine is an intermediate in the biosynthesis of 
phosphatidylcholines, and it is unlikely to be a physiological cofactor in 3’ cleavage.14 However, 
understanding the determinants of 3’ cleavage activity of this very simple structure might help us 
to design more potent activators. To learn whether all three methyl groups are necessary for 
activity, we synthesized the mono- and dimethyl phosphocholine analogs, 4.9 and 4.10 (Scheme 
4.2A). Their synthesis is shown in Scheme 4.2B. We also made an analog of phosphocholine 
with an extra carbon between the charged groups (compound 4.11, Scheme 4.2A, C). None of 
these compounds showed detectable in vitro 3’ pre-mRNA cleavage activity (not shown). The 
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lack of activity in these analogs showed that all three methyls of the trimethylammonium group 







Scheme 4.2: Phosphocholine (PhC) analogs. (A) Structures of the analogs. (B) Synthesis of analogs 4.9 and 4.10. 
(C) Synthesis of analog 4.11. 
 
4.2.6. Phosphocholine as a possible modified histone protein mimic 
Trimethyllysine and phosphoserine residues are commonly found among the histone 
proteins of chromatin,33 where in vivo transcription takes place. Since several of the 3’ cleavage 
factor proteins associate with transcribing RNA polymerase II34, 35 and the 3’ cleavage reaction is 
coupled to transcription and begins co-transcriptionally,36, 37 it is conceivable that a histone 
protein could, within the chromatin, locally interact with RNA polymerase II-associated cleavage 
factor proteins to play a role in 3’ cleavage. In trying to understand how phosphocholine 
activates 3’ cleavage in vitro, we have considered the possibility that it may mimic a modified 
histone protein having closely situated trimethyllysine and phosphoserine (or threonine) residues 
(Fig. 4.4A). In an initial test of this idea, we replaced 50 mM creatine phosphate in a 3’ cleavage 
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reaction with dipeptide 4.12, Ac-Lys(Me)3-Ser(PO4)-CO2H (Fig. 4.4B). Peptide 4.12 may also be 
viewed as a derivative of phosphoserine which, like creatine phosphate, activates 3’ cleavage in 
the 10 to 50 mM range.38 Peptide 4.12 activated in vitro 3’ cleavage at 1 mM (Fig. 4.4C), while 
phosphoserine and phosphocholine14 have no effect at this concentration. A repeat of this 
experiment is shown on Figure 4.4D. This result shows that placing the two functional groups of 
phosphocholine in the structural context of a dipeptide, where they can approach each other as 
closely as they do in phosphocholine, reduced the concentration necessary for them to activate 3’ 
cleavage. Viewed differently, placing phosphoserine in a dipeptide coupled to N-
(acetyl)trimethyllysine (to create 4.12) led to increased potency. While far from directly 
implicating a histone protein in the 3’ cleavage reaction, this result indirectly supports the 
possibility that phosphocholine works by mimicking such a cleavage-promoting modified 
histone variant. We note that the partially purified protein 3’ cleavage factors used in our assay 
are fractionated from soluble nuclear proteins, and not from the chromatin-rich insoluble nuclear 
pellet, so a cleavage-enhancing chromatin protein would be depleted or lost during cleavage 
factor preparation. Interestingly, the PPM1G family member plays a role in histone H2A-H2B 
exchange into chromatin.39 PPM1G is also involved in splicesomal splicing,40 a pre-mRNA 
processing step that can be coupled to 3’ cleavage.41 In view of this context, this result justifies 
additional study of suitably modified lysine, serine and threonine-containing peptide sequences 
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Figure 4.4: Phosphocholine (PhC) as a mimic of a modified histone 
protein tail. (A) Phosphocholine holds a trimethyl ammonium group 
close to a phosphate, as a histone protein can do with trimethylated 
lysine and phosphoserine (or phosphothreonine). (B) Structure of 
dipeptide 4.12. (C) SV40L pre-mRNA 3’ cleavage activation by 
peptide 4.12 compared to phosphocholine (PhC), creatine phosphate 
(CP) and phosphoserine (PS). R.C., relative cleavage, as defined in 




4.2.7. Inhibitory activity of pre-mRNA 3’ cleavage activators 
The small molecules that we have found to activate pre-mRNA cleavage were either 
inhibitors of a protein phosphate or analogs of inhibitors. Therefore, it is of interest to determine 
whether the small molecules were activating cleavage through inhibition of a protein 
phosphatase. While we speculate that a protein phosphatase may be involved in the cleavage 
reaction, we are uncertain as to which protein is actually involved. As a preliminary test, PPM1A 
was used as a representative enzyme. PPM1A may not be the exact protein phosphatase involved 
in the cleavage reaction, but it should be structurally homologous to the other protein 




Figure 4.5: Inhibitory activity of small molecule activators. The ability of the small molecule cleavage activators 
(creatine phosphate (CP), phosphocholine (PhC), arginine β-naphthylamide (4.1), 4.2 (an analog that is not a 
cleavage activator at the tested concentration), 4.7, dipeptide 4.12, abscisic acid (ABA), and cyclic peptide 38 
(cp38)) to inhibit PPM1A was tested using para-nitrophenylphosphate (pNPP) as the substrate. 
The inhibitory activities for a selected group of small molecules were tested at the 
concentration at which they activate cleavage using p-nitrophenylphosphate as the substrate. 
Unfortunately, besides creatine phosphate and phosphocholine, which stimulated over 40% 
reduction in activity, the other cleavage activators were not able to significantly inhibit PPM1A 
at the concentration in which they activate pre-mRNA 3’ cleavage. This result signifies that 
either the compounds were not activating cleavage through inhibiting a protein phosphatase or 
that the compounds were suppressing a protein phosphatase which was not PPM1A. 
4.3.   Conclusions 
Guided by a model proposing that a PPM1 phosphatase acts to suppress or negatively 
regulate the pre-mRNA 3’ cleavage reaction, an obligatory step in the maturation of nearly all 
eukaryotic mRNAs, we have assayed a group of structurally diverse PPM1 inhibitors and new 
synthetic small molecules for their ability to activate this reaction in vitro. Our results lend 






























vitro cleavage has been improved from 200 M to the 200 nM-100 M range. In addition, our 
results point to future experiments aiming to further the goal of developing membrane-permeable 
small molecule activators of 3’ cleavage sufficiently potent for use in tissue culture experiments. 
4.4.  Experimental procedures 
4.4.1. Materials and methods 
Unless otherwise stated, commercial reagents and solvents were used without additional 
purification. Solvents were purchased from VWR. Cyclic peptide 38 (cp38) was provided by E. 
Appella and R. Hayashi and made as previously described.22 (S)-(+)-Abscisic acid (ABA), 
phosphocholine (PhC), and phosphoserine (PS) were purchased from TCI America. Creatine 
phosphate (CP) was purchased from Calbiochem. Compound 4.1 was purchased from Bachem. 
Compound 4.8 was purchased from Fluka. Compound 4.12 was purchased from Shanghai 
Apeptide Co., Ltd. Unless otherwise stated, starting reagents were purchased from VWR. 
Analytical TLC was performed on silica gel 60 F254 plates. Flash chromatography was performed 
manually in glass columns on 230-400 mesh silica gel (Alfa Aesar). Analytical samples were 
dried overnight in vacuo over phosphorus pentoxide prior to testing. Melting points were 
measured on a Laboratory Devices Mel-Temp apparatus. 1H and 13C NMR spectra were recorded 
on a Varian Mercury 300 spectrometer or Varian Inova 500 spectrometer. High-resolution mass 
spectra (HRMS) were measured using electrospray ionization (ESI) on a Waters LCT XE (TOF) 
mass spectrometer by Dr. L. Yang (CCNY). Infrared (IR) spectra were recorded using a Thermo 
Nicolet 380 FT-IR spectrometer or Thermo Nicolet 6700 FT-IR spectrometer. 
4.4.2. General Procedure for the synthesis of compounds 4.2-4.4 
Z3-Arg-OH (Z, benzyloxycarbonyl) was dissolved in dichloromethane. 1.2 equiv. of the amine 
was added followed by 2.5 equiv. of 1-hydroxy-7-azabenzotriazole (HOAt). 1.5 equiv. of 1-
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ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (EDC) was dissolved in 
dichloromethane and slowly added to the reaction at room temperature. Reaction progress was 
monitored by TLC (ethyl acetate:dichloromethane). The solution was washed sequentially with 
0.5 M HCl solution, water, brine, dried, and concentrated. The crude was purified by flash 
chromatography.42 The resulting product was hydrogenated in methanol using a latex balloon 
with catalytic amount (approximately a spatula tip) of palladium hydroxide (Pd 20% on carbon, 
nominally 58% water) for 3 hours. The solution was then filtered through celite and concentrated 
to yield the final product.  
2-Amino-5-guanidino-pentanoic acid phenylamide (4.2). 
White solid (yield 72%, m.p. 110°C dec.). 1H NMR (D2O) δ: 7.17 - 7.32 
(m, 4H), 7.10 (m, 1H), 3.89 (t, J = 6.33 Hz, 1H), 2.95 - 3.11 (m, 2H), 
1.70 - 1.87 (m, 2H), 1.43 - 1.61 (m, 2H). 13C NMR (D2O) δ: 169.49, 
156.78, 135.98, 129.51, 129.35, 126.24, 122.05, 121.83, 53.80, 53.51, 40.43, 28.65, 23.63. IR 
(neat) ν (cm-1): 3175, 1655, 1596, 1546, 1442, 1360, 1309, 1253, 752, 691. HRMS (ESI) 
[M+H]+: Calcd for C12H19N5O m/z = 250.1668, found m/z = 250.1655. 
2-Amino-5-guanidino-pentanoic acid naphthalen-1-ylamide (4.3). 
White solid (yield 62%, m.p. 166°C dec.). 1H NMR (D2O) δ: 7.57 - 
7.75 (m, 3H), 7.21 - 7.41 (m, 4H), 4.18 (t, J = 6.33 Hz, 1H), 2.99 (t, J = 
6.60 Hz, 2H), 1.79 - 1.99 (m, 2H), 1.47 - 1.73 (m, 2H). 13C NMR (D2O) 
δ: 169.52, 156.62, 133.93, 130.49, 128.71, 128.46, 128.05, 127.07, 125.63, 124.10, 121.95, 
121.66, 53.35, 53.11, 40.34, 28.33, 23.86. IR (neat) ν (cm-1): 3149, 1658, 1536, 1497, 1348, 793, 





2-Amino-5-guanidino-pentanoic acid quinolin-3-ylamide (4.4). 
Yellow solid (yield 30%, m.p. 113°C dec.). 1H NMR (D2O) δ: 9.34 
(s, 1H), 8.97 (s, 1H), 8.02 (d, J = 8.80 Hz, 1H), 8.07 (d, J = 8.53 Hz, 
1H), 7.91 (t, J = 7.70 Hz, 1H), 7.72 - 7.84 (m, 1H), 4.19 (t, J = 6.46 
Hz, 1H), 3.11 (t, J = 6.74 Hz, 2H), 1.97 (m, 2H), 1.51 - 1.73 (m, 2H). 13C NMR (D2O) δ: 168.80, 
156.79, 138.45, 138.08, 135.98, 135.76, 135.28, 134.63, 131.59, 130.88, 129.07, 120.31, 119.94, 
53.65, 53.39, 40.37, 28.01, 23.66. IR (neat) ν (cm-1): 3159, 1663, 1558, 1491, 1466, 1365, 782, 
747. HRMS (ESI) [M+H]+: Calcd for C15H20N6O m/z = 301.1777, found m/z = 301.1786.   
2-Amino-5-(N'-ethylguanidino)-pentanoic acid naphthalen-1-ylamide 
(4.5). Boc-Ornithine(Z)-OH (500 mg, 1.36 mmol) was dissolved in 
dichloromethane (25 mL). 1-Naphthylamine (234 mg, 1.64 mmol) was 
added followed by HOAt (464 mg, 3.41 mmol) and EDC (392 mg, 2.05 
mmol). Reaction progress was monitored by TLC. The resulting material was purified by flash 
chromatography, eluting with dichloromethane/ethyl acetate (9:1) to give 4.5a (531 mg, 1.08 
mmol, 79% yield). Compound 4.5a (531 mg, 1.08 mmol) was hydrogenated for 2 h in methanol 
(50 mL) with a catalytic amount of palladium hydroxide as described in section 4.4.2. The 
solution was filtered through celite and concentrated to give 4.5b. Compound 4.5b was dissolved 
in acetonitrile (7 mL) and ethylated N, N’-bis-tert-butoxycarbonylpyrazole-1-carboxamidine 
(364 mg, 1.08 mmol) was added followed by diisopropylethylamine (181 mg, 2.34 mmol). The 
solution was stirred overnight, concentrated and purified by flash chromatography, eluting with 
dichloromethane/ethyl acetate (4:1) to give 520 mg (0.83 mmol) of a white, sticky solid. The 
resulting compound (170 mg, 0.27 mmol) was dissolved in dichloromethane (2 mL) and 





suspended in fresh dichloromethane, and extracted with water. The aqueous layer was 
concentrated and dried overnight in a drying pistol with phosphorus pentoxide to give 4.5 as a 
sticky, white solid in 68% yield. 1H NMR (D2O) δ: 7.59 - 7.81 (m, 3H), 7.24 - 7.45 (m, 4H), 4.11 
- 4.23 (m, 1H), 3.05 (m, 2H), 2.85 (q, J = 6.88 Hz, 2H), 1.85 - 2.02 (m, 2H), 1.60 (m, 2H), 0.81 
(t, J = 7.01 Hz, 3H). 13C NMR (D2O) δ: 169.49, 163.23, 162.76, 155.38, 133.99, 130.53, 128.39, 
127.09, 126.75, 125.64, 123.90, 122.11, 118.25, 114.38, 53.35, 53.13, 40.15, 36.20, 28.26, 23.84, 
13.02. IR (neat) ν (cm-1): 3208, 3051, 1659, 1542, 1181, 1131, 798, 721. HRMS (ESI) [M+H]+: 
Calcd for C18H25N5O m/z = 328.2137, found m/z = 328.2121. 
[5-Amino-5-(naphthalen-2-ylcarbamoyl)-pentyl]-trimethyl-
ammonium (4.6). Boc-Lys(Z)-OH (1 g, 2.6 mmol) was dissolved in 
dichloromethane (50 mL). 2-Naphthylamine44 (0.37 g, 2.6 mmol) 
was added followed by HOAt (0.89 g, 6.54 mmol) and EDC (0.76 g, 
3.96 mmol). After 1.5 h, the solution was concentrated and purified by flash chromatography, 
eluting with chloroform/ethyl acetate (4:1) to give 4.6a (800 mg, 1.58 mmol), in 61% yield. 
Compound 4.6a (288 mg, 0.57 mmol) was suspended in methanol (25 mL) and hydrogenated 
with a catalytic amount of palladium hydroxide. After 1.5 h, the solution was filtered through 
celite and concentrated to give 4.6b (212 mg, 0.57 mmol) in quantitative yield. Compound 4.6b 
(205 mg, 0.55 mmol) was then dissolved in acetonitrile (1 mL) and potassium carbonate (191 
mg, 1.38 mmol) was added followed by iodomethane (392 mg, 2.76 mmol). The solution was 
stirred overnight, concentrated, suspended in dichloromethane, and filtered. The filtrate was 
concentrated and the crude compound was dissolved in dichloromethane (2 mL) and 
trifluoroacetic acid (2 mL) was added. The solution was stirred for 1.5 h and then concentrated, 




concentrated and dried overnight over phosphorus pentoxide to give 4.6 as an orange, sticky 
solid in 85% yield. 1H NMR (D2O) δ: 7.88 (s, 1H), 7.66 - 7.78 (m, 3H), 7.28 - 7.40 (m, 3H), 3.99 
(t, J = 6.60 Hz, 1H), 3.06 - 3.15 (m, 2H), 2.84 (s, 9H), 1.83 - 1.94 (m, 2H), 1.66 (m, 2H), 1.34 
(m, 2H). 13C NMR (D2O) δ: 168.48, 162.78, 133.88, 133.41, 131.29, 129.43, 127.94, 127.84, 
127.33, 126.38, 121.10, 119.01, 66.12, 53.81, 53.05, 30.65, 22.31, 21.32. IR (neat) ν (cm-1): 
3049, 1671, 1198, 1128, 832, 799, 720. HRMS (ESI) [M]+: Calcd for [C19H28N3O]+ m/z = 
314.2232, found m/z = 314.2223. 
5-Guanidino-2-morpholin-4-yl-pentanoic acid naphthalen-2-
ylamide (4.7). Boc-Orn(Z)-OH (1 g, 2.73 mmol) was dissolved in 
dichloromethane (50 mL). 2-Naphthylamine44 (470 mg, 3.28 
mmol) was added followed by HOAt (929 mg, 6.83 mmol) and 
EDC (785 mg, 4.09 mmol). Reaction progress was monitored by TLC. The resulting material 
was purified by flash chromatography, eluting with dichloromethane/ethyl acetate (9:1) to give 
4.7a (570 mg, 1.56 mmol, 49% yield). Compound 4.7a (320 mg, 0.65 mmol) was dissolved in 
dichloromethane (2 mL) with trifluoroacetic acid (2 mL) and stirred at room temperature 
overnight. The solution was concentrated and used for the next step without further purification. 
The crude compound was dissolved in acetonitrile (6 mL) and refluxed with potassium carbonate 
(360 mg, 2.6 mmol) and bis(2-bromoethyl)ether (181 mg, 0.78 mmol) overnight. The next day, 
the solution was filtered and purified by flash chromatography (first 1:1 ethyl 
acetate/dichloromethane then 100% ethyl acetate) to give 4.7b (100 mg, 0.22 mmol) as a 
yellowish solid in 33% yield. Compound 4.7b was hydrogenated in methanol (12 mL) with 
catalytic amount of palladium hydroxide. After 2 h, the solution was filtered through celite and 




butoxycarbonylpyrazole-1-carboxamidine45 (27 mg, 0.87 mmol) was added followed by DIPEA 
(15 mg, 0.113 mmol). The reaction was stirred overnight, concentrated and purified by flash 
chromatography, eluting with ethyl acetate/hexanes (4:1) to give 4.7c (20 mg, 0.035 mmol) as a 
sticky, white solid in 41% yield. Compound 4.7c was dissolved in dichloromethane (1 mL) and 
trifluoroacetic acid (1 mL) was added. The solution was stirred overnight and then concentrated, 
suspended in dichloromethane, and extracted with water. The aqueous layer was concentrated 
and dried overnight over phosphorus pentoxide to give 4.7 in 85% yield. 1H NMR (D2O) δ: 7.96 
(s, 1H), 7.70 - 7.85 (m, 3H), 7.34 - 7.48 (m, 3H), 3.18 - 4.05 (m, 9H), 3.11 (t, J = 6.46 Hz, 2H), 
1.86 - 2.15 (m, 2H), 1.45 - 1.72 (m, 2H). 13C NMR (D2O) δ: 166.00, 162.95, 156.95, 133.31, 
131.47, 129.47, 127.91, 127.36, 126.56, 120.97, 119.33, 117.67, 115.35, 69.27, 63.74, 40.48, 
24.62, 23.86. IR (neat) ν (cm-1): 3360; 2877, 2718, 1668, 1563, 1508, 1435, 1364, 1200, 800, 
723, 707. HRMS (ESI) [M+H]+: Calcd for C20H27N5O2 m/z = 370.2243, found m/z = 370.2224.  
Phosphoric acid mono-(2-methylamino-ethyl) ester (4.9). 2-
Methylaminoethanol (500 mg, 6.66 mmol) was stirred with sodium 
bicarbonate (1.12 g, 13.31 mmol) in diethyl ether (6.6 mL). Benzyl chloroformate, 30-35% in 
toluene, (3.6 g, 6.66 mmol) was slowly added at 0˚C. The solution was warmed to room 
temperature after 15 minutes. After 1 h, the solution was concentrated and purified by flash 
chromatography, eluting with dichloromethane/ethyl acetate (1:1) to give 4.9a in 63% yield. 
Compound 4.9a (300 mg, 1.43 mmol) was dissolved in diethyl ether (5 mL) and diphenyl 
chlorophosphate (578 mg, 2.15 mmol) was added followed by triethylamine (290 mg, 2.87 
mmol). After 2 h, the solution was filtered and purified by flash chromatography, eluting with 
dichloromethane/ethyl acetate (9:1) to give 4.9b (633 mg) in 81% yield. Compound 4.9b (500 




mmol) and benzyl alcohol (368 mg, 3.42 mmol) in diethyl ether (5 mL). After 1 h, the solution 
was purified by flash chromatography, eluting with dichloromethane/ethyl acetate (9:1) to give 
4.9c (324 mg) in 60% yield. Compound 4.9c (324 mg, 0.69 mmol) was hydrogenated in 
methanol (25 mL) with catalytic amount of Pd/C (10% Pd, 50% wet with water) for 1 h. The 
solution was filtered through celite, and the celite pad was washed with water. The solution was 
concentrated and dried overnight over phosphorus pentoxide to give a 4.9 (90 mg, 0.58 mmol) as 
a white solid (m.p. 204 - 206°C) in 84% yield. 1H NMR (D2O) δ: 3.76 - 3.94 (m, 2H), 2.97 - 3.13 
(m, 2H), 2.49 (s, 3H). 13C NMR (D2O) δ: 60.25, 49.11, 48.99, 32.77, 32.41. IR (neat) ν (cm-1): 
3017, 2729, 2520, 1146, 1075, 1026, 923, 815. HRMS (ESI) [M+H]+: Calcd for C3H10NO4P m/z 
= 156.0426, found m/z = 156.0424. 
Phosphoric acid mono-(2-dimethylamino-ethyl) ester (4.10). 2-
Dimethylaminoethanol, 4.10a, (500 mg, 5.61 mmol) was dissolved in ether 
(5.6 mL) and diphenyl chlorophosphate (1.8 g, 6.73 mmol) was added followed by triethylamine 
(1.135 g, 11.22 mmol). After 1 h, the solution was concentrated and purified by flash 
chromatography, eluting with dichloromethane/triethylamine (9:1) to give 4.10b (1.37 g) in 76% 
yield. Compound 4.10b (540 mg, 1.68 mmol) was added to a solution containing sodium 
hydride, 57-63% in oil, (121 mg, 3.03 mmol) and benzyl alcohol (545 mg, 5.04 mmol) in ether 
(5.4 mL). After 1 h, the solution was concentrated and purified by flash chromatography, eluting 
with ethyl acetate/methanol (19:1) to give 4.10c (340 mg) in 58% yield. Compound 4.10c (166 
mg, 0.48 mmol) was hydrogenated in methanol (25 mL) with catalytic amount of palladium 
hydroxide for 1 h. The solution was filtered through celite, concentrated, and dried overnight 
over phosphorus pentoxide to give 4.10 (70 mg) as a white solid (m.p. 155 - 157°C) in 87% 




42.95, 42.43. IR (neat) ν (cm-1): 3415, 2629, 2404, 1163, 1149, 1093, 1026, 993, 951, 931, 768. 
HRMS (ESI) [M+H]+: Calcd for C4H12NO4P m/z = 170.0582, found m/z = 170.0609. 
Trimethyl-(3-phosphonooxypropyl)-ammonium iodide (4.11). 3,3-
Dimethylamino-1-propanol (500 mg, 4.846 mmol) was dissolved in 
ether (4.8 mL) and diphenyl chlorophosphate (1.56 g, 5.816 mmol) was added, followed 
immediately by triethylamine (1 g, 9.692 mmol). After 1 h, the solution was concentrated and 
purified by flash chromatography, eluting with ethyl acetate/triethylamine (19:1) to give 4.11a 
(1.45 g) in 92% yield. Compound 4.11a (1.45 g, 4.32 mmol) was added to a solution of sodium 
hydride, 57-63% in oil, (519 mg, 12.97 mmol) and excess benzyl alcohol in diethyl ether (14.5 
mL). After 1 h, the reaction was concentrated and the crude was purified by flash 
chromatography, eluting with ethyl acetate/triethylamine (19:1) to give 4.11b (246 mg) in 15% 
yield. Compound 4.11b (246 mg, 0.68 mmol) was dissolved in acetonitrile (1 mL) and 
iodomethane (192 mg, 1.35 mmol) was added. After 1 h, the solution was concentrated to give 
4.11c (337 mg), which was used in the next step without further purification. Compound 4.11c 
(337 mg, 0.67 mmol) was first hydrogenated in 50 ml methanol:water (1:1) with a catalytic 
amount of palladium hydroxide. These conditions removed only one of the two benzyl groups. 
The second benzyl group was removed by latex balloon hydrogenation in 150 ml 30% (v/v) 
aqueous formic acid with a catalytic amount of Pd/C. The reaction contents were filtered through 
a celite pad, concentrated under reduced pressure, and washed with dichloromethane. The 
aqueous layer was further evaporated under reduced pressure, and the residue was exhaustively 
dried overnight over phosphorus pentoxide to give 4.11 (80 mg) as a white solid (m.p. 230°C 
dec.) in 35% yield. 1H NMR (D2O) δ: 3.75 (m, 2H), 3.14 - 3.34 (m, 2H), 2.93 (s, 9H), 1.92 (m, 




2939, 2887, 2432, 1190, 1054, 932. HRMS (ESI) [M]+: Calcd for C6H17NO4P+ m/z = 198.0890, 
found m/z = 198.0879. 
4.4.3. Low molecular weight activator stock solutions 
Cyclic peptide 38 (cp38), kindly provided by E. Appella, was dissolved in water (1 M) and then 
serially diluted with same. Dephosphorylation of cp38 with calf intestinal alkaline phosphatase 
(CIP; Promega) and YOP Protein Tyrosine Phosphatase (NEB) were carried out as described for 
other proteins.11 The possibility of exposure of the cleavage factors to residual CIP activity was 
eliminated by using an established and validated procedure. (S)-(+)-Abscisic acid (ABA) was 
dissolved in DMSO (500 mM) and then serially diluted with water. Compounds 4.1-4.7 were 
placed in water and treated with 1-3 equiv. of 1.00 M HCl to dissolve the compounds. 
Compound 4.1 was purchased as the HCl salt and dissolved in water directly. Compounds 4.8-
4.11 were dissolved in water and treated with NaOH until the pH reached 6 - 7.9. (1.1 equiv. of 
NaOH was added to compound 4.8 and 4.9; 1.0 equiv. of NaOH was added to compound 4.10; 
1.5 equiv. of NaOH was added to compound 4.11; 0.25 equiv. of NaOH was added to compound 
4.12.) 
4.4.4. Cleavage factor fractionation from HeLa cell nuclear extract (Kindly carried out by 
my colleague, N. Nagre) 
HeLa cell pellets were purchased from the National Cell Culture Center (Biovest International). 
Nuclear extract and 3’ cleavage factor DEAE-sepharose fractions (CPSF, CstF and CFm) were 
prepared as described in detail elsewhere.11, 25 Active fractions from each cleavage factor were 
pooled, concentrated by 70% ammonium sulfate precipitation and dialyzed 2 X 3 h at 4°C 
against Buffer D50AS (20% glycerol, 20 mM Na-HEPES, pH 7.9, 0.2 mM EDTA, 0.2 mM 
PMSF, 0.5 mM DTT and 50 mM ammonium sulfate). Total protein concentration of cleavage 
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factor fractions was estimated by Bio-Rad Bradford protein assay with bovine serum albumin as 
the standard and determined to be: CPSF (3 mg/mL): CstF (3.5 mg/mL): CFm (3 mg/mL). The 
amount of 3’ cleavage factor fractions used in a 12.5 l cleavage reaction were: CPSF (0.8 L); 
CstF (0.6 L); CFm (3 µL). 
4.4.5. RNA substrate (Kindly made by my colleague, N. Nagre) 
SV40 late pre-mRNA (233 nt) was transcribed in vitro by SP6 RNA polymerase (Promega) from 
the pG3SVL-A plasmid linearized at the DraI site. Substrate RNA was uniformly labeled by 
including [-32P]-UTP (Perkin-Elmer Life Sciences) and 5’ capped during transcription using the 
5’Me7G(5’)ppp(5’)G-Cap analog (NEB). The transcript was purified on a 0.4 mm denaturing 
polyacrylamide gel, located by shadowing on film, and extracted as previously described.  
4.4.6. In vitro 3’ cleavage reactions (Kindly carried out by my colleague, N. Nagre) 
Cleavage reactions were carried out as described in detail elsewhere in 12.5 µL and contained, in 
addition to the cleavage activators indicated in the figures, tRNA (0.1 mg/mL), pH 8 EDTA (2 
mM), 2’-dATP (2 mM), DTT (0.41 mM), BSA (Roche; 40 ng/mL), placental RNase inhibitor 
(Promega, 0.32 u/mL), polyvinyl alcohol (2.5%), 10% glycerol, 10 mM HEPES-NaOH (pH 7.9), 
25 mM ammonium sulfate, the cleavage factor fractions described in section 4.4, and the RNA 
substrate (1–5 nM). The reactions were incubated at 30°C for 2 h and then digested with 
Proteinase K, phenol-CHCl3 extracted, ethanol precipitated, and resolved on a 6% denaturing 
polyacrylamide gel. After drying, the gel was exposed to a Molecular Dynamics Storm 
PhosphorImager screen and the bands were quantitated using ImageQuant software. Relative 
cleavage (R.C.) was calculated as [5’ fragment/ (5’ fragment + uncleaved RNA)] x 100. The total 
recovered RNA varied from lane to lane due to losses during phenol-CHCl3 extraction and 
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ethanol precipitation. Use of the R.C. ratio standardizes the amount cleaved and allows 
comparison of gel lanes with different amounts of total recovered RNA. 
4.4.7. PPM1A inhibition assay 
A 16.25 µL solution containing 154 mM Tris-HCl (pH 7.9), 15% glycerol, 31 mM MgCl2, and 
154 mM ammonium sulfate was placed in a microfuge tube on ice. To this was added 26.25 µL 
of a mixture containing 0.95 mg/mL BSA, 0.95 mM DTT, and 38 mM pNPP (all in water). Five 
µL of a 10X stock solution of the tested compound was then added. To start the reaction, 2.5 µL 
of a 0.05 mg/mL (approximately 1 µM) solution of PPM1A in 152 mM Tris-HCl, 5 mM 
imidazole, 3.75 mM NaCl, 30 mM MgCl2, 140 mM ammonium sulfate, and 15% glycerol was 
added. Final concentration of all components were as follows: 58 mM Tris-HCl, 6% glycerol, 12 
mM MgCl2, 53 mM ammonium sulfate, 0.5 mg/mL BSA, 0.5 mM DTT, 20 mM pNPP, 250 µM 
imidazole, 187 µM NaCl, 50 nM PPM1A, plus the inhibitor concentration as follows: CP, 
PhC: 10 and 50 mM; 4.1, 4.2: 0.2 and 1 mM; 4.7: 25, 100, 200 M; 4.12: 0.1 and 1 mM; ABA: 
50, 100, 200 M; cp38: 150, 200 nM. The solution was gently mixed, centrifuged, and incubated 
at 37°C for 2.5 h. 10 µL of 500 mM EDTA (pH 10) was added to stop the reaction and the 
absorbance at 405 nm was taken on a NanoDrop spectrophotometer.  
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Chapter 5: Use of boronic acids towards molecular recognition of DNA nicks 
5.1. Introduction 
Deoxyribonucleic acid (DNA) is a macromolecule that carries genetic information 
essential for life. The nucleotides making up DNA are linked with phosphodiester bonds, but 
some of these bonds may be broken due to damage or enzymatic activities resulting in nicks on 
the DNA. Theoretically, these DNA nicks could provide a point of recognition for designed 
small molecules to bind with the 3’ and 5’ hydroxyl-groups at the breaks. In this study, we aimed 
to substitute the phosphate group at DNA nicks with a boronate group (Scheme 5.1).  
    
 DNA                                                            Nicked DNA 
 
Scheme 5.1: Representation of a DNA fragment with the phosphate group replaced with a boronate group. 
Boronic acids are known to reversibly bind with diols with modest affinity to form 
boronic esters, and as a result, they have been used for various applications, including the 
development of saccharides sensors, nucleotide and carbohydrate transporters, affinity ligands, 
and antibody mimics.1 The close proximity of the hydroxyl groups at the DNA nick resembles a 
diol, and could possibly bind with boronic acids in a similar way. Indeed, a DNA assembly had 
been synthesized with the phosphate linkage replaced with a boronate linkage,2 demonstrating 
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that nucleotides on DNA could be bonded within a boronate linkage in a stable manner. 
Although the phosphate group could potentially be replaced with a boronate group, whether 
boronic acids easily bind to DNA nicks is still uncertain, due to the only modest affinity between 
the boronic acid and the diol. We expect that the equilibrium shown in Scheme 5.1 (right) favors 
the middle structure, i.e. nick not filled with boronate. Our long term idea is to add the boronic 
acid to other DNA-recognizing structures to increase affinity and impart selectivity for the DNA 
break. 
5.2. Experimental design 
 To determine whether boronic acids readily bind onto DNA nicks, we could simply mix 
the two together and observe if binding occurs. In order to replicate a DNA that contains nicks, 
we used two short DNA strands, DNA 1 – 5’-GTCGCC-3’ and DNA 2 – 5’-GACGGC-3’, which 




Figure 5.1: Expected interaction between boronic acid, 5.4, and the nicked DNA form from DNA 1 and DNA 2. 
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 Complementary base-pairing occurs at physiological pH (~pH 7.4). At high pH, the 
guanine and thymine bases become deprotonated, leading to less hydrogen bonding and therefore 
less pairing. The stability of the boronate ester is also pH-dependent.1 Boronate ester formation 
only occurs near or above the pKa of the boronic acid, so it was necessary to use a boronic acid 
with a lower pKa than the physiological pH of 7.4. The pKa’s of boronic acids are typically 
above pH 8, but the benzoxaborole was found to have a pKa around physiological pH, ~7.2-7.3.3 
Unfortunately, benzoxaborole only contains the boronic group on one end of the phenyl ring, and 
thus it would not be effective in producing cross-links on DNA. To produce a boronic acid with a 
pKa around physiological pH and that is able to cross-link with DNA nicks, benzoxaborole 5.4 
was synthesized. Benzoxaborole 5.4, which contains two boronic acid groups, was expected to 
bind onto the DNA nicks at around pH 7.4 (Figure 5.1).  
 One way to assess that binding has occurred was from the formation of a gel. Gels form 
when polymers are linked together. An especially well-known gel formation reaction is 
formulated using polyvinyl alcohol (PVA) and sodium tetraborate (borax).4, 5 The borate acts as 
cross-linker for PVA, and the degree of cross-linking could be modulated by changing the 
concentration of the borate or the pH of the solution.4, 5 If the benzoxaborole 5.4 is indeed linking 
together chains of DNA, then it’s likely that a gel would form. However, it’s of importance to 
ensure that the ratio of the linker and polymer to the water content is adequate for gel formation. 
To determine the appropriate ratio of linker to polymer that would lead to gel formation, 
preliminary testing was done using compounds 5.1, 5.2, and 5.3. These boronic acids were tested 
for gel formation with polyvinyl alcohol (PVA), a polymer containing a multitude of hydroxyl (-
OH) groups (as a simple though imperfect mimic of a diol). Boric acid 5.1, 5.3, and 5.4, were 
expected to form a gel with PVA through cross-linking, whereas the negative control, 
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phenylboronic acid 5.2, which contains only one boronic acid group, should not be able to form a 
gel (Scheme 5.2). Since the pKa of 5.1 (9.24), 5.2 (8.8), and 5.3 (~8.8) are all above 8, they need 
to be tested at high pH in order for gel formation to occur. (For the purpose of this experiment, 
pH 10 was used). Once a ratio was found which afford gel formation between boric acid 5.1 and 
PVA, the same ratio was used to test 5.2, which should not form a gel, and 5.3 and 5.4, which 
should form a gel with PVA. If gel formation was seen using 5.4 with PVA, then 5.4 would be 
tested with DNA at physiological pH. 
 







5.3. Results and Discussion 
 
Scheme 5.3: Synthesis of 5.4. 
Compounds 5.1, 5.2, and 5.3 were commercially available. The diboronic acid 5.4 was 
synthesized starting from tolidine. Tolidine was subjected to a Sandmeyer reaction to convert the 
amino groups to bromo-groups forming 5.4a.6 A free-radical halogenation reaction using N-
bromosuccinimide (NBS) and AiBN as the initiator was employed to brominate the methyl 
groups on 5.4a to obtain 5.4b. The primary bromo-groups on 5.4b were reacted into acetyl-
groups using potassium acetate to form 5.4c. Compound 5.4c was then subjected to a Miyaura 
borylation reaction to form 5.4d. The pinacol protecting groups on 5.4d was removed using 
sodium periodate giving the boronic acid 5.4e. Deprotection of the acetyl-groups gave the final 































Synthesized boronic acid 
 
 












 Boric acid, 
5.1,  
conc. (mM) 
Mole Ratio OH Ratio  
 
Gel? PVA Boric acid PVA Boric acid 
1 150 1.4 0 1 0 - 0 No 
2 47.5 1.8 9.5 1 5.3 53.8 1 No 
3 60 1.75 12 1 6.9 41.4 1 No 
4 72.5 1.7 14.5 1 8.5 33.3 1 Yes 
5 45 1.05 9 1 8.6 33.1 1 No 
6 72.5 1.5 14.5 1 9.7 29.4 1 Yes 
7 85 1.65 17 1 10.3 27.5 1 Yes 
8 72.5 1.3 14.5 1 11.2 25.4 1 Yes 
9 100 1.6 20 1 12.5 22.7 1 Yes 
10 72.5 1.1 14.5 1 13.2 21.5 1 Yes 
11 45 0.56 9 1 16.1 17.7 1 No 
12 72.5 0.9 14.5 1 16.1 17.6 1 Yes 
13 122.5 1.5 24.5 1 16.3 17.4 1 Yes 
14 72.5 0.7 14.5 1 20.7 13.7 1 Yes 
15 150 1.4 30 1 21.4 13.2 1 Yes 
16 150 1.26 30 1 23.8 11.9 1 Yes 
17 150 1.12 30 1 26.8 10.6 1 Yes 
18 150 1.05 30 1 28.6 9.9 1 Yes 
19 72.5 0.5 14.5 1 29 9.8 1 Yes 
20 72.5 0.3 14.5 1 48.3 5.9 1 Yes 
21 150 0.56 30 1 53.6 5.3 1 Yes 
22 72.5 0.1 14.5 1 145 2.0 1 No 
 
Table 5.2: Optimized conditions for gel formation. Carbonate buffer at pH = 10 was used. Highlighted rows are 
conditions that led to the formation of a strong gel. OH ratio for boric acid was determined from the assumption that 
each molecule of boric acid could bind with four OH groups. The PVA used for the experiment consisted of 
polymers with molecular weights ranging from 30000 to 70000 g/mol. The average molecular weight, 50000 g/mol, 
was employed for the purpose of calculating the number of monomers, and therefore the number of OH units, on 
each molecule of PVA. (Testing was done by MS Biochemistry student, Jane Tania.) 
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Before testing the synthesized benzoxaborole, 5.4, on nicked DNA, we need to determine the 
ratio of benzoxaborole to DNA that would result in the formation of a gel. Preliminary 
optimization was done with commercially available polyvinyl alcohol (PVA) and boric acid, 5.1.  
Various concentrations of PVA and boric acid (5.1) were tested to achieve gel formation. From 
the data, gel formation was most apparent at a PVA: boric acid (5.1) mole ratio of 1:10, but gel 
formation may not occur when the PVA and/or boric acid (5.1) concentration are too low, as 
exemplified by test # 5 and 11 (Table 5.2), in which the mole ratio was almost the same as the 
mole ratio for test # 4 and 12 (Table 5.2), but gel formation did not occur. Additionally, gel did 
not form at pH = 7.4, which is below the pKa of boric acid (5.1) (results not shown). Since the 
other boronic acids (5.2, 5.3, and 5.4) are less soluble in water compared to boric acid, 5.1, a few 
additional tests were done to determine the lowest concentration of boric acid that could be used 













Mole Ratio OH Ratio  
 
Gel? PVA Boric acid PVA Boric acid 
23 50 1 5 1 5 56.8 1 No 
24 50 1 10 1 10 28.4 1 Yes 
25 50 1.5 10 1 6.7 42.6 1 Yes 
26 50 1.5 7.5 1 5 56.8 1 No 
Table 5.3: Lowering boric acid concentration for gel formation. Carbonate buffer at pH = 10 was used. 
 
Gel formation could not occur at a concentration lower than 10 mM of boric acid (Table 5.3), so 























27 5.2 50 1 20 1 20 28.4 1 No 
28 5.2 50 1 10 1 10 56.8 1 No 
29 5.2 50 1.5 20 1 13.3 42.6 1 No 
30 5.2 50 1.5 10 1 6.7 85.1 1 No 
31 5.3 50 1 10 1 10 28.4 1 Yes 
32 5.3 50 1.5 10 1 6.7 42.6 1 Yes 
33 5.4 50 1 10 1 10 28.4 1 Yes 
34 5.4 50 1.5 10 1 6.7 42.6 1 Yes 
Table 5.4: Gel formation of 5.2, 5.3, and 5.4 with PVA. Carbonate buffer at pH = 10 was used. 
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As expected, phenylboronic acid, 5.2, did not form a gel with PVA at any of the concentrations 
tested (Table 5.4). Since phenylboronic acid (5.2) could only bond with two OH groups at a time, 
it is less likely to crosslink molecules of PVA together. Boronic acid 5.3 was able to form a 
partial gel with PVA. Due to the low water solubility of 5.3, it forms a gel locally before it could 
homogenize with the solution. Since benzoxaborole 5.4 has a higher solubility in water, it was 
able to form a strong gel with PVA (Table 5.4, test # 33 and 34), but here the pH was 10. We 
wanted to eventually test the benzoxaborole 5.4 with DNA at pH 7.4, so 5.4 was tested with 











Mole Ratio OH Ratio  
Gel? PVA Cpd. PVA Cpd. 
35 5.4 50 1 10 1 10 28.4 1 ppt 
36 5.4 50 1.5 10 1 6.7 42.6 1 ppt 
Table 5.5: Gel formation of benzoxaborole 5.4 at pH 7.4. (ppt = precipitated out of solution) 
 
Instead of forming a gel at the lower pH, 5.4 precipitated out of the solution (Table 5.5). To 
ensure that 5.4 fully dissolves when tested with DNA (to test for possible gel formation with 
DNA nicks), various concentrations of 5.4 were tested at pH 7.4 and pH 10 with a low 
concentration of DNA nicks (0.5 mM) formed from DNA 1 (5’-GTCGCC-3’) and DNA 2 (5’-


































37 7.4 5 0.5 0.5 0.1 1 0.2 5 1 No Clear 
38 10 5 0.5 0.5 0.1 1 0.2 5 1 No Clear 
39 7.4 5 0.5 0.5 0.3 1 0.6 1.7 1 No Clear 
40 10 5 0.5 0.5 0.3 1 0.6 1.7 1 No Clear 
41 7.4 5 0.5 0.5 0.5 1 1 1 1 No Cloudy 
42 10 5 0.5 0.5 0.5 1 1 1 1 No Clear 
43 7.4 5 0.5 0.5 2 1 4 0.25 1 No Precipitate 
44 10 5 0.5 0.5 2 1 4 0.25 1 No Precipitate 
Table 5.6: Gel formation of 5.4 with DNA1 (5’-GTCGCC-3’) and DNA 2 (5’-GACGGC-3’). 
 
Benzoxaborole 5.4 could not be tested at 10 mM as planned since it was not soluble at even 2 
































45 7.4 50 5 5 0.1 1 0.02 50 1 No 
46 10 50 5 5 0.1 1 0.02 50 1 No 
47 7.4 50 5 5 0.2 1 0.04 25 1 No 
48 10 50 5 5 0.2 1 0.04 25 1 No 
49 7.4 50 5 5 0.3 1 0.06 16.7 1 No 
50 10 50 5 5 0.3 1 0.06 16.7 1 No 
51 7.4 50 5 5 0.4 1 0.08 12.5 1 No 
52 10 50 5 5 0.4 1 0.08 12.5 1 No 
53 7.4 50 5 5 0.5 1 0.1 10 1 No 
54 10 50 5 5 0.5 1 0.1 10 1 No 
Table 5.7: Gel formation of 5.4 with higher concentration of DNA 1 (5’-GTCGCC-3’) and DNA 2 (5’-GACGGC-
3’). 
 
During the testing, the concentration of both 5.4 and the DNA were lowered to ensure that 5.4 
remained dissolved and concurrently achieve the OH ratio to achieve gel formation from the tests 
with PVA (Table 5.4, test #33 and 34). With PVA, 5.4 formed a strong gel at a ratio of ~ 30-
40(PVA):1(5.4) (Table 5.4, test #33 and 34). The DNA was adjusted to be ~10 – 50 times more 
concentrated in OH sites than the boronic acid. Unfortunately, gel formation did not occur. The 






























55 5.3 50 1 10 1 10 28.4 1 No Precipitate 
56 5.3 50 1 9 1 9 31.5 1 No Precipitate 
57 5.3 200 1 2 1 2 141.9 1 No Precipitate 
58 5.3 200 1 1 1 1 283.8 1 No Cloudy 
59 5.3 200 1 0.5 1 0.5 567.5 1 No Cloudy 
60 5.3 50 1 0.5 1 0.5 567.5 1 No Cloudy 
61 5.3 200 1 0.4 1 0.4 709.4 1 No Clear 
62 5.3 50 1 0.4 1 0.4 709.4 1 No Clear 
63 5.4 50 1 0.5 1 0.5 567.5 1 No Clear 
64 5.4 50 1 0.75 1 0.75 378.3 1 No Clear 
65 5.4 50 1 1 1 1 283.8 1 No Cloudy 
Table 5.8: Solubility at pH 7.4 (~10% DMSO). 
 
Although gel formation with DNA did not occur at the tested conditions (Table 5.7), it was still 
of interest to determine if 5.4 could affect gel formation at pH 7.4. Thus, 5.4 was further tested 
on PVA. While 5.4 is slightly more soluble than 5.3 at pH 7.4, they both were not able to form a 
































66 5.4 50 1 0.75 1 0.75 378.3 1 No Clear 
67 5.4 50 1 1 1 1 283.8 1 No Cloudy 
Table 5.9: Solubility at pH 7.4 using MOPS buffer. 
To ensure that the phosphate buffer is not interfering with the solubility of 5.4, the compound 
was retested at pH 7.4 using another buffer, MOPS. As shown on Table 5.9, 5.4 behaved 
similarly in the MOPS buffer. As with the phosphate buffer (Table 5.8, test # 64 and 65), 5.4 was 
soluble at 0.75 mM but not 1 mM (Table 5.9, test # 66 and 67). Since 5.4 is soluble and could 
form a gel at 10 mM in a pH 10 buffer (Table 5.4, test # 33 and 34), the lower pH of the 






























68 5.4 50 1 10 1 10 28.4 1 No Precipitate 
69 5.4 50 1 2 1 2 141.9 1 No Cloudy 
70 5.4 50 1 1.5 1 1.5 189.2 1 No Cloudy 
71 5.4 50 1 1.3 1 1.3 218.3 1 No Clear 
Table 5.10: Solubility at pH = 7.8 using phosphate buffer. 
Since the phosphate buffer does not appear to be affecting the solubility of the compound 
compared to other buffer (MOPS), 5.4 was again tested in a phosphate buffer with the pH 
increased to 7.8. At pH 7.4, 5.4 could only dissolve at concentrations lower than 0.75 mM, but at 
pH 7.8, 5.4 could dissolve at 1.3 mM (Table 5.10, test #71). There was an improvement in the 
solubility at pH 7.8, but unfortunately there were still not enough linkers in the solution to affect 
gel formation at physiological pH.  
5.4. Conclusions 
The synthesized benzoxaborole 5.4 was able to form a gel with PVA at pH 10, but it was 
not able to form a gel with DNA at any of the tested concentrations. This does not necessarily 
indicate that 5.4 was not binding with the DNA, seeing as the solution may be too diluted for a 
gel to form. Although the ratio (of the OH groups) of 5.4 to DNA was similar to the ratio of 5.4 
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to PVA that led to gel formation, there was a large difference in the amount of OH groups on the 
DNA compared to PVA that was in the solution, and thus the hydroxyl group concentration was 
much lower. The DNA was tested at a concentration of 5 mM whereas PVA was only tested at 
1.0-1.5 mM, but each molecule of PVA could have at least 680 OH groups, while the two DNA 
strands produce only four OH groups. Even at 1 mM, PVA has at least 34 times more OHs that 
are available for binding compared to DNA at 5 mM. In order to mimic the conditions for gel 
formation using PVA, the concentration of DNA may have to be over 100 mM, which is not 
practical for a biopolymer. Instead, other methods such as NMR, viscometry or calorimetry 
might be better to use to test for binding.     
5.5. Experimental Procedures 
Unless otherwise stated, chemical reagents and solvents were purchased from VWR 
International, Fisher Scientific, or Sigma Aldrich and used without further purification.  
Analytical TLC was performed on silica gel 60 F254 plates. Flash chromatography7 was 
performed on Teledyne Isco CombiFlash Rf-200 flash chromatography system. Melting points 
were measured on a Laboratory Devices Mel-Temp apparatus. 1H and 13C NMR spectra were 
recorded on a Varian Mercury 300 spectrometer or a Bruker Ultrashield 500 spectrometer. (Note: 
The literature procedure that was applied for each reaction is cited. The procedure may not 
necessarily be used for the synthesis of the same compound as in the literature.)  
4,4’-Dibromo-3,3’-dimethyl-biphenyl (5.4a). Compound 5.4a was 
synthesized based on literature procedure.6 Tolidine (5 g, 23.5 
mmol) was dissolved in a solution of 50% sulfuric acid (25 mL), water (100 mL), and 
acetonitrile (100 mL). The solution was cooled to 0°C and sodium nitrite (4.1 g, 60 mmol) in 




in 48% hydrobromic acid (100 mL) was added. The mixture was warmed to room temperature 
and refluxed overnight. The crude mixture was passed through a silica pad. The filtrate was 
concentrated and purified by column chromatography eluting with 100% hexanes to obtain the 
product 5.4a (3.6 g, 10.6 mmol) as a white solid (m.p. 63-65°C) in 45% yield. 1H NMR (CDCl3) 
: 7.57 (d, J = 8.3 Hz, 2H), 7.46 - 7.31 (m, 2H), 7.29 - 7.16 (m, 2H), 2.55 - 2.39 (s, 6H). 13C 
NMR (CDCl3)  
4,4’-Dibromo-3,3’-bis-bromomethyl-biphenyl (5.4b). Compound 
5.4b was synthesized based on literature procedure.8 Compound 5.4a 
(2.45 g, 7.2 mmol), N-bromosuccinimide (2.56 g, 14.4 mmol), and a 
catalytic amount of azobisisobutyronitrile (AiBN) were suspended in chloroform (30 mL). The 
suspension was refluxed overnight. The next day, the suspension was cooled and filtered to 
obtain the crude product 5.4b (3.1 g) as a white solid (m.p. 211-214°C), which was used for the 
next step without further purification. 1H NMR (CDCl3) : 7.68 - 7.61 (m, 4H), 7.35 (dd, J = 2.2, 
8.3 Hz, 2H), 4.66 (s, 4H). 13C NMR (CDCl3) δ: 139.40, 137.73, 133.96, 129.62, 128.49, 124.11, 
33.10. 
Acetic acid 3’-acetoxymethyl-4,4’-dibromo-biphenyl-3-ylmethyl 
ester (5.4c). Compound 5.4c was synthesized based on a literature 
procedure.9 The crude product 5.4b (3 g) was refluxed with 
potassium acetate (3 g, 30.6 mmol) in dimethylformamide (50 mL). After 1 h, the solution was 
cooled, diluted with water, and extracted three times with diethyl ether. The diethyl ether 
solution was extracted with brine, dried, and concentrated. The resulting material was purified by 
flash chromatography, eluting with hexanes/ethyl acetate (9:1) to obtain the product 5.4c (950 





: 7.67 - 7.62 (m, J = 8.3 Hz, 2H), 7.57 (s, 2H), 7.40 - 7.35 (m, J = 8.0 Hz, 2H), 5.25 (s, 4H), 




ylmethyl ester (5.4d). Compound 5.4c was synthesized 
based on a literature procedure.10 Compound 5.4c (950 mg, 2.08 mmol) was dissolved in dioxane 
(10.4 mL) and the solution was bubbled for 15 minutes with argon. Potassium acetate (0.98 g, 
9.98 mmol), bis(pinacolato)diboron (BPin)2 (1.16 g, 4.58 mmol), and Pd(PPh3)2Cl2 (234 mg, 
0.334 mmol) were added and the suspension was stirred at 80°C for 3.5 h under argon. The 
suspension was filtered and concentrated. The resulting residue was purified by flash 
chromatography eluting with hexanes/ethyl acetate (19:1) to obtain the product 5.4d (970 mg, 
1.76 mmol) as a yellowish oil in 85% yield. 1H NMR (CDCl3)  7.93 (d, J = 7.7 Hz, 2H), 7.62 - 
7.53 (m, 4H), 5.43 (s, 4H), 2.10 (s, 6H), 1.35 (s, 24H). 13C NMR (CDCl3) δ: 170.78, 143.25, 
142.50,  
3H,3’H-[5,5’]Bi[benzo[c][1,2]oxaborolyl]-1,1’-diol (5.4). 
Compound 5.4d was oxidized based on a literature procedure.11 
Compound 5.4d (420 mg, 0.76 mmol) was placed in THF (8.4 mL) and water (2.1 mL), and 
sodium periodate (980 mg, 4.6 mmol) was added. The suspension was stirred overnight. 2 M 
Hydrochloric acid (0.168 mL) was added and the mixture was stirred for another 24 hours. 
Methanol (35 mL) was added and the mixture was filtered. The filtrate was diluted with ethyl 
acetate, dried, concentrated to give the crude product 5.4e, which was used for the next reaction 





g, 13 mmol) in methanol for 2 hours. The suspension was acidified with 5% HCl until the 
solution became clear. The solution was diluted with water and extracted with ethyl acetate, 
dried, and concentrated. The resulting solid was triturated in methanol and then hexanes to obtain 
the product 5.4 (75 mg, 0.28 mmol) as a white solid (m.p. 339°C dec.) in 37% yield in two steps. 
1H NMR (DMSO) : 9.21 (s, 2H), 7.81 (d, J = 7.4 Hz, 2H), 7.72 - 7.63 (m, 4H), 5.04 (s, 4H). 13C 
NMR (DMSO) δ: 155.33, 143.03, 131.51, 126.50, 120.38, 70.44.  
General gel formation assay 
PVA (0.1-1.7 mM) or DNA (0.5-5 mM), buffer solution (5-50 mM), and water were added into 
an eppendorf tube and vortexed briefly. The boronic acid (0.1-30 mM) was added and the 
solution was immediately vortexed and left at room temperature overnight. If gel had not formed 
by the next day, solutions were sonicated, heated, placed at 0°C, or mixed to promote gel 
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